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Part I : Structure, dynamics and interaction studies of 
matrix metalloproteinases 
 
 
 
 
1. Introduction 
 
 
 
 
Matrix metalloproteinases (MMPs) are a class of proteolytic zinc enzymes involved in 
the degradation of several extracellular proteins, included extracellular matrix components.1-5 
The latter are a heterogeneous group of proteins and glycoproteins forming a structured 
network that provides a scaffolding for cell organization and mechanical strength.6-8 Besides 
the mechanical support to tissues, the extracellular matrix (ECM) regulates the cellular 
activity, directly or by interplaying with cytokines, growth-factors and receptors.9,10 ECM 
exerts these biological activities thanks to the tight binding to the cell cytoskeleton, and to the 
capability to bind, store and deliver cytokines and growth factors.11 The degradation of ECM 
by MMPs has a relevant physiological function for morphogenesis, tissue remodeling and 
repairing as well as for wound healing.3,12 
 
 
MMPs also process several other extracellular substrates such as extracellular domains 
of membrane receptors, cytokines and growth factors, as well as other proteases.13-17 
However, the biological effects and the physiological function of this large proteolytic activity 
is still poorly understood18. Recently, intracellular localization has been also reported for 
MMP1,19 2,20-22 and 11,23 and a role in proteolysis of intracellular substrates suggested.  
Because of the potential destructive effects on tissue and cell function, the activity of MMP in 
healthy tissues is regulated by a tight control of the expression, activation of zymogens 
precursor,24 clearance,25 and by the interaction with physiological inhibitors.14,26-30  
 
 
The uncontrolled or the pathology-driven activity of MMP is associated to a large set 
of diseases such as rheumatoid arthritis, autoimmune diseases, cancer, etc.31 The pathological 
role of MMPs has been largely investigated, and hundreds of inhibitors have been synthesized 
and tested.32-36 The research carried out in the last twenty years on MMP inhibitors (MMPI) 
was affected by a poor knowledge of the biological 37,38 and pathological functions of these 
multi-domain enzymes and by the high structural similarity among the members of the family 
that strongly affect the selectivity of the molecules.39 The progress on molecular studies of 
MMPs function and structure are now changing the perspectives for a real application of 
MMPI in the treatment of human diseases.40 
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1.1  MMPs Architecture 
 
 
 
Matrix metalloproteinases also called matrixins belong to the category of Zinc-
endopeptidases included in the metzincin superfamily. To date, 24 members of MMP family 
have been identified. These enzymes contain a three histidines motif which coordinates a zinc 
metal ion inside the catalytic domain (CAT). A glutamic acid located close to the zinc ion is 
also required for catalytic activity. An additional methionine completes the following pattern 
HExxHxxxxxHxxxxxxxM identified as a signature for metalloproteinases. 
MMP classification can be done in several ways. For example, a common 
classification consists in grouping the MMPs according to their respective substrates such as 
collagen, elastin, fibronectin… 
 
The present figure classifies the MMPs according to their domain organisation. MMPs 
can be regrouped into four groups : 
 
_ Archetypal MMPs 
_ Matrilysins 
_ Gelatinases 
_ Furin activatable MMPs 
 
 
 
 
 
Figure 1. The mammalian family of matrix metalloproteinases. Structural classification of MMPs based on their 
domain arrangement. 41 
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Archetypal MMPs : 
 
This large group can be divided into three sub-groups corresponding to the respective 
substrates : collagenases composed by MMP1, MMP8 and MMP13, stromelysins composed 
by MMP3 and MMP10 and other enzymes which are MMP12, MMP19, MMP20 and 
MMP27. 
Regarding collagenases, it was reported these proteases are not active in absence of 
their hemopexin-like (HPX) domain.42 Then collagenolytic activity required the intervention 
of both the HPX domain and the CAT domain. 
Stromelysins share a similar domain architecture respect with collagenases, have broad 
substrate specificity but are unable to perform cleavage on triple helical collagen. However, 
they have the property to activate collagenases by removing the propeptide43. In addition, 
stromelysins are able to release active form MMP9 by performing cleavage on the 
prodomain.44 
Among other archetypal MMPs, macrophage metallo-elastase (MMP12) mainly 
located in the macrophage is able to degrade a broad range of ECM substrates. MMP12 has 
the best ability of degrading elastin but is also able to process several other molecules like 
aggrecan, fibronectin, laminin and type IV collagen. 
 
 
Gelatinases : 
 
 One of the main structural characteristics of gelatinases MMP2 and MMP9 consist in 
the presence of an additional fibronectin domain composed by three sub-units inserted in the 
CAT domain. These sub-units play an important role in the degradation of gelatine which 
corresponds to a denaturated form of collagen.45 In addition gelatinases may degrade many 
other different components from ECM such as elastin, fibronectin, laminin and aggrecan.4 
Else, HPX domain of MMP9 is involved in the mechanism of cell migration.46 Gelatinolysis 
activity is important in angiogenesis through the intervention of different activating factors.47  
 
 
Matrilysins : 
 
 Matrilysin subgroup is composed by only two protein members MMP7 and MMP26. 
These proteins are constituted by a single CAT domain. Matrilysin targets are ECM 
components in particular type IV collagen, laminin, entactin and elastin. 
 
 
Furin activatable MMPs : 
 
 These proteins contain a common specific sequence between the propeptide and the 
catalytic domain which is recognized by convertase proteases allowing further activation of 
these MMPs. This category of MMP can be subdivided into three subgroups : secreted 
MMPs, membrane type MMPs and type II transmembrane MMP. The first subgroup is 
composed by MMP11, MMP21 and MMP28. MMP11 is quite similar to stromelysins in 
terms of architecture and function and participates in the degradation of collagen VI. In 
addition, the protein is playing also a role in wound healing. MMP21 is active during embryo 
development of kidney, intestine and skin. However, this protein hasn’t been extensively 
studied to date. In the same way, MMP28 was also identified in several cancers but the target 
remains unknown.48 
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Many of the furin activatable MMPs belong to the category of the membrane type 
MMPs and are also called MT1-MMP, MT2-MMP, MT3-MMP, MT4-MMP, MT5-MMP and 
MT6-MMP. These proteins are characterized by a transmembrane domain. Different patterns 
distinguish these MT-MMPs. The first group composed by MT1-MMP, MT2-MMP, MT3-
MMP and MT5-MMP contains a hydrophobic transmembrane region followed by a 
cytoplasmic tail which has been suggested to be involved activation mechanism. Other 
membrane type MMPs (MT4-MMP and MT6-MMP) contain a GPI (glycosyl phosphatidyl 
inositol) anchor motif in the transmembrane region. Due to the sub-cellular localisation of 
these MT-MMPs at the surface of the cell, these proteins play a specific role of regulating the 
cell environment. In particular, MT-MMPs are important in cell attachment. Like other MMP 
members, MT-MMPs are able to process different ECM components such as gelatine, 
collagen IV and fibronectin. Interestingly, MT-MMPs are both expressed in normal and 
tumour cells. Depending on the expression level and the cellular type ; they may induce or 
reduce tumour progression.41 
Regarding MMP23A and MMP23B, the proteins have the same amino acid sequences 
but are encoded by two distinct genes in the human genome. Differences can be found in the 
gene promoter which controls the protein expression. Then, the same protein can be found at a 
different concentration in different tissues. From the topology, MMP23 A and B are the 
unique members lacking a peptide signal, a cysteine switch motif and the hemopexin domain. 
In the other hand, they contain a cysteine array and an immunoglobulin domain. Inversely 
respect with the MT-MMPs, the transmembrane domain is located at the N-terminal part of 
the protein. Regarding the role of MMP23 A and B, it can be noticed they are expressed in 
ovary, testis and prostate.49 
This suggests a probable role in reproduction process; however, the protein activity in 
vivo still has to be investigated. 
 
 
Evolutionary events 
 
 
The MMPs domain organisation is the consequence of several evolutionary events. 
Indeed, MMPs are also present in invertebrates and plants. From the CAT domain sequences, 
it appears MMPs from invertebrates are more similar to plants than to vertebrates, suggesting 
a very ancient origin of this family protein.50 Moreover, HPX domain is not present in plants. 
To date, the main theory regarding MMP family evolution suggests the existence of a 
common gene ancestor coding for the CAT domain which had duplicated and evolved in 
order to generate the actual MMP family. Then, the multi-domain organisation of the protein 
would be originally the consequence of a fusion of two genes. Interestingly, association 
between a CAT domain and another structural domain has increased the protein specificity.  
Matrilysins MMP7 and MMP26 appeared from a deletion of HPX domain. This 
evolutionary event constitutes an exception respect with the main tendency of MMPs to 
recruit additional structural domains.51 
The most conserved regions in MMPs correspond to the CAT domain. In the other 
hand, less conserved sequences may correspond to important protein regions for specificity in 
particular the HPX domain which is possibly involved in the substrate recognition. 
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1.2 Structure and biological activity of the extracellular matrix  
 
 
Extracellular matrix (ECM) is constituted by a complex of biomolecules assembled in 
a network. Inside this biological architecture, each molecule is related to a specific function. 
Interestingly, as in many others biological systems the function is highly correlated to the 
structure. The major components of the ECM are collagen molecules, glycoproteins and 
proteoglycans. Association of these different components forms heterochimeric complexes. 
Collagen molecules are the most abundant molecules of the ECM. They consist 
mainly in repeated G-X-Y motifs in different chains which assemble to form triple helical 
structures. The following figure represents the different types of collagen. 
 
 
 
 
 
Figure 2.  Schematic representation of typical collagen 
molecules.6 
 
Thick dotted lines : helical rods;  
Circles, ellipses : NC domains.  
Only the processed molecules are shown for collagen I and VII 
 
 
 
 
Due to its triple helical structure, collagen forms a very robust and stable base for the 
matrix allowing then the binding of additional components. The biomolecular complexes 
formed become resistant enough to accommodate the cell organisation forming the different 
tissues. In particular, collagen is the most abundant proteins in bones (more than 90%). Some 
collagen fragments were identified in fossils by mass spectrometry. In order to illustrate the 
collagen robustness, it can be mentioned that some collagen fragments were extracted from 
bones of a 68-million-year-old Tyrannosaurus Rex.52 
 
Some particular motifs such as fibronectin or von Willebrand factor53 can be found 
inside the different chains forming the collagen. ECM also contains non collagenous 
molecules in particular some glycoproteins such as elastin or fibronectin.6 
Fibronectin (Fn) is composed by a repetition of three different motifs (Fn I, Fn II and 
Fn III) which are connected together in a single amino-acid chain. Several subunit repetition 
structures have been resolved both by X-ray crystallography and magnetic resonance.54 
Interestingly, three fibronectin type II modules are present in gelatinases MMP2 and MMP9. 
This structure similarity found between an ECM component and gelatinases should be 
important for interaction. 
Elastin, as its name indicates shows some elasticity properties and represents around 
2-4 % of skin composition.55 This protein contains in particular a lot of cross-links and 
repetition of hydrophobic residues VPGVG which renders the protein particularly insoluble. 
The fibrils which form the ECM are composed by a heterogeneous assemblage of 
different types of triple helical collagen. These fibrils, in addition to collagenous fragments 
are connected also to proteoglycans. Then, proteoglycans are able to connect collagen fibrils 
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to the elastin network. Other connections were observed between fibronectin domains and 
collagen fibrils mediated by interactions with proteoglycans.56 
 
ECM formation can be initiated by a self-polymerisation of type IV collagen and 
followed by a self-assembly mechanism of laminin 1. These steps may provide a scaffold to 
allow the binding of other members which form the extracellular matrix. 
Once the ECM formation is complete, cell binding function to the matrix is enabled. 
Interaction between ECM components and cell receptors regulates several cellular activities : 
in particular, cell adhesion, migration, differentiation, proliferation, and apoptosis. Cell 
adhesion function was observed in some fibronectin modules but also for some collagen 
fragments which have been mapped.57 
In order to emphasize the ECM importance, a loss of cell adhesion may lead to several 
diseases, in particular cancer development due to cell proliferation. 
 
 
1.3 Pathologies related to MMPs 
 
 
Matrix metalloproteinases are involved in several processes such as cell proliferation, 
cell migration, cell adhesion, embryogenesis, angiogenesis, wound healing and bone 
development. MMPs activity is tightly regulated in several ways : 
_ A gene can be activated by hormones, cytokines and growth factor. 
_ At the DNA level, histone acetylation or DNA methylation may occur. 
_ At the RNA level, mRNA stability may be a factor of modulation. 
_ At the protein level, a pro-domain maintain the protein in an inactive form.41 
_ Active protein may be inhibited naturally by the intervention of TIMPs (tissue 
inhibitor of matrix metalloproteinases.58 
In vivo experiments based on gain and loss of functions have demonstrated the role of 
MMP in the development of diseases. 
 
 
Cancer : 
 
MMPs are believed to promote tumour progression by initiating carcinogenesis, 
enhancing tumour angiogenesis, disrupting local tissue architecture to allow tumour growth 
and finally by breaking down basement membrane barriers for metastatic spread. 
Initial studies emphasized the degradation of type IV collagen, a major component of 
basement membranes by MMP-2 and MMP-9 in tumour tissues. Subsequently, other findings 
demonstrated ECM components could be processed by different MMPs rendering the 
interpretation more complex. Most MMPs in tumours are produced by stromal cells rather 
than cancer cells. In fact, MMP expression by fibroblasts can be stimulated by a cell surface 
glycoprotein expressed by tumour cell.59 
 
 
Inflammatory diseases : 
 
Involvement of MMP1, MMP3 and MMP9 were observed in rheumatoid and 
osteoarthritis. At the same time, an important role for aggrecanase, a member of the ADAM 
family has been proposed in articular damage. 
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Cardiovascular disease : 
 
There has been a long standing interest in the role of MMPs in cardiovascular disease. 
Numerous studies have demonstrated increased levels of MMPs at sites of atherosclerosis and 
aneurism formation.60 The idea that inflammatory process could be connected to a 
development of atherosclerosis plaque was suggested by extracellular matrix degradation 
induced by macrophages. In this mechanism, macrophages are known to secrete and activate 
MMPs provoking then inflammation. 
 
 
Lung disease 
 
Elevated MMPs levels have been implicated in various lung pathologies, including 
acute respiratory distress syndrome, asthma, bronchiectasis and cystic fibrosis. In particular, 
MMPs and TIMPs are produced in many cells from lung tissues rendering more complicated 
the analysis of individual metalloproteinase in lung disease. 
 
 
Central nervous system disease 
 
 From observations obtained on animal models resembling multiple sclerosis and 
Guillain-Barre’s syndrome, MMP9 role has been evidenced in different types of neurologic 
diseases.61 Some treatment using MMP inhibitors has reversed the pathology in animal 
models of brain injury. 
 
 
Shock syndromes 
 
MMP8 and MMP9 are located in the granules of polymorphonuclear leukocytes. 
These cells are key effectors in inflammatory and infectious processes. A role for these MMPs 
in shock is supported by studies in MMP9 deficient mice shown to be resistant to endotoxic 
shock.62 
 
Bone disorders 
 
 Mutations in MMPs may cause several disorders in the protease activity leading to an 
altered ECM turnover in function. For example, in MMP2, a Y244X mutation causes an 
abrupt end of transcription due to the presence of a codon stop in RNA and subsequently the 
absence of the following functional domains.63 This non functional protein results in 
osteolysis and bone disorders.  
 
 
Single nucleotide Polymorphism (SNP) modifying MMP expression 
 
In rare cases, some disease can appear due to dramatic changes in MMP expression 
caused by a single nucleotide polymorphism (SNP) in DNA. The protein remains functional 
but regulation of protein expression is affected. For example, insertion of an additional 
Guanine in the MMP1 gene promoter increases gene expression by providing an additional 
binding site for a transcription factor. The consequence is an increase of mRNA transcription 
leading to a high MMP1 expression in particular in colorectal and lung cancer.64 
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1.4 Development of inhibitors 
 
 
The over-expression of one or more MMPs in several pathological tissues has 
prompted the development of synthetic inhibitors since the early 80’. In particular, high-level 
expression of various MMPs were observed in several cancer cell lines and in the stromal 
cells of the tissue surrounding the tumor mass.65,66 These experimental evidences and the idea 
that the breaking of the extracellular matrix components was crucial to enable tumor cells to 
invade the neighboring tissue and to reach blood vessels 67,68 have suggested MMPs as 
potential targets for cancer therapy. The active site on the CAT domain is an obvious target to 
inhibit the enzymatic activity, and was first considered to develop new MMP inhibitors69 
Succinate peptidomimetic hydroxamates based on substrate sequences were developed at the 
end of the 80’ and then tested in clinical trials against several cancer types.70-72 For 
collagenases, the cleavage site sequence of collagen was used to design the corresponding 
inhibitors (figure 3). This cleavage site was determined by mass spectrometry and Edman 
degradation from the released fragments after collagenolysis.  
 
 
Collagenase cleavage site 
Collagen fibril 
– Pro – Gln – Gly        :         Ile   – Ala – Gly –   Human α 1 (I) 
– Pro – Gln – Gly        :         Ile   – Ala – Gly –   Human α 1 (I) 
– Pro – Gln – Gly        :         Leu – Leu – Gly –   Human α 2 (I) 
 
   S3      S2      S1     Zn ++      S1’     S2’     S3’   
Enzyme subsites (S)            O 
 
 
 
Figure 3. Design of matrix metalloproteinase inhibitors based on the collagen cleavage site.32 ZBG : zinc 
binding group. 
 
– Pro – Gln – Gly – CNH  –  Ile  – Ala – Gly –   Natural substrate 
   P3  –  P2  –  P1 –  ZBG  –  P1’ –  P2’ –  S3’   combined inhibitor 
                                 ZBG  –  P1’ –  P2’ –  S3’      right hand side inhibitor 
   P3  –  P2  –  P1 –  ZBG          left hand side inhibitor 
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These molecules bind the active site in a way that resembles the substrate in the 
transition state, establishing a network of hydrogen bonds with the protein backbone, fitting 
the deep S1’ pocket with a lipophilic moiety and binding the catalytic zinc ion in a bidentate 
fashion.73,74 Although these hydroxamates are potent inhibitors of the catalytic domain, they 
have broad-spectrum inhibitory activity and modest stability in vivo.32 
Sulfonamide hydroxamates derivatives constitute the largest class of MMPs inhibitors. 
32,36,75,76 The general formula contains a hydroxamic group designed to bind the catalytic zinc 
ion, and a large hydrophobic moiety targeted to the S1’ cavity. The two groups are tethered by 
a sulfonamide moiety forming hydrogen bonds with the binding site.77,78 Their easy synthetic 
accessibility explains the popularity of these molecules among medicinal chemists. 
Unfortunately, they suffer from most of the same drawbacks of the peptidomimetic 
hydroxamates.39 
In particular, the hydroxamic moiety has been long considered the zinc binding group 
(ZBG) of choice for MMP inhibitors (MMPI) thanks to its unique capability to bind the 
catalytic metal ion in the active site of matrix metalloproteinases.79 However, hydroxamate is 
metabolically labile80 and it contributes to increase toxicity due to its low metal binding 
selectivity.81 In the last two decades several non-hydroxamate inhibitors have been 
developed.36 The carboxylic acid has been often selected as ZBG in MMPI, despite its 
relatively weak affinity for the zinc ion.82 The use of a carboxylic acid to replace the 
hydroxamic acid warrants higher stability of the inhibitor under physiological conditions,80 
improves the solubility and provides better bioavailability.83 Following the auto-inhibitory 
activity of prodomain, several thiol-based ligands have been also designed and tested.84-86 As 
the hydroxamate derivatives, also the compounds with a thiol such as ZBG are broad-
spectrum MMPI but with a better oral availability. Pyrimidinetrione derivatives 87,88 constitute 
a further class of orally-available MMPI and, though rather unselective, they seem to cause 
fewer adverse neuromuscular effects. Phosphinic and phosphonate moieties, mimicking the 
gem-diol group of the transition state, are good ZBGs.79,89,90 Some phosphorus-based ligands 
exhibit a good selectivity towards specific matrix metalloproteinases but the problems related 
to a generally poor oral availability still have to be solved.91 Hydroxypyrone, 
hydroxypyridinone and hydroxy-urea are further examples of ZBG exploited to design 
MMPI.92,93 In particular, the structural features of hydroxypyrone-, hydroxypyridinone-based 
ZBGs seems to provide a relevant contribution to the observed selectivity  in this class of 
inhibitors.81 It has been hypothesized that several side-effects observed during the clinical 
trials with MMPI could be related to the poor specificity and selectivity of the investigated 
molecules.39 These include musculoskeletal pain and inflammation which often required the 
interruption of the therapy. Several attempts to design selective inhibitors have been carried 
out by using the structure-based strategy.94;95-97 Although this strategy has been successfully 
applied in drug discovery against several protein targets,98,99 in case of MMPs the results have 
been relatively disappointing. The poor results of the structure-based approach in designing of 
MMPI can be likely due not only to the high homology of the MMP’s members but also to the 
poor knowledge of the dynamical features of these proteins.100  
Actually, the structural data considered in structure-based drug design resulting from 
X-ray structures doesn’t take into account protein flexibility. The detrimental effect of protein 
flexibility for MMPI selectivity is particularly evident  for MMP1, where the small and 
shallow S1’ pocket can accommodate a large hydrophobic moiety by reorienting arginine 
214,101 but it has been also observed in MMP-12 where internal conformational adjustments 
occur upon binding of the inhibitor.102 
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X-ray crystallography can provide high resolution protein structures, although it 
cannot sample the conformational heterogeneity related to protein mobility but only the 
structure corresponding to the energy minimum in those experimental conditions. 
Complementary information can be achieved by NMR structures, where the poor definition of 
specific protein regions together with dynamic information provide evidence of internal 
flexibility.103-108 Recently, the active sites of several MMPs have been structurally 
characterized by X-ray and NMR and in all investigated proteins exhibits highly similar 
structural and dynamical features. A comparative analysis carried out on solution and crystal 
structures of different MMP shows that several regions of the catalytic domain undergo 
relatively wide and collective motions.109 The analysis of the RMSD per residue performed on 
NMR structures of different MMPs shows that all the investigated proteins are disordered in 
the same loop regions. 
 
 
1.5 Interaction studies between MMPs and ECM components 
 
 
1.5.1 Identification of the cleavage site in the triple helical collagen and development of 
peptide models 
 
 
In parallel with development of MMP inhibitors, a deeper investigation of the 
interaction between MMPs and their respective substrates has been carried out. Cleavage sites 
composed by a Gly-Ile-Ala and Gly-Leu-Ala motif were identified in the triple helical region 
of type II and type III collagen. A similar cleavage site was found also in type I collagen.110 
Further studies111 showed collagen can be cleaved into ¾ and ¼ fragments specifically 
by collagenases. Moreover, it appears that triple helical structure of collagen cannot be 
cleaved by other broad-specificity proteases like trypsin, elastase, or thermolysin but only by 
collagenases. Indeed, to ensure the ECM stability, collagen molecule shouldn’t be sensitive to 
degradation by a non specific peptidase. These results underlined the ability of collagenases to 
degrade collagen contained into fibrils despite the low solubility of collagen.  
In order to study interaction between proteins and collagen fibrils, triple helical 
peptide (THP) collagen models were synthesised. Peptide assembly was achieved by building 
disulfide bridges in order to bring the three chains together into a heterotrimer (figure 4).112 
 
 
α1    H2N-(GPO)5 GPQGIAGQRGVVGCGG-OH 
                              ⎜ 
α2   H2N-(GPO)5 GPQGLLGAOGILGCCGG-OH 
                             ⎜ 
α1’ H2N-(GPO)5 GPQGIAGQRGVVGLCGG-OH 
 
 
Figure 4. Sequences of a heterotrimeric collagenous peptide containing the collagenase cleavage site P4-P'9/10 of 
the αl, α2 and αl' chain of type I collagen flanked at the C-terminus by an artificial cystine- knot and at the N-
terminus by Gly-Pro-Hyp repeats known to induce and stabilize the triple helical conformation.112 
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A crystal structure of a collagen like type III model peptide was solved113  (figure 5) in 
which triple helical structure is maintained along the entire fragment containing the cleavage 
site. This structure may contradict a previous hypothesis which suggested a local unfolding 
around the cleavage site allowing collagenases to perform cleavage on collagen. However, the 
region around cleavage site may not be completely rigid in solution. 
 
 
Figure 5.  A partial sequence from human type III collagen and the sequence of the T3-785 peptide. The 
sequence (Ile 785–Gly 796) included in the peptide is highlighted and shown in red.113 
 
 
 
Considering the structure above, enzymatic cleavage may not occur without a local 
unwinding around the cleavage site by collagenases. One mechanism proposed was the triple 
helical collagen unwinding would be obtained by removal of water molecules. The 
consequence would be an opening of the triple helix by destabilizing hydrogen bonds which 
maintain the structure. However, such mechanism is uncertain because it would lead to 
multiple cleavage sites whereas only one cleavage site was found on type I collagen after 
hydrolysis by MMP1 collagenase. 
 
 
 
Figure 6. Zoom on the cleavage site of Type I collagen microfibrillar structure from pdb 3HQV.114 
 
 
 
A low resolution structure of a microfibrillar type 1 collagen in situ has been solved 
(figure 6). This 3D structure confirms a triple helical organisation for collagen in the fibril 
unit. 
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1.5.2 Insights collagenolytic activity : 
 
 
Regarding catalytic mechanism, unwinding process is necessary before cleavage 
considering the collagenases active site in CAT domains is too narrow to accommodate an 
entire triple helix collagen (figure 7). About unwinding mechanism, a cooperative 
intervention of CAT and HPX domain was suggested considering each domain is required. 
Still this mechanism has not been completely elucidated. 
Moreover, the interaction model described between MMP1 and collagen peptide115 
based on X-ray structures doesn’t take into account the possible motions between, CAT, HPX 
domain and linker peptide in MMP1 and motions inside the triple helical collagen. Actually, 
NMR studies showed triple helical peptides showed some backbone mobility close to the 
cleavage site at a temperature of 25°C.116 
Interestingly, at a physiological temperature of 37°C, MMP1 is able to process 
efficiently collagen but at a temperature lower than 25°C, cleavage of gelatine corresponding 
to denaturated collagen is more efficient than cleavage of collagen which confirms activity of 
collagenases depends both on the temperature and on substrate behaviour. 
 
 
 
 
 
 
 Triple helical 
peptide   
 
Figure 7. Alignment of the triple-helical 
peptide with the active site of MMP1.117 
Collagen triple-helical peptides113 were 
manually aligned into the active site of the 
catalytic domain of porcine MMP1118 
using Insight II/Discover and the image 
was produced with Swiss PDB viewer.119 
CAT domain  
 
 
 HPX domain 
 
 
 
 
 
Finally, the following mechanism has been proposed.117 The description consisted into 
two distinguished steps where the first is to unwind of the triple helical collagen and the 
second is the cleavage by the collagenases. Experiments were performed using a E219A 
MMP1 mutated in the active site. Mutant alone was unable to cut collagen but cleavage 
activity was restored by supplying the system with another wild type CAT domain which is 
normally unable to perform the cleavage alone. Another interesting result obtained by 
denaturation experiment in presence of MMP1 showed that collagen unwinding occurs only 
locally. This result is consistent with the fact that only one cleavage site was identified for 
MMP1 on type 1 collagen. 
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Interestingly, collagenase activity can be obtained by the reassociation of isolated 
CAT and HPX domain using a higher concentration of the isolated domains respect with the 
full-length (FL) protein. This result indicates both CAT and HPX domains are essential and 
complementary for collagenolysis. According to these data, linker peptide function consists in 
enhancing the cooperation between the two structural domains by increasing entropic 
contribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Steps involved in collagenolysis. 
Collagenase binds to and locally unwinds 
collagen before it cleaves the triple-helical 
interstitial collagen.117 
 
 
 
 
 
 
 
 
  
 
 To summarise this collagenolysis mechanism, MMP1 first binds the triple helical 
collagen, unwinds locally around the cleavage site and hydrolyses subsequently the three 
chains which composes the collagen (figure 8). 
 This mechanism is also probably facilitated by a reduced density of hydroxyprolines 
around the Gly-Ile cleavage site.120 By looking at the residue sequence of type III collagen for 
example for both chains α1 and α2, it appears that dipeptide Gly-Ile can be found several 
times. Nevertheless, there is a unique cleavage site for MMP1. Then, unrolling capability of 
the triple helical chain could depend on a local low density of hydroxyprolines. Mutations 
around the cleavage site replacing natural amino-acids by hydroxyprolines render the protein 
resistant to hydrolysis. However, it was shown that collagen binding by MMP1 was retained.  
In addition to collagen binding, HPX domain is responsible for other functions. From 
the pro-MMP1crystal structure,121 it is evidenced the prodomain interacts also with the HPX 
domain.  
For MMP2, HPX domain is involved in a cascade reaction leading to the enzyme 
activation.122 
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1.5.3 Gelatinases follow the degradation process of collagen : 
 
 
After collagen hydrolysis by collagenases, gelatinases like MMP2 or MMP9 can 
continue the degradation on unfolded collagen also called gelatine. MMP2 cleavage activity 
during blood coagulation of fibrinogen glycoprotein is mediated by its HPX domain. Removal 
of this domain doesn’t abolish the hydrolysis but reduces dramatically the catalytic activity.123 
Furthermore, hydrolysis of fibrinogen in the absence of the HPX domain gives rise to 
additional cleavage sites. This indicates HPX domain, may function as a guide to address 
MMPs to their respective targets. 
Some experiments have shown HPX-MMP9 can also bind gelatine.124 Isolated HPX 
domain in solution inhibits the enzyme activity by competition with the full length MMP9. 
In addition to CAT and HPX domain, MMP2 and MMP9 contain three sub-unit of 
fibronectin-like II domain. These three sub-units have a high similarity with the fibronectin 
ECM component able to bind collagen.56 Interestingly, fibronectin binding site to collagen 
corresponds also to the cleavage site by collagenases around G775-I776 from the type I 
collagen sequence. Moreover, mutations in this area affect fibronectin binding but also 
fibrillogenesis. 
 
 
 
 
 
 
 
 
 
Figure 9. Structure of proMMP2. The pro-
domain, catalytic domain, fibronectin domains, 
and hemopexin domain are shown in red, blue, 
green, and yellow, respectively. Zn2+ ions are 
indicated in red, and Ca2+ ions are magenta 
Asterisk indicates the cleavage site for MT1-
MMP.125 
 
 
 
 
 
 
 
 
 
 
 
The three fibronectin II like modules are able to bind denaturated collagen type I 
(gelatine I), IV and V and elastin.126 The role of the interaction between fibronectin-like 
modules and gelatine type I was investigated.127 Recombined enzyme MMP2 lacking these 
three modules has a significantly reduced efficiency respect with the full-length (FL) protein. 
In addition, experiments performed in presence of both FL-MMP2 and fibronectin like 
modules alone resulted in competition for interaction with substrate. 
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1.5.4 Matrix metalloproteinases involved in elastin degradation 
 
 
Elastin is an important component of ECM, its function is to provide elasticity to 
tissues in particular in the skin. From its nature of a cross-linked compound with hydrophobic 
properties, elastin is very stable and highly resistant to most of the non-specific proteases. 
Among the MMP family, gelatinases MMP2 and MMP9, matrilysins and macrophage 
metalloelastase MMP12 are responsible for elastolytic activity128. For MMP12, HPX domain 
is not indispensable for this activity.129 For matrilysins, the enzyme is only composed by the 
CAT domain. For gelatinases, it was suggested only CAT domain is responsible for elastin 
degradation. However, experiments performed using constructs containing only the CAT 
domain showed MMP2 and MMP9 without their fibronectin II like modules are unable to 
degrade elastin. Activity was restored then by using constructs containing both CAT domain 
with insertion of fibronectin-like modules. Nevertheless, for elastin degradation by gelatinases 
HPX domain doesn’t seem to be crucial. 
Comparing all energy requirements for collagenolysis, gelatine and elastin hydrolysis 
by their respective enzymes has revealed elastin is the substrate which has the lowest 
activation barrier130 with respect to other enzymatic cleavages. Probably, energy level 
depends on the nature of the substrate. In particular, more conformational changes are 
necessary for hydrolysis of a triple helix in collagen rather than in elastin were cleavage sites 
are directly accessible. Enzymatic assay in presence of elastin and several enzymes was 
performed. Elastin was successfully degraded by human MMP12 human, murine MMP12, 
MMP9 and a matrilysin but not by collagenase MMP1 despite a high similarity with MMP12. 
 
 
 
 
 
 
 
Figure 10. Strategy for characterizing proteinase cleavage sites in insoluble elastin.130 
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By using dinitrophenol (DNP) labelling, it was possible to identify several amino acids 
located at the different cleavage sites. Interestingly, the most abundant residues found were 
Gly, Leu and Ile which are also present in the cleavage site of collagen. In addition, some Val 
and Ala residues were also identified. 
MMP12 is one of the most active enzymes involved in elastin degradation. Respect 
with MMP1 which recognises a unique cleavage site on a particular triple helical structure of 
collagen, or with MMP2 which may recognise two or three cleavage sites,117 MMP12 
recognises a larger diversity of substrates from ECM such as elastin, fibronectin, laminin, 
entacin and also type IV collagen.129 This broad spectrum of substrates catalysed by MMP12 
may explain its requirement for macrophage activity where the protein is essentially found. 
 As already mentioned, MMP12 actively degrades elastin but was found also to 
activate other MMPs such as MMP2 and MMP3.131 In a recent work, a detailed 
characterisation of MMP12 activity towards elastin was performed in order to identify 
cleaved fragments of elastin132 to obtain a map of the cleavages sites in the protein sequence. 
Physiologically, MMP12 is expressed at a very low concentration in the skin. To study elastin 
in vitro a partial hydrolysis by chemical agents is required for solubilisation considering its 
cross-linked nature and its high hydrophobic content. Fragment peptides from degradation by 
CAT-MMP12 were collected, separated and analysed by mass spectrometry. Peptides 
sequences were also confirmed by de novo sequencing. Forty one fragments were identified 
from 4 to 41 residues which allowed locating cleavage site in the human elastin protein 
sequence. Similarly to the previous results,130 several Gly-Leu and Gly-Ile cleavage sites were 
identified. In addition, these sites could be inserted in the context of elastin sequence (Swiss 
Prot P15502) which allows taking into account the fragment with residues surrounding. Else a 
better understanding of recognition site by MMP12 becomes available. 
MMP12 also degrades tropoelastin which is the precursor of cross-linked elastin.133 
Expression of tropoelastin is enhanced in response to UV damage which occurs on skin.134 
Respect with elastin, tropoelastin is more soluble and also more exposed to cleavage by Cat-
MMP12. Then, more cleavage sites were found for tropoelastin respect with hydrolysis of 
CAT-MMP12 on elastin but surprisingly with longer average fragments which mainly 
overlap. Presence of more cleavage sites could be explained partially because tropoelastin in 
not cross-linked, then more sites may be accessible to the enzyme. 
 
 20
1.6 Aim of the research 
 
 
 The present research has been carried out to clarify the molecular mechanisms by 
which MMPs degrade structurally organized ECM components such as collagen and elastin. 
Actually, the available crystal structures of collagenase MMP1 show a compact arrangement 
of the two domains, which are connected by a 14 aa linker. Docking calculations performed 
on these structures suggest that the interaction with triple helical collagen should occur in a 
way that can lead to first unwinding and then cleavage of individual filaments. In particular, it 
has been recently suggested that such concerted action could occur much more easily if the 
two domains could enjoy at least a partial conformational independence.  
In this research, NMR experiments have been performed on MMP1 and MMP12 to 
assign hydrogen, nitrogen and carbon resonances of the proteins and to monitor protein 
dynamics. The NMR analysis has been integrated with small angle X-ray scattering (SAXS) 
data and, in case of MMP12, also with crystallographic information.  
Then, the research has been focused on the recognition by MMP1 and MMP12 of their 
natural substrates, collagen and elastin respectively. The interaction between MMP12 and a 
soluble mixture of elastin fragments has been investigated by NMR and docking calculations. 
The results have provided the structural determinants relevant for the binding of MMP12 to 
elastin cleavage sites.  
Also, the interaction between MMP1 and a synthetic triple helical collagen peptide has 
been investigated by NMR during this research. Actually, the proteolytic steps occurring 
during collagen hydrolysis by MMP1 were not elucidated. In particular, the role of the HPX 
domain, and the possible role of the interdomain flexibility were debated. The interaction of 
the selected collagen model with MMP1 monitored by NMR has provided evidence for the 
role of the interdomain flexibility in collagen unwinding and hydrolysis allowing identifying 
the protein regions involved in collagen recognition and cleavage. 
 
 
The present thesis is based on the following articles : 
 
 
? Bertini I, Calderone V, Fragai M, Jaiswal R, Luchinat C, Melikian M, Mylonas E, 
Svergun DI. Evidence of reciprocal reorientation of the catalytic and hemopexin-like 
domains of full-length MMP-12. 
 J Am Chem Soc. 130 (22) : 7011-21. (2008). 
 
 
? Bertini I, Fragai M, Luchinat C, Melikian M, Mylonas E, Sarti N, Svergun DI. 
Interdomain flexibility in full-length matrix metalloproteinase-1 (MMP-1).  
J Biol Chem. 284 (19) : 12821-8 (2009). 
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2.1 NMR 
 
2.1.1 Protein assignment experiments 
 
The experiments for the protein assignment, mobility measurements and titration 
experiments of the isolated CAT and HPX domain and of the full length proteins MMP1 and 
MMP12 were performed on protein samples at concentrations ranging between 0.2 and 0.7 
mM. Sample conditions were usually 0.1 M of NaCl for ionic strength, 10 mM of CaCl2 and 
0.1 mM of ZnCl2 using a tris-HCl buffer at pH 7.2 . 
All NMR experiments were performed at 298K, 306K and 310K and acquired on 
Bruker AVANCE900, AVANCE800, AVANCE700 AVANCE 600 and DRX 500 
spectrometers. All instruments are equipped with triple resonance CRYO-probes. 
Experiments for backbone resonance assignment of HPX-MMP12 and HPX-MMP1 : 
HSQC1,2,3,4, HNCA5, CBCA(CO)NH6 and HNCACB7,8 were performed at 900MHz for HPX-
MMP12 and 500 MHz for HPX-MMP1. For HPX-MMP12, spectra were recorded at 298K 
while for HPX-MMP1, temperature was set to 310K to prevent aggregation. 
 The assignment of the 2H-,15N-, and 13C-enriched FL-MMP1 was obtained by the 
analysis of 1H-15N TROSY9 TROSY-HNCA10 and TROSY-HNCACB11,12 performed on an 
800 MHz spectrometer at 310K. A 13C decoupling sequence was used on 1H-15N 2D 
TROSY experiment and a 2H decoupling sequence was used for the 3-dimensional triple 
resonance experiments. The protein assignment and the mobility measurements for both FL-
MMP12 and FL-MMP1 were performed on the NNGH-inhibited and E219A mutant proteins, 
necessary conditions to provide high stability by preventing the self-hydrolysis activity. 
The assignment of the aliphatic side-chain resonances of HPX-MMP12 was performed 
through the analysis of 3D (H)CCH-TOCSY13 spectra at 500 MHz, together with 3D 15N-and 
13C-NOESY-HSQC14,15,16,17,18 spectra at 900 MHz. These experiments were performed at 
298K. 
JHNH coupling constants were determined through the HNHA19,20 experiment at 500 
MHz. Backbone dihedral φ angles were independently derived from JHNH coupling constants 
through the appropriate Karplus equation21. Backbone dihedral ψ angles for residue i-1 were 
also determined.  
The protein assignment and the mobility measurements on FL-MMP12 where 
performed on the NNGH-inhibited, cadmium(II)- substituted Phe171Asp/Glu219Ala 
mutant22, due to its high stability to the self-hydrolysis.  
 
 
2.1.2 Residual dipolar coupling 
 
Residual dipolar couplings (RDCs) have been measured on FL-MMP12 in the 
presence of an external orienting medium constituted by a binary mixture of C12E5 (penta-
ethyleneglycoldodecylether, Fluka) and neat n-hexanol (Fluka), with a molar ratio C12E5/n-
hexanol of 0.96 and with a C12E5/water ratio of 5wt%.23 One-bond 1H 15N coupling constants 
were measured at 298K and 900MHz by using the IPAP method.24 Two-hundred fifty-nine 
RDC values could be measured that ranged from 46 to 25Hz. Of them, only those RDC values 
corresponding to residues experiencing neither mobility nor large RMSD (140 residues 
,mostly in α or β secondary structures) have been used for structure calculations25 and to 
investigate the reciprocal mobility of the two domains. 
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2.1.3 Pseudo-contact shift 
 
In order to visualise pseudo-contact shifts (PCS)26 from a FL-MMP12 protein sample 
in presence of a paramagnetic cobalt ion in the active site, 2D HSQC and TROSY 
experiments were performed. The sample was prepared by substituting the natural catalytic 
zinc metal ion of the enzyme by a cobalt ion in a dialyse membrane. A reference spectrum 
from a sample containing the zinc ion was also acquired at the 900 MHz. Comparison 
between reference spectrum and spectrum obtained in paramagnetic condition, allowed to 
visualise PCS. 
Similar experiments were performed with a CAT-MMP12 sample containing a cobalt 
ion and another CAT-MMP12 with a zinc ion. These experiments using the isolated CAT 
domains were performed to compare the PCS observed from the CAT domain alone and the 
FL protein. 
 
 
2.1.4 Relaxation experiments 
 
 
 T1, T2 and NOE 
 
Mobility measurements on the catalytic domain were performed on the NNGH-
inhibited, zinc (II) form of the Phe171Asp mutant.22  
Experiments for the determination of 15N longitudinal and transverse relaxation 
rates,15 and 1H-15N NOE27 were performed at 298 K and 700 MHz on 15N-enriched samples 
of FL-MMP12 and isolated domains. The 15N longitudinal relaxation rates (R1) were 
measured using a sequence modified to remove cross correlation effects during the relaxation 
delay.28 Inversion recovery times ranging between 2.5 and 3000 ms, with a recycle delay of 
3.5 s, were used for the experiments. The 15N transverse relaxation rates (R2) were measured 
using a Carr-Purcell-Meiboom-Gill (CPMG) sequence29 with delays ranging between 8.5 and 
237.4 ms for the CAT domain, between 8.5 and 203.5 ms for the HPX domain, and finally 
between 8.5 and 135.7 ms for the FL-MMP12 protein with a refocusing delay of 450 µs. 
Similar relaxation experiments were performed with CAT, HPX and FL-MMP1 
samples at the 700 MHz spectrometer with a temperature of 306K. 
 
 
Paramagnetic Relaxation Enhancement Measurements 
 
The paramagnetic relaxation enhancements of the backbone NH protons30 were 
obtained by adding a stock water solution (50mM) of Gd(DTPA_BMA) to a solution of FL-
MMP1 (0.2 mM protein in a buffer containing 20mM Tris, pH 7.2, 10mM CaCl2, 0.3 M 
NaCl, 0.2 M acetohydroxamic acid, 1mM ZnCl2, and 3mM NNGH) up a final concentration 
of 1.4 mM. Experiments were also performed at 700 MHz at 306°K. 
NH proton longitudinal relaxation times were measured through an inversion recovery 
HSQC sequence obtained by introducing a 1H 180° pulse followed by a variable delay τ in 
front of a standard 1H-15N-HSQC sequence. T1 values were obtained from a series of spectra 
obtained with the following τ values (in ms): 20, 50, 80, 100, 200, 400, 500, 800, 1000, 1400, 
2000, 2200, 3000, and 3500. A recycle delay of 4 seconds was inserted between two scans. 
The measurement was repeated on the free protein and after each addition of the paramagnetic 
complex. Peak volumes as a function of the τ value were fitted to a monoexponential recovery 
with a three-parameter fit. 
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2.1.5 NMR titration experiments 
 
 
MMP12 Interaction studies with elastin 
 
Full-length MMP12, its CAT domain and the HPX domain were expressed and 
purified as described previously.31 The replacement of the catalytic zinc with the inactive 
cadmium ion was performed by exhaustive dialysis against a buffer containing 20 mM Tris 
pH 7.2, 10 mM CaCl2, 0.15 M NaCl, 0.2 M acetohydroxamic acid (AHA) and 0.3 mM of 
CdCl2. The acetohydroxamic acid was removed during the last dialysis. Soluble elastin from 
bovine neck ligament was purchased from Sigma–Aldrich. Lyophilised elastin was dissolved 
in the final buffer (20 mM Tris pH 7.2, 10 mM CaCl2, 0.15M NaCl and 0.3 mM of CdCl2) 
and extensively dialyzed before the addition to the protein solution. 
In order to study the interaction in solution by NMR between MMP12 and elastin, 
HSQC, TROSY and FAST HMQC32 2D experiments were performed at the 700 MHz and 
900 MHz. The reference spectra were acquired on the protein alone and other titration spectra 
were recorded after each addition of elastin. Experiments were performed for the FL-MMP12, 
CAT domain and HPX domain alone and in presence of elastin fragments. 
Soluble elastin (0.7 mg) was added to 0.5 mL of FL-MMP12 (0.35 mM). The same 
amount of soluble elastin was added to 0.5 mL of isolated CAT and HPX domains at a 
concentration of 0.3 mM. The final concentration of soluble elastin in solution, calculated as 
tropoelastin (MW~65 kDa), was estimated to be 2.2 x 10-2 mM. However, taking into account 
the presence of several cleavage sites in the substrate (up to 86 in tropoelastin and up to 36 in 
insoluble elastin33,34, the concentration of binding sites for the catalytic domain in the samples 
may range from 0.8 up to 1.9 mM, that is, in large stoechiometric excess. The heterogeneous 
composition of soluble elastin and the presence of several binding sites, plausibly with 
different affinities, prevent the calculation of any dissociation constant. 
 
MMP1 interaction studies with a triple helical peptide (THP) model of collagen 
 
For MMP1 protein, experiments were performed using FL-MMP1 in absence and in 
presence of the triple helical peptide (THP) model of collagen35. The samples were prepared 
and concentrated till 0.2 mM in a buffer containing 0.1 M NaCl ; 10 mM CaCl2 ; 1 mM 
CdCl2 and 20 mM tris-HCl at pH 7.2 . TROSY spectra were acquired at the 900 MHz 
spectrometer at a temperature of 310K. Peptide was added in solution to reach a final 
concentration of 0.08 mM. Due to a severe decrease in peak intensity, it was impossible to 
increase the concentration of the peptide.  
In order to assign the unlabelled THP, two dimensional H-H TOCSY36 spectra were 
also acquired at 700 MHz spectrometer at a temperature of 310K. First, 1 mg of lyophilised 
THP (MW ≈ 10 kDa) was dissolved into water to obtain a reference spectrum for NMR 
assignment at a concentration of 0.5 mM. Then another mg of THP was dissolved into a 
buffer tris-HCl pH 7.2 to report its assignment in the buffer condition of interaction. 
To visualise chemical shift changes on the HPX domain, NMR titration was 
performed acquiring HSQC and TROSY spectra at the 900 MHz spectrometer. A reference 
spectrum was acquired with a protein sample at 0.2 mM. Several amounts of peptide model 
THP were added to the HPX-MMP1 sample to reach final peptide concentrations respectively 
of 0.04, 0.08, 0.15, 0.23, 0.30 and 0.40 mM. 
TOCSY spectra were recorded at 700 MHz spectrometer from HPX domain 0.2 mM 
(control), THP peptide 0.5 mM and HPX-THP complex from the previous titration (0.2 mM : 
0.4 mM). Experiments were performed at 310°K and 298°K. 
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2.2 Assignment strategy 
 
 
 
All spectra were processed with the Bruker TOPSPIN software Packages and analyzed 
by the program CARA (Computer Aided Resonance Assignment, ETH Zürich).37 
Assignment can be divided into three main steps. The first step consisting in 
identifying the amide proton and nitrogen located in the backbone of the protein is called 
backbone assignments.  
The backbone resonance assignment of HPX-MMP12 and HPX-MMP1 was obtained 
by the analysis of HNCA, HNCO, HNCACB, and CBCA(CO)NH. The assignment of the 
aliphatic side-chain resonances was performed through the analysis of 3D (H)CCH-TOCSY, 
together with 3D 15N-and 13C-NOESY-HSQC. 
The backbone assignment of the 2H-, 15N-, and 13C-enriched FL-MMP1 was 
obtained by the analysis TROSY-HNCA, TROSY-HNCACB, TROSY-HNCOCACB.  
The technique requires comparing the 2D and 3D spectra in order to associate the 
different carbon resonances which belong to each amide proton. 
Once these are identified, it becomes possible to find connexions between the amide 
protons through alpha and beta carbons. The fragments obtained are then analysed in order to 
be assigned inside the sequence of the protein. Each protein has a unique assignment 
corresponding to its 3D structure. However, proteins which belong to the same family may 
have several resonances close to each other. In the example of HPX-MMP1 assignment, its 
sequence was aligned with the one of HPX-MMP12. Then, the available PDB structures have 
been superimposed and eventually, NMR assignment of HPX-MMP12 was used as reference 
assignment to help finding HPX-MMP1 assignment. In addition to the comparison with HPX-
MMP12, SPARTA38 and PROSHIFT39 programs were used to obtain a chemical shift 
prediction from X-ray or NMR structure. The programme SPARTA is based on the relation 
between dihedral angles found in structures contained in the PDB database for the backbone 
and the backbone assignment chemical shifts deposited on BMRB database. Then, the 
programme calculates the best agreement of probable chemical shifts with the submitted 
structure. PROSHIFT programme has also been used. It also starts from the PDB structure but 
uses a different algorithm based on artificial neurones which combines entry information and 
provides the best compromise. 
Backbone assignment is mainly used to study the structure and mobility of the protein. 
In addition, backbone assignment is used to work on RDCs and PCS. It is also used to study 
the interaction between the protein and a partner. 
After backbone assignment the two following steps of assignment will depend 
strongly on it. Second step is the side-chain assignment used to identify carbons and protons 
of each residue which belong to the same spin system starting from already assigned Cα and 
Cβ. Some side-chain Hα and Hβ protons are also required to start the side-chain assignment. 
These resonances are also provided by the use on the 15N 3D HNH NOESY spectra. The 
third step consists in finding connections between protons by studying signals observed on 
NOESY spectra. These NOE cross peaks can be integrated and the volume obtained is 
correlated to the distances between atoms. This information is required to calculate the 
structures (see chapter related on structure calculation). 
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2.3 Mobility studies from relaxation data 
 
 
To calculate longitudinal and transverse relaxation, a reference peaklist was obtained 
by importing the protein amide proton assignment on the reference spectra of mobility (in 
generally the shortest relaxation time). Then, peaks are centred in the maximum of intensity. 
A normalisation is realised to obtain a homogeneous integration of the different peaks. All the 
peaks are integrated in all the different spectra. Then a plot is realised by reporting intensity 
(volume) as a function of time. Fitting experimental data is obtained from the equation :  
 
f(t) = Io × e(-Rt) + 
Ao 
 
Where f(t) is the volume calculated, t is the variable time in seconds used and R is the 
relaxation constant R1 or R2 in (s-1) which has to be determined. I0 and A0 are constants for 
the fitting of the curve. The R1 and R2 parameters provide indications for the regional 
mobility for the molecule. R1 and R2 parameter can be fitted by using the exponential decay 
function in the software origin. 
 In addition to R1, R2 determination, NOE experiment can provide NOE data by a 
splitting on the spectra (NOE and non-NOE). Non-NOE/NOE ratio calculated for each 
residue provides information about the local mobility. 
 
Estimates of R1 and R2 values for CAT and HPX and  FL-MMP12 and for CAT, HPX 
and FL-MMP1 were determined by using the program HydroNMR40 which simulates 
conditions of magnetic field and temperature from the three-dimensional structures of the 
proteins taken as input for the programme with respectively the X-ray structure of the FL-
MMP141 and the corresponding model of FL-MMP12 protein. 
 
Regarding paramagnetic relaxation enhancement measurements in the presence of the 
paramagnetic probe, peak intensity volumes are integrated in same the way as for the 
determination 15N longitudinal and transverse R1 and R2 relaxation rates by preparing a 
peaklist. 
Then R parameter is obtained from the equation 
 
f(t) = Io × (1 - 2 × e(-Rt) ) + Ao 
 
Where f(t) is the volume calculated, t is the variable time in seconds used and R is the 
relaxation constant in (s-1) which has to be determined. I0 and A0 are constants for the fitting 
of the curve. 
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2.4 Structure calculations 
 
 
The first step consists in generating an upper limit distance by calculating NOE cross 
peaks volumes. Caliba program was used for this purpose. A calibration is required because 
the NOE signals observed on the spectra depend on the nature of the cross-peaks. For 
example, intensity measured may be influenced in case of degenerated protons or if these 
protons are directly connected through bonds.  
From the intensity ratio of the dN(i-1,i) and dN (i,i) NOEs present on the 15N (i) plane 
of residue i obtained from the 15N-edited NOESY-HSQC spectrum 3D 15N-and 13C-
enriched NOESY-HSQC cross-peak intensities were integrated using the integration routine 
implemented in CARA and converted into interatomic upper distance limits by CALIBA42 
programme. 
A solution structure can be calculated using also torsion angles located on the 
backbone. As mentioned in the paragraph related to NMR experiment, angles can also be 
determined by using the properties of Karplus Curve from HNHA experiments. Else, 
Chemical Shift Index (CSI)43 method can predict the secondary structure of residues from the 
chemical shifts of the backbone atoms. TALOS44 programme can be used to predict a torsion 
angle range from chemicals shifts measured on to three consecutives residues. In addition, 
TALOS can approximate angles for residues located in loops or turns of a protein. 
Nevertheless, The JHNH coupling constant method based on experiment data remains 
more reliable rather than CSI or TALOS predictions based on statistical data. However, a 
comparison between experimentally defined secondary structure and prediction can provide a 
confirmation of the data. 
DYANA45 programme was used to calculate the NMR solution structure of the protein 
by combining distances, angles (restraints) and RDCs. Each calculation generates a family of 
structures on a pdb format and an output file with an overview containing the target function 
of each conformer with a list of violations and the RMSD (root mean square deviation) of the 
ensemble. The pdb file can be displayed by using molmol46 software initially developed to 
analyse NMR ensemble structure from calculation. The target function depends on the 
agreement between constraints and calculated structure. By checking the list of violations, 
mistakes can be indentified to be corrected in order to improve the structure quality. RMSD 
indicate the structure precision considering convergence of the data. Then, RDCs constraints 
complementary to distance and angle constraints generate a protein tensor. 
DYANA was run to calculate a family of 1600 structures of the isolated HPX domain 
starting from randomly generated conformers in 20000 annealing steps. The family was 
energy-minimized by iterative cycles of DYANA with the program FANTAORIENT.47 
Structure calculation statistics and the structural quality were evaluated using the program 
PROCHECK_NMR48 which in particular displays the Ramachandran plot49. Most of the 
residues must have their respective torsion angle in the core and allowed regions rather than in 
generously and disallowed regions. 
The structure obtained by DYANA calculation can be also minimised to decrease total 
energy by using AMBER50 programme and then re-evaluated by ProCHECK-NMR  
In addition to RDCs, complementary constraints can be obtained by the use of PCS. 
PCS observed on the spectra are conversely proportional to the distance between the 
paramagnetic ion and a given amino-acid located in the range of paramagnetic effects. 
Interestingly, a paramagnetic metal ion can provide long range constraints with distances 
higher than 10 Å.  
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2.5 Docking Calculation 
 
 Haddock51 programme online was used to calculate the interaction model between 
MMP12 and elastin fragments and between MMP1 and the collagen peptide model. The first 
step consisted in selecting active residues in order to drive the docking on the base on their 
chemical shift perturbation from NMR experiments and solvent accessibility. The two latter 
conditions should be respected. Regarding chemical shift perturbation, a threshold needs to be 
defined. For example, residues with chemical shift changes higher than the average value plus 
the standard deviation value can be selected. Second, relative accessibility for a defined 
residue should exceed 50%. Naccess52 programme calculates protein surface from a pdb file 
and provides information about accessibility of each individual residue. Once active residues 
have been defined for the two partners of the interaction, the next step consists in selecting the 
flexible fragments. These flexible fragments for docking were chosen around the active 
residue to allow local conformation change to improve the energy binding. 
At the end of the calculation run, results are classified according to an energy score 
and grouped into clusters on the basis of an RMSD cut-off. Output files for energy and RMSD 
are provided by the programme.  
 
Interaction model of a MMP12 – Elastin fragments complex 
 
Regarding interaction between MMP12 and elastin fragments, selection of active 
residues was done from chemical shift changes during titration and intensity decrease of some 
peaks from the CAT domain (see results section). From elastin, only the information about the 
cleavage site sequences is available33 which allow binding the CAT domain at its active site 
close to the metal ion to elastin peptide fragments which can be randomly generated by 
DYANA programme. Information about possible binding of the HPX to elastin has not been 
reported to date. 
 
Interaction model of a MMP1 - triple helical peptide (THP) model of collagen complex 
 
For MMP1, the selection was done for both partners of the docking (MMP1 and THP). 
Preliminary docking was performed from results obtained on separated domains. Atom 
coordinates of MMP1 were taken from the FL X-Ray structure (pdb entry 2CLT).41  
For the THP, a model was generated according to the crystal collagen peptide 
structures already known (see introduction p. 14). 
Active residues on HPX domain were selected from the titration results in the presence 
of THP by HSQC and TROSY experiments. Reciprocal active residues on THP were taken 
from chemical shift changes on the TOCSY spectra. 
Active residues on CAT domain were taken from chemical shift changes from titration 
of the FL-protein by THP. Additional distances were used from an X-ray structure of CAT-
MMP1 in complex with a single chain collagen fragment. Reciprocal active residues from the 
THP were selected around the cleavage site.  
In order to obtain the interaction model of the FL-MMP1 with THP, two strategies 
were used : one consisted in fitting the two domains docking models on THP. Then, the linker 
peptide was rebuilt using modeller53 and Haddock was rerun on the rebuilt FL-MMP1. A 
complementary approach consisted in starting from the X-ray structure. A first docking step 
consisted in binding the HPX domain to the THP. Then, CAT domain was moved around 
THP using a flexible linker parameter by iterative docking steps to finally reach the cleavage 
site.  
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Abstract: The proteolytic activity of matrix metalloproteinases toward extracellular matrix components (ECM),
cytokines, chemokines, and membrane receptors is crucial for several homeostatic and pathological
processes. Active MMPs are a family of single-chain enzymes (23 family members in the human genome),
most of which constituted by a catalytic domain and by a hemopexin-like domain connected by a linker.
The X-ray structures of MMP-1 and MMP-2 suggest a conserved and well-defined spatial relationship
between the two domains. Here we present structural data for MMP-12, suitably stabilized against self-
hydrolysis, both in solution (NMR and SAXS) and in the solid state (X-ray), showing that the hemopexin-
like and the catalytic domains experience conformational freedom with respect to each other on a time
scale shorter than 10-8 s. Hints on the probable conformations are also obtained. This experimental finding
opens new perspectives for the often hypothesized active role of the hemopexin-like domain in the enzymatic
activity of MMPs.
Introduction
Matrix metalloproteinases (MMP) are an important family
of 23 proteins which are involved in a number of extracellular
processes1–3 including the degradation of the extracellular
matrix.4 The latter is constituted by structural proteins such as
collagen and elastin, by proteoglycans, and by adhesive proteins
such as fibronectin, laminin, and tenascin.5 MMPs are single-
chain enzymes secreted by cells as inactive proenzymes. The
active form is liberated outside the cell by the cleavage of the
prodomain by other proteases, including MMPs themselves,6,7
thereby implying a complex regulation mechanism which also
involves other proteins such as tissue inhibitors of MMPs (called
TIMPs).8,9
All active MMPs but MMP-7 are constituted by two domains,
a catalytic (CAT) and a hemopexin-like (HPX) domain. The
CAT and HPX domains are connected by a linker whose length
varies from 14 to 68 AA.10,11 For many MMPs the linker is
relatively short (14-23 AA) whereas for MMP-9 and MMP-
15, at the other extreme, the intervening residues between the
CAT and HPX domains (68 and 63 AA, respectively) constitute
a further, highly glycosylated, domain termed OG domain.12,13
The CAT domain alone bears full proteolytic activity toward a
range of peptides and proteins.14–17 However, efficient pro-
teolysis of, for instance, triple helical collagen requires the full-† CERM, University of Florence.
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length active protein.18,19 For this reason, it is often hypothesized
that the HPX domain helps the local unwinding of the triple
helix, in such a way that a single peptide strand can be
accommodated in the active site of the CAT domain and
cleaved.20,21 It has been also hypothesized that a relative
mobility of the HPX domain is necessary for this function.22–25
This seems to be the case for MMP-9, for which small-angle
X-ray scattering (SAXS) and atomic force microscopy (AFM)
experiments indicate that the OG domain is able to lose its
globular shape and transiently assume elongated structures,
thereby allowing relative motion of the CAT and HPX do-
mains.26 On the other hand, X-ray structures of the full-length
proenzyme forms of other MMPs lacking the OG domain
display a well-defined structural relationship between the CAT
and HPX domains, and this relationship is the same in the two
different pro-MMPs studied (i.e., pro-MMP-125 (14 AA linker)
and pro-MMP-227 (20 AA linker)).25 The structures of active
MMP-1,28 and of its porcine ortholog,29 are also compact and
show a slightly different orientation of the HPX domain with
respect to pro-MMP. This difference, although small, has been
highlighted as evidence of the potential ability of the HPX
domain to move with respect to the CAT domain.25,28
Here we have addressed the general problem of the relative
conformational freedom of the two domains of MMPs in
solution by NMR. NMR in solution is a powerful tool to
investigate internal mobility of biomolecules30–42 and can also
provide precious information on interprotein and interdomain
mobility.43–49
We selected MMP-12 (16 AA linker), for which an extended
NMR assignment of the CAT domain is available, as well as
high-resolution solid state and NMR structures. In this work,
we have assigned the NMR signals of the HPX domain, solved
its solution structure, and assigned the full-length protein. We
have then obtained relaxation data (R1, R2, NOE) for the full-
length protein and compared it with the same data for its isolated
CAT and HPX domains. These data show that the two domains
are not held rigidly to one another but must undergo independent
motions. Residual dipolar couplings (RDC) on the full-length
protein in the presence of an external orienting device were also
obtained and found inconsistent with a rigid conformation of
the protein.
Repeated attempts to crystallize full-length MMP-12 for X-ray
diffraction finally yielded crystals of modest quality, which
diffracted to 3 Å resolution. This low resolution was, however,
largely sufficient to establish that the structure is less compact
and the relative orientation of the two domains totally different,
with respect to the four X-ray structures of MMP-1 and MMP-2
already described. Small-angle X-ray scattering (SAXS) data
are consistent with the determined structure in the crystal
representing the major conformation in solution but also point
to a conformational mobility of the domains in MMP-12.50
Materials and Methods
Protein Expression. The cDNA encoding the G106-C470
sequence of full-length MMP-12 was generated by a polymerase
chain reaction (PCR) from an IMAGE consortium clone using two
synthetic oligonucleotides as primers. The cDNA obtained was
cloned into the pET21a (Novagen) using the restriction enzymes
Nde I and Xho I (New England BioLabs). One additional methionine
at position 105 was present in the final expression product.
The expression vector encoding for the full-length protein (FL-
MMP-12) was transformed into competent Escherichia coli BL21
(DE3) Codon Plus strain, and colonies were selected for Ampicillin
and chloramphenicol resistance. Bacteria were grown in LB medium
containing 34 µg/mL chloramphenicol and 50 µg/mL ampicillin in
a shaker flask at 37 °C. Protein expression was induced with 0.5
mM IPTG at an OD600 ) 0.6, and cell growth was continued for a
further 5 h. For expression of 15N and 13C-enriched FL-MMP-12,
the bacteria were grown in minimal medium containing 15N
enriched (NH4)2SO4 and 13C enriched glucose (Cambridge Isotope
Laboratories). Cells were harvested by centrifugation and resus-
pended in a buffer containing 25% sucrose, 50 mM Tris-HCl (pH
8), 0.1 M NaCl, 0.2 M EDTA, 1 mM DTT. Five to ten milligrams
of lysozyme were added to the resulting suspension and stirred for
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15-20 min at 4 °C. A buffer containing 2% Triton, 50 mM Tris-
HCl (pH 8), 0.1 M NaCl, 0.2 M EDTA, and 1 mM DTT was added,
and the suspension was sonicated (7-8 30 s cycles) and centrifuged
at 40 000 rpm for 20 min at 4 °C. The pellets were resuspended in
6 M Urea, 20 mM Tris-HCl (pH 8) and centrifuged. The resulting
inclusion bodies were solubilized in 6 M Gdn-HCl, 20 mM Tris-
HCl (pH 8), 10 mM DTT, and 20 mM cystamine and stirred
overnight at 4 °C. The insoluble material was removed by
centrifuging at 9000 rpm for 10 min. Protein molecular weight and
purity was checked on 15% gel by SDS-PAGE. The F171D, E219A
mutant of FL-MMP-12 was produced using the quick-change site-
directed mutagenesis kit (Qiagen), and the expression and purifica-
tion of the protein and of its 15N- and 13C-15N-enriched versions
completed using the same procedure described above.
Refolding was carried out by a serial dilution method.51 The
protein was diluted to a final concentration of 0.13 mg/mL in 6 M
Gdn-HCl, 20 mM Tris-HCl (pH 8), 1 mM DTT, and 0.05% Brij-
35, stirred at 4 °C for 30-60 min, and dialyzed overnight against
a buffer containing 20 mM Tris (pH 7.2), 10 mM CaCl2, 0.1 mM
ZnCl2, 0.15 M NaCl, 5 mM -mercaptoethanol, 1 mM 2-hydroxy-
ethyl disulfide, and 0.05% Brij-35. The refolded protein was then
purified using a Sepharose column (Amersham) with a buffer
containing 20 mM Tris (pH 7.2), 10 mM CaCl2, 0.3 M NaCl and
0.1 M acetohydroxamic acid (AHA). The protein solution was
concentrated up to 5 mL and purified by size exclusion chroma-
tography using a High Load 16/60 Superdex 75 (Amersham
Biosciences) and eluted with 20 mM Tris pH 7.2, 10 mM CaCl2,
0.3 M NaCl, and 0.2 M AHA. The eluted fractions were checked
for purity on 15% gel by SDS-PAGE, and those containing the
FL-MMP-12 protein were pooled and concentrated.
Samples of cadmium(II) substituted FL-MMP-12 protein were
prepared by exhaustive dialysis against a buffer containing 20 mM
Tris pH 7.2, 10 mM CaCl2, 0.3 M NaCl, 0.2 M AHA, and 0.3 mM
of CdCl2.52 Equimolar concentrations of N-isobutyl-N-[4methox-
yphenylsulfonyl] glycyl hydroxamic acid (NNGH) were added to
the samples to further increase the protein stability.
The cDNA encoding for the HPX domain (E278-C470) was
generated by polymerase chain reaction and cloned into pET21a,
using Nde I and Xho I as restriction enzymes. The expression vector
was then transformed into competent E. coli BL21 (DE3) Gold
strain, and the colonies were selected for Ampicillin resistance.
Protein refolding for both nonlabeled and for 13C and/or 15N
enriched samples was carried out by using the same protocols
previously described for the preparation of FL-MMP-12 samples.
Samples of the zinc(II) catalytic domain (F171D mutant) were
prepared as previously described.50
NMR Measurements and Solution Structure Calculations.
The experiments for the structure calculation and mobility measure-
ments of the isolated HPX domain were performed on protein
samples at concentrations ranging between 0.5 and 0.7 mM (pH
7.2). For FL-MMP-12, all NMR experiments were performed on
samples at a concentration of 0.5 mM (pH 7.2).
All NMR experiments were performed at 298 K and acquired
on Bruker AVANCE 900, AVANCE 800, AVANCE 700 and DRX
500 spectrometers. All instruments but one are equipped with triple
resonance CRYO-probes. The 700 MHz spectrometer is equipped
with a triple resonance (TXI) 5 mm probe with a z-axis pulse field
gradient.
All spectra were processed with the Bruker TOPSPIN software
packages and analyzed by the program CARA (Computer Aided
Resonance Assignment, ETH Zu¨rich).53
The backbone resonance assignment was obtained by the analysis
of HNCA, HNCO, HN(CA)CO, HNCACB, and CBCA(CO)NH
spectra performed at 900 MHz. The assignment of the aliphatic
side-chain resonances was performed through the analysis of 3D
(H)CCH-TOCSY spectra at 500 MHz, together with 3D 15N- and
13C-NOESY-HSQC spectra at 900 MHz. The obtained assignments
are reported in Tables S1 and S2 for the full length protein and
tables S3 and S4 for the hemopexin domain. 3JHNHR coupling
constants were determined through the HNHA experiment at 500
MHz. Backbone dihedral  angles were independently derived from
3JHNHR coupling constants through the appropriate Karplus equa-
tion.54 Backbone dihedral ψ angles for residue i-1 were also
determined from the ratio of the intensities of the dRN(i-1,i) and
dNR(i,i) NOEs present on the 15N(i) plane of residue i obtained from
the 15N-edited NOESY-HSQC spectrum.
3D 15N- and 13C-enriched NOESY-HSQC cross peak intensities
were integrated using the integration routine implemented in CARA
and converted into interatomic upper distance limits by the program
CALIBA.55
The protein assignment and the mobility measurements on FL-
MMP-12 where performed on the NNGH-inhibited, cadmium(II)-
substituted Phe171Asp/Glu219Ala mutant, due to its high stability
to the self-hydrolysis. Mobility measurements on the catalytic
domain where performed on the NNGH-inhibited, zinc(II) form of
the Phe171Asp mutant.50
Residual dipolar couplings have been measured on FL-MMP-
12 in the presence of an external orienting medium constituted by
a binary mixture of C12E5 (penta-ethyleneglycol dodecyl ether,
Fluka) and neat n-hexanol (Fluka), with a molar ratio C12E5/n-
hexanol of 0.96 and with a C12E5/water ratio of 5 wt %.56 One-
bond 1H-15N coupling constants were measured at 298 K and 900
MHz by using the IPAP method.57,58 Two-hundred fifty-nine rdc
values could be measured that ranged from -46 to +25 Hz. Of
them, only those rdc values corresponding to residues experiencing
neither mobility nor large rmsd (140 residues, mostly in R or 
secondary structures, see Table S5, Supporting Information) have
been used for structure calculations and to investigate the reciprocal
mobility of the two domains.
The program DYANA59 was used to calculate a family of 1600
structures of the isolated HPX domain starting from randomly
generated conformers in 20 000 annealing steps. The solution
structure statistics are reported in Table S6 (Supporting Informa-
tion). The family was energy-minimized by iterative cycles of
DYANA with the program FANTAORIENT.60 The quality of the
structures calculated by DYANA can be assessed by a properly
defined energy function (target function) proportional to the squared
deviations of the calculated constraints from the experimental ones,
plus the standard covalent and nonbonded energy terms. Structure
calculation statistics and the structural quality were evaluated using
the program PROCHECK_NMR.61
R1, R2, and NOE Measurements. The experiments for the
determination of 15N longitudinal and transverse relaxation rates
and 1H-15N NOE were recorded at 298 K and 700 MHz on 15N-
enriched samples. The 15N longitudinal relaxation rates (R1) were
measured using a sequence modified to remove cross correlation
effects during the relaxation delay.62 Inversion-recovery times
(51) Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Mangani, S.;
Terni, B. Angew. Chem. Int. Ed. 2003, 42, 2673–2676.
(52) Bertini, I.; Fragai, M.; Lee, Y.-M.; Luchinat, C.; Terni, B. Angew.
Chem. Int. Ed. 2004, 43, 2254–2256.
(53) Keller, R. L. J. The Computer Aided Resonance Assignment Tutorial,
1.3; Cantina: Verlag, 2004.
(54) Vuister, G. W.; Bax, A. J. Am. Chem. Soc. 1993, 115, 7772–7777.
(55) Guntert, P.; Braun, W.; Wu¨thrich, K. J. Mol. Biol. 1991, 217, 517–
530.
(56) Ru¨ckert, M.; Otting, G. J. Am. Chem. Soc. 2000, 122, 7793–7797.
(57) Otting, G.; Ruckert, M.; Levitt, M. H.; Moshref, A. J. Biomol. NMR
2000, 16, 343–346.
(58) Ottiger, M.; Delaglio, F.; Bax, A. J. Magn. Reson. 1998, 131, 373–
378.
(59) Guntert, P.; Mumenthaler, C.; Wu¨thrich, K. J. Mol. Biol. 1997, 273,
283–298.
(60) Bertini, I.; Luchinat, C.; Parigi, G. Concepts Magn. Reson. 2002,
14, 259–286.
(61) Laskowski, R. A.; Rullmann, J. A. C.; MacArthur, M. W.; Kaptein,
R.; Thornton, J. M. J. Biomol. NMR 1996, 8, 477–486.
(62) Kay, L. E.; Nicholson, L. K.; Delaglio, F.; Bax, A.; Torchia, D. A.
J. Magn. Reson. 1992, 97, 359–375.
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ranging between 2.5 and 3000 ms, with a recycle delay of 3.5 s,
were used for the experiments. The 15N transverse relaxation rates
(R2) were measured using a CPMG sequence62,63 with delays
ranging between 8.5 and 237.4 ms for the CAT domain, between
8.5 and 203.5 ms for the HPX domain, and finally between 8.5
and 135.7 ms for the FL-MMP-12 protein with a refocusing delay
of 450 µs. The relaxation data are reported in Table S7 (Supporting
Information). R1 and R2 data measured on the full length protein
were found nosier and less uniform with respect to those of the
single catalytic and hemopexin domains. This is related to the
overlap of the signals in a so large protein and to the relative low
solubility of the full length construct.
Crystallization, Data Collection, and X-ray Structure
Determination. Crystals of the zinc(II) Phe171Asp/Glu219Ala
FL-MMP-12 were obtained using the vapor diffusion technique at
20 °C from a solution containing 0.1 M Tris-HCl, 30% PEG-8000,
200 mM AHA, pH 8.0. The final protein concentration was
0.7 mM.
The data collection was carried out in-house, using a PX-Ultra
copper sealed tube source (Oxford Diffraction) equipped with an
Onyx CCD detector. The data set was collected at 100 K and the
crystals used for data collection were cryo-cooled using a solution
containing 10% ethylene glycol in the mother liquor.
The crystal diffracted to 3.0 Å resolution; it belongs to space-
group C2 with one molecule in the asymmetric unit, a solvent
content of about 50%, and a mosaicity of about 1.0°.
The data was processed using the program MOSFLM64 and
scaled using the program SCALA65 with the TAILS and SEC-
ONDARY corrections on (the latter restrained with a TIE SUR-
FACE command) to achieve an empirical absorption correction.
The structure was solved using the molecular replacement technique
in two following steps; in the first step, the model used to find the
correct orientation of the catalytic part of the structure was 1Y93
whereas the one used for the hemopexin domain was the same
domain in proMMP-1 structure (1SU3). In both steps, inhibitors,
water molecules, and ions were omitted from the models.
The correct orientation and translation of the molecules within
the crystallographic unit cell was determined with standard Patterson
search techniques66,67 as implemented in the program MOLREP.68,69
The isotropic refinement was carried out using REFMAC570 and
default weights for the crystallographic term and the geometrical
term were used.
In between the refinement cycles, the models were subjected to
manual rebuilding by using XtalView.71 The same program was
used to model AHA molecule. Water molecules have been added
by using the standard procedures within the ARP/WARP suite.72
The stereochemical quality of the refined models was assessed using
the program PROCHECK.73 The Ramachandran plot is of average
quality for such a resolution structure. Of the seven violations four
(Asp303, Ser311, Lys315, and Asn363) are located in the he-
mopexin domain; it is interesting to compare these outliers to the
equivalent residues in MMP-1 (1SU3) which has a higher resolution
(2.2 Å). Asp299 (corresponding to Asp303 in MMP-12) is an outlier
as well, and in the place of Ser311 there is a proline residue
(Pro307) which has of course a unique stereochemistry; furthermore
in the place of Asn363 there is Gly359 in MMP-1, which again is
unique from the stereochemical point of view. Therefore, three out
of the four residues that are in disallowed regions in the HPX
domain may actually assume peculiar positions in the 3-D structure.
Table S8 (Supporting Information) reports the data collection and
refinement statistics.
SAXS Experiments and Data Analysis. Synchrotron X-ray
scattering data from solutions of the NNGH-inhibited, cadmium(II)-
substituted Phe171Asp/Glu219Ala double mutant of FL-MMP-12
were collected on the X33 beamline of the EMBL (DESY,
Hamburg),74 using a MAR345 image plate detector. The scattering
patterns were measured with a 2 min exposure time for several
solute concentrations in the range from 0.8 to 8.3 mg/mL. To check
for radiation damage, two 2 min exposures were compared, and
no changes were detected. Using the sample-detector distance of
2.7 m, a range of momentum transfer of 0.01 < s < 0.5 Å-1 was
covered (s ) 4π sin(θ)/λ, where 2θ is the scattering angle, and
λ ) 1.5 Å is the X-ray wavelength). The data were processed using
standard procedures and extrapolated to infinite dilution using the
program PRIMUS.75 The forward scattering, I(0), and the radius
of gyration, Rg, were evaluated using the Guinier approximation,76
assuming that at very small angles (s < 1.3/Rg) the intensity is
represented as I(s) ) I(0) exp(-(s2Rg2)/3. The values of I(0) and
Rg, as well as the maximum dimension, Dmax, and the interatomic
distance distribution functions, (p(r)), were also computed using
the program GNOM.77 The molecular mass of FL-MMP-12 was
evaluated by comparison of the forward scattering with that for a
reference solution of bovine serum albumin (66 kDa).
The scattering from the high resolution models was computed
using the program CRYSOL.78 Given the atomic coordinates, the
program either predicts the theoretical scattering pattern or fits
the experimental intensity by adjusting the excluded volume of the
particle and the contrast of the hydration layer to minimize the
discrepancy
x
2 ) 1N- 1∑i [Iexp(Sj)- cIcalc(Sj)σ(Sj) ]2 (1)
where N is the number of experimental points, c is a scaling factor,
Iexp(sj) and Icalc(sj) are the experimental and calculated intensities,
respectively, and σ(sj) is the experimental error at the momentum
transfer sj.
To assess the conformational variability of MMP-12, an ensemble
optimization method (EOM) was used,79 allowing for coexistence
of multiple conformations in solution. About 5000 randomized
models of MMP-12 differing by the conformation of the interdo-
main linker were generated using the program DYANA starting
from randomly generated conformers of the full-length protein
where only the dihedral angles of the linker region were left free
to vary. These models formed a pool of possible structures, for
which the scattering patterns were computed by CRYSOL. The
EOM program employs a genetic algorithm to select from the pool
a small number (usually about 20) of representative structures such
that the average scattering from the selected ensemble fits the
experimental data. Multiple runs of EOM were performed and
the results were averaged to provide quantitative information about
(63) Peng, J. W.; Wagner, G. Methods Enzymol. 1994, 239, 563–596.
(64) Leslie, A. G. W. In Molecular data processing; Moras, D., Podjarny,
A. D., Thierry, J.-C., Eds.; Oxford University Press: Oxford, 1991;
pp 50-61.
(65) Evans, P. R. Joint CCP4 and ESF-EACBM Newsletter 1997, 33,
22–24.
(66) Rossmann, M. G.; Blow, D. M. Acta Crystallogr. 1962, 15, 24.
(67) Crowther, R. A. The Molecular Replacement Method; Rossmann,
M. G., Ed.; Gordon & Breach: New York, 1972.
(68) Vagin, A.; Teplyakov, A. J. Appl. Crystallogr. 1997, 30, 1022–1025.
(69) Vagin, A.; Teplyakov, A. Acta Crystallogr. D: Biol. Crystallogr.
2000, 56, 1622–1624.
(70) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Acta Crystallogr.
1997, D53, 240–255.
(71) McRee, D. E. J. Mol. Graphics 1992, 10, 44–47.
(72) Lamzin, V. S. Acta Crystallogr. D: Biol. Crystallogr. 1993, 49, 129–
147.
(73) Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M.
J. Appl. Crystallogr. 1993, 26, 283–291.
(74) Roessle, M. W.; Klaering, R.; Ristau, U.; Robrahn, B.; Jahn, D.;
Gehrmann, T.; Konarev, P. V.; Round, A.; Fiedler, S.; Hermes, S.;
Svergun, D. I. J. Appl. Crystallogr. 2007, 40, s190–s194.
(75) Konarev, P. V.; Volkov, V. V.; Sokolova, A. V.; Koch, M. H. J.;
Svergun, D. I. J. Appl. Crystallogr. 2003, 36, 1277–1282.
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1995, 28, 768–773.
(79) Bernado, P.; Mylonas, E.; Petoukhov, M. V.; Blackledge, M.;
Svergun, D. I. J. Am. Chem. Soc. 2007, 129, 5656–5664.
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the flexibility of the protein in solution (in particular, about the Rg
distribution in the selected ensembles).
Results and Discussion
Design and Production of a Stable Full-Length MMP-12.
Several MMPs, both as isolated catalytic domains (CAT) or
full-length (FL) proteins, are relatively unstable in Vitro due to
self-proteolysis (while the inactive isolated hemopexin domain
(HPX) is stable). In the case of MMP-12, the CAT domain can
be stabilized by a Phe171Asp mutation that prevents self-
proteolysis and increases the solubility. This mutation is far both
from the active site and from the CAT-HPX interface (see later)
and does not perturb the catalytic activity of the enzyme.
Therefore, a FL construct with the Phe171Asp mutation was
initially produced. The resulting protein was well folded and
fully active but still sensitive to the self-proteolysis at the linker
region even in the presence of the inhibitor NNGH.
To increase the stability, the catalytically relevant Glu219
was mutated to an Ala. This mutation had been shown to
decrease the catalytic activity of the isolated CAT domain of
MMPs by two-3 orders of magnitude,80 whereas the three-
dimensional structure of the domain is fully retained.81 The
Phe171Asp/Glu219Ala double mutant of the FL protein was
stable for several days.
Finally, we substituted the catalytic zinc(II) ion, responsible
for the residual activity, with a cadmium(II) ion. The resulting
derivative, complexed with NNGH, resulted stable to proteoly-
sis, showing no trace of cleaved CAT and HPX domains in the
gel after three weeks of NMR measurements. The analysis of
the HSQC spectra revealed that no structural alteration were
caused by the replacement of zinc(II) with the cadmium(II) ion.
The NNGH-inhibited, cadmium(II)-substituted Phe171Asp/
Glu219Ala double mutant of FL-MMP-12 was therefore used
in all NMR experiments reported hereafter.
Low-Resolution X-Ray Structure of FL-MMP-12 and
Comparison with Existing Structural Information on
FL-MMP. Crystals diffracting at 3.0 Å were obtained for the
AHA-inhibited, zinc(II) Phe171Asp/Glu219Ala double mutant
of FL-MMP-12.
The X-ray structure of this construct was solved from
diffraction data obtained in-house and deposited in PDB (PDB
code: 3BA0). Despite the low resolution, the electron density
was of generally good quality throughout the entire molecule,
the only exception being residues 271-274 in the middle of
the linker region (see below), which spans from Asp264 to
Pro279. The overall structure of the CAT domain is very similar
to the high resolution structure of the isolated CAT domain.50
The mutations are both clearly visible; the active site contains
both the native catalytic zinc ion and the structural zinc ion.
Three calcium atoms are also present in the structure of the
CAT domain. Finally, a AHA molecule bound to the zinc ion
in the usual geometry50 is present at the active site. The HPX
domain has the expected four-blade propeller, hemopexin-like
foldpreviouslyobservedinotherHPXdomainsofMMPs.22,25,27,29,82–85
The disulfide bridge between Cys282 and Cys470 is clearly
present, and a calcium ion is bound in the central region of the
domain.
The relative orientation of the two domains could be
unambiguously determined from the 3 Å X-ray data (Figure
1A). The two domains are in contact through a relatively small
surface (∼165 Å2) which includes a possible salt bridge between
His112 of CAT domain and the C-terminal of Cys470 in the
HPX domain, and van der Waals interactions between residue
113 of CAT and residues 284 and 463 on the HPX side. The
first part of the linker (residues 264, 265, 266, 270, 271, and
273) is in touch with the CAT domain (residues 112, 143, 144,
249, 259, and 263) through a surface of 902 Å2 and the last
part (residues 277 and 279) with the HPX domain (residues
280, 307, and 470) through a surface of 571 Å2 (Figure 1A).
Furthermore, the linker residue Lys266, besides being in contact
with the CAT domain, forms a salt bridge with the C-terminal
of HPX domain. The central part of the linker (residues
271-274) shows a rather poor electron density, but its structure
can be reasonably modeled to match the arrangement of the
initial and final linker residues. It is apparent that the whole
molecule is held together mainly by interactions between each
single domain and the linker rather than between the two
domains. The presence of the intact linker was confirmed by a
gel experiment on a protein solution obtained after redissolving
crystals collected from the same wells of those used for X-ray.
Figure 1C shows a superposition of the X-ray structures of
human proMMP-1 and proMMP-2, the only FL-proMMPs
structures available to date, where the prodomain and the
fibronectin domains (in case of MMP-2) have been omitted for
clarity. The CAT-HPX interface is very similar in the two
proteins and relatively extended (ca. 753 and 866 Å2, respec-
tively, as opposed to ca. 165 Å2 in FL-MMP-12), suggestive
of a stable domain-domain interaction. Figure 1D shows a
superposition of the structures of active human FL-MMP-128
and of its porcine ortholog.29 Again, the two structures are very
similar, and the CAT-HPX interface is again extended (ca. 735
and 747 Å2, respectively). The relative orientation of the HPX
domain is slightly different in these active forms with respect
to the pro-enzyme forms (cfr. Figure 1D and 1C, where the
CAT domain has the same orientation), as previously noticed.28
Relative to the CAT domain, the HPX domain in FL-MMP-
12 lies at about 120° with respect to its orientation in the
structures of MMP-1 and MMP-2 (Figure 1E), and the two
domains have a less compact arrangement (cfr. Figure 1A and
1B). The interface region is completely different, both viewed
from the CAT and from the HPX domain, is sensibly smaller
(ca. 165 vs 735-866 Å2), and the complementarity between
the surfaces of the two domains is poor with respect to that
observed in the experimental structures of FL-MMP-1 and FL-
MMP-2.
NMR Characterization of FL-MMP-12. The NNGH-inhib-
ited, cadmium(II)-substituted Phe171Asp/Glu219Ala double
mutant of FL-MMP-12 (FL-MMP-12 hereafter) yields 15N-1H
HSQC spectra of surprisingly good quality for a protein of
42 000 Da (see Figure 2A) (spectra of this type were obtained
on all constructs of FL-MMP-12 described before).
Figure 2B shows the 15N-1H HSQC spectrum of FL-MMP-
12 (in black) superimposed to those of the isolated CAT domain
(in green), prepared as previously reported, and of the isolated
HPX domain (in red, see below). The similarity is striking:
except for a number of peaks that are not present in either the
(80) Cha, J.; Auld, D. S. Biochemistry 1997, 36, 16019–16024.
(81) Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Maletta, M.; Yeo,
K. J. Angew. Chem., Int. Ed. 2006, 45, 7952–7955.
(82) Morgunova, E.; Tuuttila, A.; Bergmann, U.; Tryggvason, K. Proc.
Natl. Acad. Sci. U.S.A. 2002, 99, 7414–7419.
(83) Libson, A. M.; Gittis, A. G.; Collier, I. E.; Marmer, B. L.; Goldberg,
G. I.; Lattman, E. E. Nat. Struct. Biol. 1995, 2, 938–942.
(84) Gohlke, U.; Gomis-Ruth, F. X.; Crabbe, T.; Murphy, G.; Docherty,
A. J.; Bode, W. FEBS Lett. 1996, 378, 126–130.
(85) Cha, H.; Kopetzki, E.; Huber, R.; Lanzendorfer, M.; Brandstetter,
H. J. Mol. Biol. 2002, 320, 1065–1079.
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isolated CAT and HPX domains, which must therefore belong
to the linker, all other FL-MMP-12 peaks are superimposable,
or nearly superimposable, to a peak of either the isolated CAT
or HPX domain. Furthermore, the peaks of FL-MMP-12 were
only marginally broader that the corresponding peaks in the
isolated domains.
The 13C, 15N, and 1H spectral assignment of the CAT domain
was available,50 whereas that of the HPX domain was performed
during this research. Also the solution structure of the HPX
domain, up to now unavailable for MMP-12, was experimentally
solved here (see Table S6 and Figure S1, Supporting Informa-
tion) and deposited in PDB (PDB code: 2JXY). Ribbon
representations of the solution and crystal structures are reported
in Figure S1. The relatively high rmsd between the two
structures (BB ) 1.88 Å, secondary structure elements ) 1.16
Å) is within the indetermination of both the X-ray (3.0 Å
resolution) and NMR structures (BB rmsd ) 1.38 Å, heavy atom
rmsd ) 2.13 Å).
The 15N-1H HSQC spectrum of FL-MMP-12 could be
largely assigned by direct comparison with the isolated CAT
and HPX spectra. Nevertheless, 97% of the nonlinker residues
were reassigned by recording the same set of 3D spectra used
for the structure of the isolated domains. Despite the crowding,
the spectra were of good enough quality to assign most of the
backbone atoms of the two domains as well as a large fraction
of side-chain atoms (Table S1, Supporting Information). 3D
NOESY spectra were also recorded. The NOESY patterns were
largely the same as those observed in the isolated CAT and
HPX domains, indicating that the domain structures are indeed
unaltered in the FL protein, as it was already apparent from the
comparison of the HSQC spectra. No interdomain NOEs could
be found. The largest difficulties in the assignment were
encountered in the linker region. Although several of the linker
15N-1H HSQC peaks could be identified as the extra peaks
present in the FL protein spectra and not corresponding to peaks
of any of the two domains, several of the necessary sequential
connectivities were missing in the 3D spectra. In addition, very
few NOEs could be seen for these peaks. A protonless CON
experiment86 allowed us to identify two of the linker prolines.
Ten linker peaks could be identified, and four of them sequence-
specifically assigned (Table 1).
Relaxation Data. The 700 MHz R1 and R2 data for FL-MMP-
12 as well as for the isolated CAT and HPX domains are shown
in Figure 3A-D. R1 and R2 values can be accurately estimated
from the atomic coordinates of a macromolecule of known
structure assuming a rigid-body hydrodynamics by using
computer programs like HYDRONMR.87 In this study, the
X-ray structure of the CAT domain (PDB code: 1Y93),50 the
present solution structure of the HPX domain, and the present
X-ray structure of the full length protein (Figure 1E) were used
as input files in HYDRONMR. As shown in Figure 3, while
for the isolated domains the experimental data nicely match the
calculated values, for FL-MMP-12 sizably faster longitudinal
and sizably slower transverse relaxation rates with respect to
the calculated values were measured. These differences are
clearly statistically significant, despite the larger errors due to
the signal overlap and lower signal-to-noise ratios in the spectra
(86) Bermel, W.; Bertini, I.; Duma, L.; Emsley, L.; Felli, I. C.; Pierattelli,
R.; Vasos, P. R. Angew. Chem., Int. Ed. 2005, 44, 3089–3092.
(87) de la Torre, J. G.; Huertas, M. L.; Carrasco, B. J. Magn. Reson.
2000, 147, 138–146.
Figure 1. Space-filling representations of the X-ray structures of FL-MMP-12 (A, present work) and FL-MMP-1 (B).28 Superimposition of the X-ray
structures of (C) human pro-MMP-125 (red) and pro-MMP-227 (yellow) (where the prodomain of both and the fibronectin domains of MMP-2 have been
omitted for clarity), (D) human28 (violet) and porcine29 (green) FL-MMP-1, and (E) human FL-MMP-128 (violet) with the present FL-MMP-12 (blue).
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of FL-MMP-12. The R1 and R2 values measured on FL-MMP-
12 are intermediate between the expectation from the isolated
domains and a rigid full length structure. At the same time, the
NOE values for FL-MMP-12 (Figure 3E) demonstrate that the
single domains (catalytic and hemopexin) forming the full length
protein behave as rigid bodies. Therefore, relaxation data can
be collectively taken as evidence that the full length protein
does not exhibit a rigid body hydrodynamics but experience
flexibility. Such flexibility must depend on the presence of a
flexible linker that permits sizable reciprocal mobility of the
two domains on a time scale that is faster than the reorientation
time of the whole molecule.
Figure 2. 900 MHz 15N-1H HSQC spectra of the uniformly 15N-labelled NNGH-inhibited, cadmium(II)-substituted Phe171Asp/Glu219Ala double mutant
of FL-MMP-12 (A), and superimposed spectra of FL-MMP-12 (black), CAT-MMP-12 (green), and HPX-MMP-12 (red) (B).
Table 1. 1H, 15N, and 13C Chemical Shifts for the Identified Linker Residues of FL-MMP-12
HN N CA HA CB other NOE
264 D 7.88 116.40 48.44 4.55 36.50 HB2 3.77, HB3 2.53
272 P 60.17 29.20 CG 24.29, CD 46.96
273 N 8.38 119.79 48.44 4.78 35.86 HB2 2.72, HB3 2.56 0.25
279 P 59.92 4.20 29.18 HB2 2.12, HB3 1.67, HG2 1.87, HG3 1.5, HD2 3.18, HD3 3.84
L1 8.28 120.71 53.34 4.17 29.97 QB 1.78, CG 38.97, QG 2.87
L2 8.17 109.42 57.03 4.83 39.62 HB2 3.05, HB3 2.60
L3 7.89 122.58 49.62 4.18
L4 8.16 121.91 53.24 4.19 30.91 0.28
L5 7.34 107.95 56.64 0.35
L6 8.37 123.69 51.65
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Indeed, three linker peaks (N273, L4, L5) display grossly
altered relaxation values, and particularly 15N-1H NOEs that
are sizably smaller than expected (0.25, 0.28, and 0.35
respectively; Table 1). This is another indication that the linker
is at least partially involved in some fast conformational
rearrangement, consistent with a sizable degree of reciprocal
mobility of the two domains. Incidentally, similar NOE values
were observed in the linker region of calmodulin, a two-domain
protein known to sample an extremely large conformational
space,43,45,50,88 and more recently in the two-domain xylanase
Cex.89 All R1 and R2 data on FL-MMP-12 and on its isolated
CAT and HPX domains, together with NOE data, are reported
in the Supporting Information (Table S7).
Residual Dipolar Couplings. Residual dipolar couplings
(RDC) in the presence of the external orienting device C12E5/
hexanol56 have been measured. They can be fitted very well to
the structures of the two isolated domains (Figure 4A,B)
separately, but with sensibly different orientation tensor values.
The data are, instead, in striking disagreement with the solid
state X-ray structure (Figure 4C). Figure 4D shows that the
agreement is modest also for any of the four rigid two-domain
structures that can be obtained by fitting both domains to a single
orientation tensor. None of these four structures bears a
resemblance with the X-ray structure in terms of relative domain
orientation (Figure S2, Supporting Information). These structures
are also different from any other X-ray structure of FL-MMPs.
On this basis, and on the basis of the relaxation data, these
solutions are discarded.
SAXS Experiments. The processed X-ray scattering pattern
from FL-MMP-12 presented in Figure 5 yields a molar mass
estimate of 40 ( 4 kDa, compatible with that calculated from
the sequence (42.5 kDa), indicating that the protein is mono-
meric in solution. The experimental radius of gyration Rg and
maximum size Dmax are 31 ( 1 Å and 110 ( 10 Å, respectively.
These values significantly exceed the parameters calculated from
the X-ray structure of FL-MMP-1 (Rg ) 25 Å, Dmax ) 85 Å),
while they are in better agreement with those computed from
the less compact X-ray structure of FL-MMP-12 determined in
the present study (Rg ) 29 Å, Dmax ) 95 Å). Moreover, the
scattering pattern calculated from the FL-MMP-1 model using
CRYSOL78 fails to fit the experimental data (discrepancy  )
5.8, curve 2 in Figure 5).
The scattering curve computed from the present FL-MMP-
12 structure displays a much better agreement to the experiment
( ) 2.5, curve 3 in Figure 5), but still displays some systematic
deviations. For flexible MMP-12, neither individual models, nor
averaging over the random pool allowed one to fit the SAXS
data. The representative ensembles selected to fit the data give
information about the preferable conformations of the protein.
Given the potential conformational flexibility of MMP-12 in
solution suggested by the NMR data, an alternative analysis
approach was applied, allowing for the coexistence of multiple
protein configurations. A large number of models was generated
(88) Bertini, I.; Del Bianco, C.; Gelis, I.; Katsaros, N.; Luchinat, C.; Parigi,
G.; Peana, M.; Provenzani, A.; Zoroddu, M. A. Proc. Natl. Acad.
Sci. U.S.A. 2004, 101, 6841–6846.
(89) Poon, D. K. Y.; Withers, S. G.; McIntosh, L. P. J. Biol. Chem. 2007,
282, 2091–2100.
Figure 3. Calculated (grey bars) and experimental (filled circles) backbone 15NH R1 (A, B) and R2 (C, D) values for the isolated CAT and HPX domains
(A, C) and for the full-length protein (B, D). Although the agreement between experimental and calculated R1 and R2 values for the isolated domains is
excellent, for the full-length protein the experimental R1 values are sizably larger (B) and the R2 values sizably smaller (D) than the ones calculated for the
rigid X-ray structure. Experimental NOE values for the full-length protein (E).
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obtained by the linker randomizations representing possible
conformations of MMP-12 in solution. None of these random
models yielded a computed scattering in agreement with the
experimental data. This was not unexpected, as SAXS “sees”
the conformational and orientational average over the large
(approx. 1016) ensemble of protein molecules in the illuminated
specimen volume. A simple average intensity of the generated
pool also did not agree with the experiment, suggesting a
nonrandom configuration of the linker in MMP-12. To assess
the preferable conformations in solution, the EOM method79
was used. Given a representative pool of (random) structures,
the method employs a genetic algorithm to select the ensembles
from this pool that best fit the experimental data, as explained
in materials and methods. Several EOM runs yielded reproduc-
ible ensembles neatly fitting the experimental data with dis-
crepancy  in the range 1.1-1.3, and a typical fit provided by
the ensemble selected by EOM is given in Figure 5, curve 4.
All the fits from different EOM runs are graphically indis-
tinguishable from curve 4 in Figure 5.
The Rg distributions of the particles in the initial pool and
in the selected ensembles are compared in the insert to Figure
5. The former distribution is rather broad, and covers the Rg
range from about 23 to 50 Å, corresponding to extremely
compact and completely extended domain configurations,
respectively. In contrast, the Rg distribution of the selected
ensembles displays a relatively sharp peak around Rg ) 28-29
Å, including about 55% of the particles in the selected
ensembles. Visual inspection of the models in the peak indicates,
not unexpectedly, that they have a shape similar to that of the
MMP-12 structure in the crystal (although with varying inter-
domain orientations). In contrast, not a single structure with Rg
< 27 Å was selected in multiple EOM reconstructions,
indicating that models similar to the crystal structure of FL-
MMP-1 were never present. These results indicate that the
present crystal structure of FL-MMP-12 may be significantly
present also in solution, but also that the protein experiences
noticeable conformational flexibility, as revealed by the presence
of a more or less uniform distribution of particles in the range
between Rg ) 30 and 50 Å and of a significant spike, which
was always observed for the most extended particles (Figure 5,
insert). We also tried to explore the possibility of a two-state
exchange situation allowing for only two conformations in the
mixture. The two-state fits were however always poorer than
those from twenty-state EOM populations. In particular, by
fixing the first state to be the crystal structure and allowing EOM
to select the second state, discrepancies not better than 1.5-1.6
could be obtained. These results suggest that MMP12 adopts a
manifold of conformations in solution, in full agreement with
NMR observations.
Concluding Remarks and Biological Implications
The present data demonstrate that full-length MMP-12 shows
relative mobility of its catalytic and hemopexin domains. The
observation of R1 and R2 values intermediate between those of
the isolated domains and those expected for any rigid structure
of the full-length protein is particularly striking in this respect.
Figure 4. Best fit vs experimental 900 MHz RDC values for the NNGH-inhibited, cadmium(II)-substituted Phe171Asp/Glu219Ala double mutant of FL-
MMP-12 in a binary mixture of C12E5 (penta-ethyleneglycol dodecyl ether) and neat n-hexanol. The separate fits for the CAT and the HPX domains and the
best fit orientation tensor values are shown in A and B respectively. The poor global fit assuming the rigid X-ray structure is shown in C, and that obtained
by best fitting the reciprocal orientation of the two domains to the RDC values is shown in D. In all panels, triangles refer to the CAT and filled circles refer
to the HPX domain.
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Indeed, even in the case of calmodulin, the two-domain protein
that constitutes a paradigmatic example of large interdomain
mobility,43,45,90,91 the R1 and R2 values are only modestly
different from what expected for a rigid structure.45,90 Appar-
ently, in the case of FL-MMP-12 the reorientation of the
backbone NH vectors with respect to the magnetic field occurs
on a time scale that is faster than the rotational time of the whole
molecule, whereas in calmodulin it is of the same order.45,90
Conversely, the amplitude of the motion is probably lower for
FL-MMP-12 than it is for calmodulin, as judged from the SAXS
data that suggest that the molecules spend about half of the
time in a conformation that is more or less as compact as the
solid state structure. A similar behavior is probably experienced
by the two-domain protein xylanase Cex, whose flexibility has
been recently demonstrated.89
The present data are a significant example of the synergy
between NMR and SAXS techniques.92–96 NMR provides
evidence of conformational freedom and of the time scale,
whereas SAXS provides insight into the types and variety of
the sampled conformations. About half of the conformations
that are likely to be experienced by FL-MMP-12 in solution
are as compact as the solid state structure but with different
relative orientations of the two domains, while another half a
re more extended, and some even highly extended. In this
respect the X-ray structure does not provide meaningful
information on the conformation of the protein in solution.
Relative mobility of the CAT and HPX domains has been
recently suggested for MMP-9, where the two domains are
separated by the OG domain.97 In the case of MMP-9 it has
been argued26 that the long and flexible OG domain may
mediate protein-substrate interactions. Independent domain
movements might even mediate enzyme translocation on a
collagen fibril.98,99 Another interesting possibility is that domain
flexibility can mediate the activation of the enzyme and the
cleavage of the pro-domain by promoting long-range confor-
mational transitions induced by the binding of the activator
proteins.100 It is possible that MMP-12 can be representative
of all other MMPs where the two domains are connected by a
short linker rather than by a long one (Figure 6). However, this
has to be demonstrated for those cases in which the contact
area between the CAT and HPX domains is much larger than
in the present case. Notably, the possibility of reorienting the
hemopexin with respect to the catalytic domain during catalysis
has been often invoked to rationalize the fact that, for collage-
nases (MMP-1, MMP8, and MMP-13), the catalytic domain
alone is not able to attack collagen, whereas the full-length
protein does.18,19
On the contrary, noncollagenase MMPs such as MMP-2 and
MMP-12 do not degrade the native triple helix collagen. The
(90) Wang, T. Z.; Frederick, K. K.; Igumenova, T. I.; Wand, A. J.;
Zuiderweg, E. R. P. J. Am. Chem. Soc. 2005, 127, 828–829.
(91) Bertini, I.; Gupta, Y. K.; Luchinat, C.; Parigi, G.; Peana, M.; Sgheri,
L.; Yuan, J. J. Am. Chem. Soc. 2007, 129, 12786–12794.
(92) Mattinen, M. L.; Paakkonen, K.; Ikonen, T.; Craven, J.; Drakenberg,
T.; Serimaa, R.; Waltho, J.; Annila, A. Biophys. J. 2002, 83, 1177–
1183.
(93) Perry, A.; Tambyrajah, W.; Grossmann, J. G.; Lian, L. Y.; Scrutton,
N. S. Biochemistry 2004, 43, 3167–3182.
(94) Grishaev, A.; Wu, J.; Trewhella, J.; Bax, A. J. Am. Chem. Soc. 2005,
127, 16621–16628.
(95) Marino, M.; Zou, P. J.; Svergun, D.; Garcia, P.; Edlich, C.; Simon,
B.; Wilmanns, M.; Muhle-Gol, C.; Mayans, O. Structure 2006, 14,
1437–1447.
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Figure 5. Experimental X-ray scattering from the NNGH-inhibited,
cadmium(II)-substituted Phe171Asp/Glu219Ala double mutant of FL-MMP-
12, and scattering from the models. (1) experimental data with error bars;
(2-3) computed scattering from the crystallographic models of FL-MMP-1
and FL-MMP-12, respectively; (4) a typical fit by the selected ensemble of
structures. The logarithm of the scattering intensity is plotted against the
momentum transfer. Insert: the frequency of the models with the given Rg
in the initial pool of structures with randomized interdomain linkers (blue
broken line) and in the selected ensembles (red solid line); the latter
distribution is obtained by the averaging of several EOM runs. Both Rg
distributions are normalized to the integral value of unity.
Figure 6. Linker lengths in matrix metalloproteinases. Arrows indicate
MMPs for which interdomain mobility has been demonstrated (26 and
present work).
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real function of these noncollagenase proteins is still unknown.
MMP-2 is able to degrade gelatin, a product of partial hydrolysis
of collagen, and MMP-12 elastin, but we do not know if these
are their real physiological roles. For MMP-12 it has been
reported that the catalytic domain alone is able to degrade elastin
even without the hemopexin domain. However, if during
evolution the hemopexin domain has been maintained in spite
of selective pressure, it is difficult to believe that it is useless.
In this respect, the present discovery of relative mobility of the
two domains in MMP-12 might be important for this still
unknown function.
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Complementary results :  
 
 
Pseudo Contact Shifts observed in presence of Cobalt on MMP12 
 
 
Catalytic domain contains a zinc metal ion in its active site. This zinc ion can be 
substituted by a paramagnetic ion such as cobalt without changing the protein structure for 
structural studies. From the catalytic domain containing the paramagnetic ion, 59 significant 
PCS were found (table 1). Considering the hypothesis of a rigid FL-MMP1 protein, simulated 
PCS on HPX domain from FL-MMP1 X-ray structure were calculated. However, none of 
these PCS were observed experimentally. As a result, HPX domain is probably moving 
respect with the CAT domain which contains the metal ion. 
 
 
 
num res  HN  N 
 
110 ARG  0.14  0.17 
113 TYR  0.20  0.31 
114 ILE  0.24  0.27 
115 THR  0.17  0.15 
116 TYR  0.16  0.20 
119 ASN -0.09 -0.03 
120 ASN -0.11 -0.26 
121 TYR -0.14 -0.24 
126 ASN -0.09 -0.07 
127 ARG -0.07 -0.01 
129 ASP -0.05 -0.02 
130 VAL -0.04 -0.16 
133 ALA  0.05  0.06 
134 ILE  0.11  0.16 
138 PHE  0.58  0.72 
141 TRP  0.77  1.03 
142 SER  0.62  0.58 
143 ASN  0.45  0.49 
144 VAL  0.47  0.43 
145 THR  0.38  0.26 
150 SER  0.22  0.13 
151 LYS  0.14  0.26 
157 ALA -0.03 -0.03 
158 ASP  0.07  0.02 
162 VAL -0.34 -0.37 
163 PHE -0.20 -0.21 
164 ALA -0.32 -0.73 
165 ARG -0.22 -0.27 
169 GLY -0.35 -0.31 
176 GLY -0.05 -0.04 
 
num res  HN  N 
 
178 GLY -0.11 -0.04 
179 GLY  0.17  0.21 
188 GLY -0.03 -0.22 
189 SER -0.20 -0.17 
190 GLY -0.09 -0.19 
191 ILE -0.25 -0.37 
192 GLY -0.22 -0.19 
201 GLU -0.38 -0.57 
203 TRP -0.42 -0.47 
204 THR -0.36 -0.35 
205 THR -0.15 -0.11 
206 HIS -0.22 -0.14 
209 GLY -0.26 -0.18 
210 THR -0.16 -0.32 
212 LEU -0.30 -0.36 
213 PHE -0.18 -0.28 
214 LEU -0.22 -0.24 
227 GLY  0.45  0.50 
231 ASP -0.87 -0.64 
234 ALA -0.15 -0.38 
241 LYS -1.26 -1.23 
243 VAL -0.28 -0.16 
248 PHE  0.08  0.05 
249 ARG  0.13  0.18 
251 SER  0.36  0.29 
257 GLY  0.24  0.13 
260 SER  0.20  0.18 
261 LEU  0.26  0.22 
263 GLY  0.21  0.14
 
 
Table 1. Pseudo contact shift observed from the CAT domain of FL-MMP12 (in ppm) 
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The presence of extensive reciprocal conformational freedom
between the catalytic and the hemopexin-like domains of full-
lengthmatrixmetalloproteinase-1 (MMP-1) is demonstrated by
NMRand small angle x-ray scattering experiments. This finding
is discussed in relation to the essentiality of the hemopexin-like
domain for the collagenolytic activity ofMMP-1.The conforma-
tional freedom experienced by the present system, having the
shortest linker between the two domains, when compared with
similar findings onMMP-12 andMMP-9 having longer and the
longest linker within the family, respectively, suggests this type
of conformational freedomtobe a general property of allMMPs.
Matrix metalloproteinases (MMP)2 are extracellular hydro-
lytic enzymes involved in a variety of processes including con-
nective tissue cleavage and remodeling (1–3). All 23 members
of the family are able to cleave simple peptides derived from
connective tissue components such as collagen, gelatin, elastin,
etc. A subset of MMPs is able to hydrolyze more resistant pol-
ymeric substrates, such as cross-linked elastin, and partially
degraded collagen forms, such as gelatin and type IV collagens
(4). Intact triple helical type I–III collagen is only attacked by
collagenases MMP-1, MMP-8, and MMP-13 and by MMP-2
and MMP-14 (5–12). Although the detailed mechanism of
cleavage of single chain peptides by MMP has been largely elu-
cidated (13–19), little is known about the process of hydrolysis
of triple helical collagen. In fact, triple helical collagen cannot
be accommodated in the substrate-binding groove of the cata-
lytic site of MMPs (9).
All MMPs (but MMP-7) in their active form are constituted
by a catalytic domain (CAT) and a hemopexin-like domain
(HPX) (20–22). The CAT domain contains two zinc ions and
one to three calcium ions. One zinc ion is at the catalytic site
and is responsible for the activity, whereas the other metal ions
have structural roles. The isolated CAT domains retain full cat-
alytic activity toward simple peptides and single chain poly-
meric substrates such as elastin, whereas hydrolysis of triple
helical collagen also requires the presence of the HPX domain
(9, 23–25). It has been shown that the isolated CAT domain
regains a small fraction of the activity of the full-length (FL)
protein when high amounts of either inactivated full-length
proteins or isolated HPX domains are added to the assay solu-
tion (9). Finally, it has been shown that the presence of theHPX
domain alone alters the CD spectrum of triple helical collagen
in a way that suggests its partial unwinding (26, 27). It is tempt-
ing to speculate that full-length collagenases attack collagen by
first locally unwinding the triple helical structure with the help
of the HPX domain and then cleaving the resulting, exposed,
single filaments (9, 28).
Until 2007, three-dimensional structures of full-length
MMPs had been reported only for collagenaseMMP-1 (29–31)
and gelatinase MMP-2 (32). The structures of the two proteins
are very similar and show a compact arrangement of the two
domains, which are connected by a short linker (14 and 20
amino acids, respectively). It is difficult to envisage that rigid
and compact molecules of this type can interact with triple
helical collagen in a way that can lead to first unwinding and
then cleavage of individual filaments. It has been recently sug-
gested that such concerted action could occur much more eas-
ily if the two domains could enjoy at least a partial conforma-
tional independence (9). Slight differences in the reciprocal
orientation of the CAT and HPX domains of MMP-1 in the
presence (29) and absence (30, 31) of the prodomain were
indeed taken as a hint that the two domains could experience
relative mobility (29).
Two recent solution studies have shown that conformational
independence is indeed occurring in gelatinase MMP-9 (33)
and elastase MMP-12 (34), whereas the x-ray structure of the
latter (34) is only slightly less compact than those of MMP-1
(29–31) and MMP-2 (32). Among MMPs, MMP-9 features an
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exceptionally long linker (68 amino acid) (33, 35), which in fact
constitutes a small domain by itself (the O-glycosylated
domain) (33), and therefore, this inspiring observation can
hardly be taken as evidence that conformational freedom is a
general characteristic of the two-domainMMPs. MMP-12 fea-
tures a much more normal 16-amino acid linker, thereby mak-
ing more probable a general functional role for this conforma-
tional freedom (34). However, both MMP-9 and MMP-12
retain their full catalytic activity against their substrates even
when deprived of the HPX domain (9). Therefore, the question
remains of whether conformational freedom is also a required
characteristic for thoseMMPs that are only active as full-length
proteins, i.e. collagenases. Interestingly, the three collagenases
(MMP-1, MMP-8, and MMP-13) have the shortest linker (14
amino acids) among all MMPs. Demonstrating or negating the
presence of conformational freedom in one of these collag-
enases would therefore constitute a significant step forward to
formulate mechanistic hypotheses on their collagenolytic
activity.
Our recent studies on MMP-12 in solution (34) have shown
that a combination of NMR relaxation studies and small angle
x-ray scattering (SAXS) is enough to show the presence and the
extent of the relative conformational freedom of the two
domains of MMPs. Here we apply the same strategy to full-
length MMP-1 and show that sizable conformational freedom
is indeed experienced even by this prototypical collagenase,
although somewhat less pronounced than that observed for
MMP-12.
EXPERIMENTAL PROCEDURES
Preparation of Protein Samples—The cDNA encoding the
sequence (Asn-106–Asn-469) of the MMP-1 full-length pro-
tein was amplified from TrueClone cDNA (OriGene) by PCR
and cloned into the pET21 (Novagen) expression vector using
NdeI and XhoI (New England Biolabs) as restriction enzymes.
One additional methionine at position 105 was present in the
final expression product. The recombinant vector was trans-
formed into Escherichia coli strain BL21(DE3) CodonPlus RIPL
(Stratagene), and colonies were selected for ampicillin and
chloramphenicol resistance. The bacteria were grown in 2YT
medium. When a cell density corresponding to 0.6 A was
reached, the expression of the protein was induced by adding
0.5 mM isopropyl--D-thiogalactoside, and the incubation at
37 °C was continued for another 5 h. The full-length MMP-1
precipitated in the inclusion bodies, and these were solubilized,
after lysis of the cells, in a solution of 8 M urea, 20 mM dithio-
threitol, and 20mMTris-HCl, (pH 8.2). The protein was diluted
with a buffer containing 6 M urea, 10 mM CaCl2, 0.1 mM ZnCl2,
20mM cystamine, 20mMTris-HCl (pH 8) and refolded by using
a multistep dialysis against solutions containing 50 mM Tris-
HCl (pH 8), 4 M urea, 10mMCaCl2, 0.1mMZnCl2, 5mM-mer-
captoethanol, 1 mM 2-hydroxyethyl disulfide, then against a
solution containing 50 mM Tris-HCl (pH 7.2), 2 M urea, 10 mM
CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl, and then against the same
solution without urea. The protein was purified by size-exclu-
sion chromatography on the HiLoad 26/60 Superdex 75 pg
(Amersham Biosciences). For expression of 15N- and 13C-en-
riched FL-MMP-1, the bacteria were grown in minimal
medium containing 15N-enriched (NH4)2SO4 and 13C-en-
riched glucose (Cambridge Isotope Laboratories). The result-
ing inclusion bodies were solubilized in 8 M urea, 20 mM Tris-
HCl (pH8), 20mMdithiothreitol. Proteinmolecular weight and
purity were checked on a 17% gel by SDS-PAGE and by mass
spectroscopy (matrix-assisted laser desorption). The E219A
mutant of FL-MMP-1 was produced using the QuikChange
site-directed mutagenesis kit (Qiagen), and the expression and
purification of the protein and of its 15N- and 13C-15N-enriched
versions were completed using the same procedure described
above. Samples of 2H-13C-15N-enriched full-length human
MMP-1 protein were obtained by adapting E. coli cells in
mediumwith different percentages of deuteriumuntil reaching
100%, and then growing the cells inOD2 Silantesmedia carbon,
deuterium, nitrogen (CDN). Samples of cadmium(II)-substi-
tuted FL-MMP-1 protein were prepared by exhaustive dialysis
against a buffer containing 20 mM Tris, pH 7.2, 10 mM CaCl2,
0.3 MNaCl, 0.2 M acetohydroxamic acid, and 0.3mMCdCl2 (36).
Equimolar concentrations ofN-isobutyl-N-[4-methoxyphenyl-
sulfonyl] glycyl hydroxamic acid (NNGH) were added to the
samples to further increase the protein stability. The cDNA
encoding for the HPX domain (Thr-274–Asn-469) was gener-
ated by polymerase chain reaction and cloned into pET21a
using NdeI and XhoI as restriction enzymes. The expression
vector was then transformed into competent E. coli BL21(DE3)
CodonPlus RIPL strain, and the colonies were selected for
ampicillin and chloramphenicol resistance. Protein refolding
both for non-enriched samples and for 13C- and/or 15N-en-
riched samples was carried out by using the same protocols
described previously for the preparation of FL-MMP-1 sam-
ples. Samples of the zinc(II) catalytic domain (Asn-106–Gly-
261, E219A inactive mutant) were prepared as described previ-
ously (37).
NMR Measurements and Protein Assignment—The experi-
ments for the protein assignment and mobility measurements
of the isolated domains (CAT and HPX) were performed on
protein samples at concentrations ranging between 0.3 and 0.7
mM (pH 7.2). For FL-MMP-1, all NMR experiments were per-
formed on samples at a concentration of 0.3mM (pH 7.2). NMR
experiments were performed at 298 and 306 K and acquired on
Bruker AVANCE 900, AVANCE 800, AVANCE 700, AVANCE
600, and DRX 500 spectrometers equipped with triple reso-
nance cryo-probes. All spectra were processed with the Bruker
TOPSPIN software packages and analyzed by the program
CARA (Computer Aided Resonance Assignment, ETHZu¨rich)
(38)). The backbone resonance assignment of HPX domainwas
obtained by the analysis of HNCA, HNCACB, and CBCA-
(CO)NH spectra performed at 500 and 900 MHz, whereas the
assignment of the 2H-, 15N-, and 13C-enriched FL-MMP-1 was
obtained by the analysis TROSY-HNCA, TROSY-HNCACB
TROSY-HNCOCACB performed on an 800-MHz spectrome-
ter. The obtained assignments are reported in supplemental
Table S1 for the full-length protein, in supplemental Table S2
for the catalytic domain, and in supplemental Table S3 for the
hemopexin-like domain.
The protein assignment and the mobility measurements on
FL-MMP-1 were performed on the NNGH-inhibited, E219A
mutant, due to its high stability to the self-hydrolysis. Mobility
Interdomain Flexibility in Full-lengthMMP-1
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measurements on the catalytic domain were performed on the
NNGH-inhibited form of the protein.
R1, R2, and NOE Measurements—The experiments for the
determination of 15N longitudinal and transverse relaxation
rates and 1H-15NNOEwere recorded at 306 K and 700MHz on
15N-enriched samples. The 15N longitudinal relaxation rates
(R1) were measured using a sequence modified to remove cross
correlation effects during the relaxation delay (39). Inversion
recovery times ranging between 2.5 and 3000ms, with a recycle
delay of 3.5 s, were used for the experiments. The 15N trans-
verse relaxation rates (R2) were measured using a Carr-Purcell-
Meiboom-Gill (CPMG) sequence (39, 40) with delays ranging
between 8.5 and 237.4ms for theCATdomain, between 8.5 and
203.5ms for theHPXdomain, and finally between 8.5 and 135.7
ms for the FL-MMP-1 proteinwith a refocusing delay of 450s.
The relaxation data are reported in supplemental Table S4. R1
and R2 data measured on the full-length protein were found
nosier and less uniform with respect to those of the single cat-
alytic and hemopexin-like domains. This is related to the over-
lap of the signals in such a large protein and to the relative low
solubility of the full-length construct.
Paramagnetic Relaxation Enhancement Measurements—
The paramagnetic relaxation enhancements of the backbone
NH protons were obtained by adding a stock water solution (50
mM) of Gd(DTPABMA) to a solution of FL-MMP-1 (200 M
protein in a buffer containing 20mMTris, pH 7.2, 10mMCaCl2,
0.3 MNaCl, 0.2 M acetohydroxamic acid, 1mMZnCl2, and 3mM
NNGH) up a final concentration of 1.4 mM. NH proton longi-
tudinal relaxation times were measured through an inversion
recovery HSQC sequence obtained by introducing a 1H 180°-
pulse followed by a variable delay  in front of a standard
1H-15N-HSQC sequence. T1 values were obtained from a series
of spectra obtained with the following  values (in ms): 20, 50,
80, 100, 200, 400, 500, 800, 1000, 1400, 2000, 2200, 3000, and
3500. The measurement was repeated on the free protein and
after each addition of the paramagnetic complex. Peak volumes
as a function of the  value were fitted to a monoexponential
recovery with a three-parameter fit.
SAXS Experiments and Data Analysis—Small Angle x-ray
scattering data from solutions of the NNGH-inhibited, cadmi-
um(II)-substituted E219Amutant of FL-MMP-1were collected
on the X33 beamline of the EuropeanMolecular Biology Labo-
ratory (EMBL) (Deutsches Elektronen Synchrotron (DESY),
Hamburg) (41) using aMAR345 image plate detector. The scat-
tering patterns were measured with a 2-min exposure time for
several solute concentrations in the range from 0.8 to 8.3
mg/ml. To check for radiation damage, two 2-min exposures
were compared, and no changes were detected. Using the sam-
ple-detector distance of 2.7m, a range ofmomentum transfer of
0.01 s 0.5Å1was covered (s 4 sin()/, where 2  is the
scattering angle and   1.5 Å is the x-ray wavelength). The
data were processed using standard procedures and extrapo-
lated to infinite dilution using the program PRIMUS (42). The
forward scattering, I(0), and the radius of gyration, Rg, were
evaluated using the Guinier approximation (43), assuming that
at very small angles (s 1.3/Rg), the intensity is represented as
I(s)  I(0)exp((s2Rg2)/3). The values of I(0) and Rg, as well as
the maximum dimension, Dmax, and the interatomic distance
distribution functions, (p(r)), were also computed using the
program GNOM (44). The scattering from the high resolution
models was computed using the program CRYSOL (45). Given
the atomic coordinates, the program predicts the theoretical
scattering pattern and fits the experimental intensity by adjust-
ing the excluded volume of the particle and the contrast of the
hydration layer to minimize the discrepancy
2 
1
N 	 1
j
 Iexpsj	 cIcalcsj
sj 
2
where N is the number of experimental points, c is a scaling
factor, Iexp(sj) and Icalc(sj) are the experimental and calculated
intensities, respectively, and 
(sj) is the experimental error at
the momentum transfer sj. To assess the conformational varia-
bility ofMMP-1, an ensemble optimizationmethod (EOM)was
used (46), allowing for the coexistence of multiple conforma-
tions in solution. About 10,000 randomized models of
FL-MMP-1 differing by the conformation of the interdomain
linker were generated, and their scattering patterns were com-
puted using the program RanCh of the EOM package. These
models formed a pool of possible structures for which the scat-
tering patterns were computed by CRYSOL. The EOM pro-
gram employs a genetic algorithm to select from the pool a
small number (usually about 20) of representative structures
such that the average scattering from the selected ensemble fits
the experimental data. Multiple runs of EOM were performed,
and the results were averaged to provide quantitative informa-
tion about the flexibility of the protein in solution (in particular,
about the Rg distribution in the selected ensembles).
RESULTS ANDDISCUSSION
Full-length human MMP-1 and its CAT-(106–261) and
HPX-(274–469) domains were expressed as described under
“Experimental Procedures.” In both FL-MMP-1 and its CAT
domain, an E219A mutation was introduced. Such mutation
ensures a dramatic lowering of the catalytic activity (13, 19),
which is needed in the present investigation to prevent self-
hydrolysis. In addition, the strong active site-directed hydrox-
amic inhibitor NNGH (15) was always added. Finally, when
needed, cadmium(II) was substituted for zinc(II) in the catalytic
site to further reduce the residual activity as it was already
shown for FL-MMP-12 and its CAT domain (34). 15N-, 13C-
15N-, and 2H-13C-15N-enriched samples were used for NMR
investigations. The samples were stable under the NMR exper-
imental conditions for severalmonths. For the presentmobility
studies, the assignment of the 1H-15N HSQC spectra of the
three constructs was needed. The two-dimensional and three-
dimensional experiments that were used for this purpose are
described under “Experimental Procedures.” The 1H-15N-
TROSY-HSQC spectra of the three constructs, acquired at 306
K, are superimposed in Fig. 1. The spectral quality, especially
for the FL and HPX domains, is better at 306 K than at 298 K.
This prompted us to perform all subsequent work at 306 K.
Moreover, the latter temperature is closer to the physiological
value of 310 K, so the resulting mobility data will be more
meaningful.
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Analysis of the Chemical Shift Differences between
FL-MMP-1 and Its Isolated Domains—For clarity, the spec-
trum of the full-length protein in Fig. 1 is from a triply labeled
2H, 13C, 15N sample, which displays much sharper lines. From
visual inspection, it already appears that the FL spectrum is
largely the superposition of the CAT and HPX spectra as the
majority of the signals in the FL spectrum overlap with either a
CATor anHPX signal. There are a number of additional signals
in the FL spectrum that are attributed to the portion of the
interdomain linker (262–275), which is missing in both the
CAT and the HPX isolated domains. Furthermore, a few more
signals undergo a modest shift on passing from the isolated
domains to the FL protein. These signals could arise from con-
tacts between each domain and the linker, contacts between the
two domains, or both. In the latter two cases, evidence of inter-
domain contacts would imply that either the FL length struc-
ture is rigid or, that even in the presence of conformational
freedom, “closed” compact structures contribute to the overall
description of the molecule.
The assignments for the three constructs are reported in sup-
plemental Tables S1–S3. From a comparison of the 1H and 15N
chemical shifts in the 1H-15N-TROSY-HSQC spectra for the FL
and the two isolated domains, a mean shift difference plot (47)
was generated (Fig. 2). It appears that the number of peaks
experiencing chemical shift differences is rather limited and
clustered in the 112–115, 139–149, 244–261, and 277–316
regions. Fig. 3A shows the experimental x-ray three-dimen-
sional structure of the FL protein (30) as well as of its isolated
domains and linker, exploded to show the regions of contact of
the CAT and HPX domains with one another (green) and with
the linker (red). Fig. 3B shows the same structures, where the
intensity of the colored residues correlates with the size of the
mean shift difference experienced by the FL with respect to the
isolated domains. It is apparent that most of the chemical shift
differences arise from contacts of the CAT and HPX domains
with the linker, and very few and with relatively low values are
attributable to direct interdomain contacts. It can be concluded
that it is likely that the compact structure observed in the x-ray
structure of the active FL protein is in equilibrium with other
more open structures in solution.
Relaxation Measurements—Measurements of longitudinal
(R1) and transverse (R2) relaxation rates of backbone amide
nitrogens at 700-MHz 1H Larmor frequency and 306 K have
been performed on 15N-enriched samples of both the isolated
CAT domains and the isolated HPX domains as well as of FL-
MMP-1. Estimates of R1 and R2 values for these three con-
structs under the chosen experimental conditions of magnetic
FIGURE 1. 1H-15N-TROSY-HSQC spectra of FL-MMP-1 (2H-13C-15N-labeled
NNGH-inhibited, E219A mutant) (black), superimposed with CAT-
MMP-1 (15N-labeledNNGH-inhibited,E219Amutant) (red) andwithHPX-
MMP-1 (15N-labeled) (green).
FIGURE 2. Plot of mean shift differences experienced by FL MMP-1 with
respect to the isolated CAT or HPX domains. avg. indicates average.
FIGURE 3. Mapping of the residues at the interface between the CAT
domain, the linker and the HPX domain. A, exploded space fill representa-
tion of the experimental three-dimensional x-ray structure of FL-MMP-1 (24)
where the regions of contact between CAT and HPX domains are colored in
green and the regions of contact of either of the two domains with the linker
are colored in red. The arrangement of the two domains and the linker in the
crystal structure is visible in the background. B, the same exploded space fill
representation where the intensity of the colored residues, from yellow to
dark-orange, correlateswith the size of themean shift difference experienced
by FL-MMP-1 with respect to the isolated domains. The similarity of the areas
experiencing shift changes due to the lack of the linker in Bwith the contact
areas in red, but not with those in green in A, show that most of the shift
perturbation arises from the contacts with the linker and not between the
two domains.
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field and temperature were obtained using the program
HydroNMR (48), and the three-dimensional structures of the
constructs were taken from the x-ray structure of the FL pro-
tein (30). The experimental and theoreticalR1 andR2 values are
reported in Fig. 4, A–E), together with the corresponding data
for MMP-12 (Fig. 4, F–L) (34) at the same field and 298 K, for
comparison purposes. If the experimental data do not agree
with the calculated data, outside the experimental error, then
they are inconsistent with the structural model. As far as the
catalytic domain is concerned (left side), it is clear that the R1
and R2 data for the isolated domain are in excellent agreement
with the theoretical expectations. On the contrary, the experi-
mental R1 data for the CAT domain, when it is part of the FL
protein, are sizably higher, and the R2 data are sizably lower,
with respect to the theoretical values for a rigid FL protein.
Higher R1 and lower R2 values, taken together, indicate that the
two domains behave as if they belonged to a lower molecular
weight protein; that is, the CAT domain possesses some degree
ofmotion, which is independent of themotion of the FL protein
as a whole.
In principle, the same should hold for the HPX domain.
Indeed, the R1 and R2 data for the HPX domain in the full-
length protein are also higher and lower, respectively, than the
theoretical estimate, but here the difference is less marked than
for theCATdomain. A plausible explanation lies in the fact that
the R1 and R2 data for the isolatedHPX domain show the oppo-
site behavior, i.e. the R1 values are lower and the R2 values are
higher than expected. This is typically encountered in the pres-
ence of self-aggregation. The HPX domain does possess a
rather hydrophobic surface, which could allow for the existence
of a fraction of dimeric or higher order aggregation species in
solution. Partial aggregation brought about by theHPXdomain
in the FL proteinwould of course artificially attenuate the effect
of interdomain mobility on R1 and R2. The hypothesis of HPX
aggregation is easy to check by changing the protein concentra-
tion. Indeed, for isolated HPX solutions of higher concentra-
tion, the discrepancy with the calculated data sizably increases
(data not shown). In conclusion, the HPX data (i) demonstrate
the presence of aggregation but also (ii) confirm interdomain
mobility in the full-length protein, which is still apparent from
R1 and R2 data despite the attenuation of the effect due to
aggregation.
A further proof of the interdomain mobility is provided by
the very smallNOE values of four adjacent residues in the linker
region (267, 268, 270, and 271) (Fig. 4E). Comparison with the
MMP-12 data (Fig. 4, F–L), collected at lower temperature,
shows that interdomainmobility inMMP-1, although certainly
present, is less extensive than in MMP-12. This is possibly
related (i) to the shorter linker (14 versus 16 residues) and (ii) to
the more extensive interdomain contact present in the x-ray
structure of active FL-MMP-1 with respect to that observed in
the x-ray structure of MMP-12.
A Paramagnetic Probe Monitors Interdomain Surface
Exposure—Paramagnetic probes dissolved in protein solutions
have been previously used (i) to identify surface residues to help
structure determination (49–56), (ii) to determine the orienta-
tion of membrane-bound peptides on the membrane surface
(57–59), and (iii) to monitor the formation of proteinprotein
FIGURE 4.Comparison of NMR relaxation data forMMP-1 (data collected at 306 K) andMMP-12 (data collected at 298 K). The calculated (gray bars) and
experimental (filled circles) backbone 15NH R1 and R2 values for the isolated CAT and HPX domains of MMP-1 are shown in A and C, and those of MMP-12 are
shown in F and H. The 15NH R1 and R2 values for the full-length MMP-1 and MMP-12 are shown in B, D, G, and I, respectively. The experimental NOE values for
the full-length proteins are shown in E and L for MMP-1 and MMP-12, respectively. In both proteins, the agreement between experimental and calculated R1
values for the isolateddomains is excellent,whereas for the full-lengthproteins, the experimental R1 values are sizably larger (B andG) than theones calculated
for the rigid x-ray structures. R2 values (D and I) are also in good agreement if a slight tendency of the HPX domain to aggregate is taken into account. The data
comparisons are only consistent with interdomain flexibility in MMP-1, which is somewhat less extensive than in MMP-12.
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complexes by detecting residues that become shielded from the
probe upon complex formation (4, 60, 61). In analogy with the
latter strategy, we have used the gadolinium complex
Gd(DTPABMA) (57) to probe the CAT-HPX interface in the
FL protein. An inversion recovery HSQC sequence was used to
measure the R1 values of the backbone NH protons of
FL-MMP-1 in the absence (R1dia) and in the presence (R1para) of
1.4 mMGd(DTPABMA), as detailed under “Experimental Pro-
cedures.” The residues for which the relaxation rate difference
R1para  R1dia is higher than a threshold value of 0.7 s1 are
reported in supplemental Table S5. Among them, on the HPX
side, residue Leu-314 should be shielded by the CAT domain;
on the CAT side, residue Asp-231 should be shielded by the
linker, and residues Asp-245, Val-246, and Gln-247 should be
shielded by theHPXdomain. On the contrary, all of them expe-
rience paramagnetic effects particularly strong for Asp-245 (2.7
s1) and Val-246 (2.4 s1). These effects are inconsistent with
the compact x-ray structure of FL-MMP-1 and confirm that the
protein must spend a non-negligible fraction of time in an
extended conformation so that the CAT-HPX interface
becomes accessible to the probe.
SAXS Measurements—The processed x-ray scattering pat-
tern from FL-MMP-1 is shown in Fig. 5. The experimental
radius of gyration Rg is 29  1 Å. This value significantly
exceeds that calculated (Rg 25 Å) from the x-ray structure of
active FL-MMP-1 (30). Moreover, the scattering pattern calcu-
lated from the active FL-MMP-1 model using CRYSOL (45)
fails to fit the experimental data (discrepancy   4.22, Fig. 5,
curve 2). Interestingly, the fit to the FL-MMP-12model is better
(discrepancy   1.8, Fig. 5, curve 3). If a distribution of FL-
MMP-1 conformations, including compact and extended ones,
is taken into consideration, neither individual models nor aver-
aging over the random pool allowed one to fit the SAXS data
satisfactorily ( 1.9 in both cases). The representative ensem-
bles selected to fit the data give information about the prefera-
ble conformations of the protein. To assess the preferable con-
formations in solution, the EOMmethod (46)was used. Given a
representative pool of (random) structures, the method
employs a genetic algorithm to select the ensembles from this
pool that best fit the experimental data, as explained under
“Experimental Procedures.” Several EOM runs yielded repro-
ducible ensembles neatly fitting the experimental data with dis-
crepancy less than 1.2, and a typical fit provided by the ensem-
ble selected by EOM is given in Fig. 5, curve 4. All the fits from
different EOM runs are graphically indistinguishable from Fig.
5, curve 4 . TheRg distributions of the particles in the initial pool
and in the selected ensembles are compared in Fig. 5 (inset).
The former distribution is rather broad and covers the Rg range
from about 20 to 45 Å, corresponding to extremely compact
and completely extended domain configurations, respectively.
In contrast, the Rg distribution of the selected ensembles dis-
plays a relatively sharp peak around Rg  25–26 Å, including
about 70% of the particles in the selected ensembles. Visual
inspection of the models having Rg values in the peak range
indicates, not unexpectedly, that their shape is similar to that of
the FL-MMP-1 structure in the crystal (30) (although with
varying interdomain orientations).However, an extended tail at
higherRg values up to around 40Å, accounting for about 30% of
the particles, is apparent from the multiple EOM reconstruc-
tions. These results indicate that the crystallographic confor-
mation of FL-MMP-1 (30) is largely present also in solution, but
in addition, the protein experiences noticeable flexibility with a
significant amount of extended conformations in equilibrium
with the closed one(s).We also tried to explore the possibility of
a two-state exchange situation allowing for only two conforma-
tions in themixture. In such a case, two structures with an Rg of
around 25 and 32 Å are selected. It is interesting that
FL-MMP-1 (30) appears much more compact than
FL-MMP-12 (34), as shown by the comparison in Fig. 5, inset,
indicating that the two extra residues in the linker region of
FL-MMP-12 increase its flexibility.
Concluding Remarks and Biological Implications—The pres-
ent data demonstrate that FL-MMP-1 shows relative mobility
of its catalytic and hemopexin-like domains, as recently
observed for FL-MMP-12 (34). As in the latter case, the reori-
entation of the backbone NH vectors with respect to the mag-
netic field occurs on a time scale that is faster than the rota-
tional time of the whole molecule (62). The amplitude of the
motion is probably smaller for FL-MMP-1 than it is for FL-
MMP-12, as judged from the SAXS data that suggest that the
molecules spend two-thirds of the time in a conformation
that is more or less as compact as the solid state structure but
is ample enough that the residues at the interface between
FIGURE 5. Experimental x-ray scattering from the NNGH-inhibited, FL-
MMP-1 and scattering calculated from the following models: curve 1,
experimental data with error bars; curves 2 and 3, computed scattering
from the crystallographic models of FL-MMP-1 and FL-MMP-12, respec-
tively; and curve 4, a typical fit by the selected ensemble of structures.
The logarithm of the scattering intensity is plotted against the momentum
transfer. Inset, the frequency of themodelswith the given Rg in the initial pool
of structures with randomized interdomain linkers (FL-MMP-1 (blue) and FL-
MMP-12 (magenta)) and in the selected ensembles (FL-MMP-1 (red) and FL-
MMP-12 (green); the latter distribution is obtainedby the averaging of several
EOM runs. All histograms are normalized to the integral value of unity.
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the two domains are significantly exposed to a paramagnetic
probe in solution. Besides MMP-12, relative mobility of the
CAT and HPX domains has also been recently suggested for
MMP-9, where the linker between the two domains is much
longer and constitutes a domain by itself (O-glycosylated
domain) (63). In the case of MMP-9, it has been argued (33)
that the long O-glycosylated domainmay be flexible andmay
mediate protein-substrate interactions (64, 65). However,
the present finding of flexibility in FL-MMP-1 has further
biological implications because MMP-1 is a collagenase that
is able to hydrolyze intact triple helical type I–III collagen
but only in the full-length form, i.e. the presence of the HPX
domain is crucial for the function. Notably, the possibility of
reorienting the HPX with respect to the CAT domain during
catalysis has often been invoked as a means to unwind the
collagen triple helix in preparation for the catalytic cleavage
(66).
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Characterisation of the MMP-12–Elastin Adduct
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Dedicated to the Centenary of the Italian Chemical Society
MMP-12 (matrix metalloproteinase 12)is an important
protein of the MMP family.[1–4] Its substrate is elastin,[5–8]
which is composed of a cross-linked insoluble network of
polypeptide chains of tropoelastin of MW 65 kDa each.[9] In-
soluble elastin is responsible for keeping some extracellular
connective tissues elastic.
The full-length MMP-12 is made up by a catalytic (CAT)
domain and a hemopexin-like (HPX) domain. The two do-
mains have relatively large conformational freedom,[10] as
also recently found in MMP-1[11] and MMP-9.[12] The role of
the HPX domain is not certain, as the CAT domain is
always active by itself,[13] even if it may have a smaller turn-
over for some substrates.[14]
Experimental structures and models, representative of the
binding mode of peptide substrates on protein active site
are already present in the Protein Data Bank. However, the
interaction of native elastin with full length MMP-12 and its
isolated domains had not been structurally investigated so
far. Here we report a NMR study of MMP-12 with elastin.
MMP-12, with the catalytic zinc replaced by cadmium[10,15]
and with the catalytically competent Glu219 replaced by ala-
nine, is inactive[16] and allows the investigation of its interac-
tion with elastin without cleavage of the substrate. Insoluble
elastin can be made soluble by limited proteolysis[17] that
provides a mixture of cross-linked polymers of several tens
of kDa or more. The soluble mixture from bovine neck liga-
ment (elastin hereafter) is the closest viable model to native
elastin. This protein shares 76% identity (excluding long in-
sertions/deletions) with the human ortholog. The assignment
of the 13C-, 2H- and 15N-labelled full-length MMP-12 protein
is available.[10]
In the presence of elastin some 1H-15N HSQC signals are
shifted, as reported in Figure 1A. Shifted signals are ob-
served both in the CAT and HPX domains; in the former
these are more numerous and a decrease in intensity of sev-
eral signals is also observed. The spectra of the isolated
CAT domain in the presence of elastin undergo similar
shifts and intensity decreases as those observed for the full-
length protein (Figure 1B) and the isolated HPX domain
also maintains similar shifts (Figure 1C). Comparison of Fig-
ures 1B and 1C with 1A shows that both interactions are
clearly operative separately, although an overall reinforce-
ment of the interaction of the CAT domain in the full-
length protein may be noted, possibly brought about by a
cooperative behaviour of the HPX domain. A comparison
of the chemical shift changes with their signs in the full-
length protein and in the isolated domains is reported in
Supporting Information (see Figure S1). The pattern of resi-
dues shifted upon addition of elastin is largely similar in the
full length protein and in the isolated domains, but is more
pronounced in the former (Figure S2). The overall pattern is
consistent with a simultaneous interaction of both domains
with the elastin polymer, also in view of the recently report-
ed conformational flexibility of the two domains.[10] While
this finding suggests that the HPX domain may have a role
in elastin recognition, it is clear that the isolated CAT
domain is essentially able to recognise its natural substrate
by itself.
By analyzing in more detail the pattern of shifted NH
nuclei in the isolated CAT domain, it is immediately appar-
ent that the affected nuclei all belong to the active crevice
and to the internal basal layer of the catalytic domain of
MMP-12 (Figure 2).[10] These results demonstrate the occur-
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rence of a specific localised interaction of elastin with the
catalytically competent site of MMP-12 and, therefore, indi-
cate that the only relevant interaction(s) indeed concerns
recognition of the elastin cleavage site(s). This is a nice
result, although in line with expectations. Of course, the de-
tected specificity is only on the MMP-12 side and not neces-
sarily on the elastin side. Actually, there are as many as 36
cleavage sites in insoluble elastin, detected by proteolysis
and mass spectrometry,[7] and many more (86 sites) in tro-
poelastin,[19] on account of the increased number of accessi-
ble cleavage sites in the absence of cross-linking.[7,19] We
know[7] that most of the cleavage sites in elastin occur at G-
L (30 sites) and some at G-V (11 sites) and A-L (11 sites).
Selected sequences that correspond to cleavage sites that
appear in more than one peptide fragment are shown in
Table 1 for both bovine and human elastin. We calculated
the structures of the adducts between CAT MMP-12 and
each polypeptide in Table 1 by positioning the CO to be
Figure 1. Plot of the 1H-15N HSQC chemical shifts ({[(dH)
2+ (dN/5)
2]/2}1/2)[18] and normalised intensity changes per residue observed in 0.35 mm full-length
MMP-12 (A) and 0.30 mm of its isolated CAT (B) and HPX (C) domains upon addition of 1.4 mgmL1 elastin.
Figure 2. Residues of the CAT domain of MMP-12 experiencing substan-
tial NH shifts/intensity changes upon addition of elastin, highlighted on
the atomic resolution structure[25] of the protein. The dark blue spheres
indicate the NH groups of the residues at the forefront of the interaction
with elastin, while the sky blue spheres indicate nonsolvent-exposed resi-
dues in the rear b-strand that are indirectly affected by the interaction
with elastin through the hydrogen-bonding network. The grey spheres
represent the NH groups of the residues experiencing a smaller interac-
tion which is not directly connected with the main one and is not ana-
lyzed further. The side chains of the residues involved are shown as
sticks of the corresponding colors. The magenta sphere represent zinc
ions, the green ones the calcium ions.
Table 1. Selected bovine and human elastin sequences (P=4-hydroxy-
proline) that correspond to cleavage sites appearing in more than one
peptide fragment.[7] All peptides were tested using the program Had-
dock[21] for their interaction with the active residues in the CAT domain
(dark blue spheres in Figure 2), starting from 6-AA long fragments cen-
tred at the G-L, A-L or G-V cleavage sites (in bold) up to a length of 15
residues. The length of each fragment is that showing optimal Haddock
interaction parameters in each case, as judged by the best 40 structures
for each run.
1 bovine ACHTUNGTRENNUNG(43–53) FPGAGLGGLGV
human (44–53) PGAGLGALGG
2 bovine ACHTUNGTRENNUNG(64–72) KpGVGGLVG
human (64–72) KpVpGGLAG
3 bovine ACHTUNGTRENNUNG(554–563) QFRAAAGLPA
human (574–583) QLRAAAGLGA
4 bovine ACHTUNGTRENNUNG(573–581) GVPGLGVGA
human (593–601) GVPGLGVGA
5 bovine ACHTUNGTRENNUNG(628–635) GIpGGVAG
human (681–688) GIpGGVVG
6 bovine ACHTUNGTRENNUNG(649–657) KAAQFGLGG
human (703–711) KAAQFGLVG
7 bovine ACHTUNGTRENNUNG(659–668) GGLGVGGLGA
human (715–725) LGGLGVGGLGV
8 bovine ACHTUNGTRENNUNG(668–677) AVPGAVGLGG
human (724–733) GVPGVGGLGG
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cleaved (G or A) close to the metal-coordinated catalytic
water,[16,20] the hydrophobic leucine or valine side chains in
the S1’ pocket and by assuming that the MMP-12 residues
interacting with the peptide are those that experience shifts
and intensity reduction on the protein surface (dark blue
spheres in Figure 2). The program Haddock was used.[21] We
found that a sequence of 4–7 amino acids (AA) before G-L
(or G-V or A-L) and two after them are enough to justify
the NMR shifts. This finding is absolutely consistent with
the mechanism previously proposed,[16] and with the avail-
able structures and models representative of the binding
mode of the peptide substrates on the protein active
site.[20,22–24]
A representative example of a CAT–peptide complex is
shown in Figure 3. It can be noted that the peptide nicely
fits within what is known as the active site crevice and forms
a number of hydrogen-bonding interactions with it (Table
S1; see Supporting Information). There is a striking similari-
ty between the present peptide binding mode and the X-
ray-deduced structure of a 6-AA collagen-derived peptide
and its cleaved fragments bound to MMP-12 CAT domain,
strongly corroborating the present results.[20] The peptide in
Figure 3 is prolonged by a few residues in both directions to
highlight the fact that the detected interaction is not with a
small peptide but with macromolecular elastin. The hetero-
geneous composition of the elastin sample and the cross-
linked structure of the polymer prevent the identification of
longer peptides possibly able to simultaneously bind to both
the catalytic and the hemopexin domains. On the other
hand, the elastin parts responsible for the interaction with
the HPX domain are not necessarily close in sequence to
those interacting with the CAT domain and may even
belong to cross-linked stretches originated from different
tropoelastin monomers.
In conclusion, light has been shed on the recognition by
MMP-12 of its natural substrate elastin. The interaction
occurs at both the CAT and HPX sites, the former being
stronger and largely maintained in the isolated CAT
domain, consistent with the reported ability of the isolated
CAT domain to retain substantial catalytic activity. The pat-
tern of affected residues on the CAT domain very clearly
points to an extended interaction within the active site crev-
ice, involving 8–11 elastin residues. Although the structural
features of cross-linked elastin are largely unknown, it is in-
teresting to note that such extended stretches of residues, as
they appear from the present work to be necessary for a
productive interaction, are likely to be available for interac-
tion with MMP-12, because they are generally far away in
sequence from the lysines involved in cross-linking, fully
consistent with the observation that no cleavage sites are
observed in proximity of lysines.
Experimental Section
Full-length MMP-12, its catalytic domain and the hemopexin-like domain
were expressed and purified as described previously.[10,16] The replace-
ment of the catalytic zinc with the inactive cadmium ion was performed
by exhaustive dialysis against a buffer containing 20 mm Tris pH 7.2,
10 mm CaCl2, 0.15m NaCl, 0.2m acetohydroxamic acid (AHA) and
0.3 mm of CdCl2. The acetohydroxamic acid was removed with the last di-
alysis. Soluble elastin from bovine neck ligament was purchased from
Sigma–Aldrich. Lyophilised elastin was dissolved in the final buffer
(20 mm Tris pH 7.2, 10 mm CaCl2, 0.15m NaCl and 0.3 mm of CdCl2) and
extensively dialyzed before the addition to the protein solution. Soluble
elastin (0.7 mg) was added to 0.5 mL of full length MMP-12 (0.35 mm).
The same amount of soluble elastin was added to 0.5 mL of isolated cata-
lytic and hemopexin domains at a concentration of 0.3 mm. The final con-
centration of soluble elastin in solution, calculated as tropolelastin (MW
~65 KDa), was estimated to be 2.2102 mm. However, taking into ac-
count the presence of several cleavage sites in the substrate (up to 86 in
tropoelastin and up to 36 in insoluble elastin[7, 19]) the concentration of
binding sites for the catalytic domain in the samples may range from 0.8
up to 1.9 mm, that is, in large stoichiometric excess. The heterogeneous
composition of soluble elastin and the presence of several binding sites,
plasusibly with different affinities, prevent the calculation of any dissocia-
tion constant.
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3.4 Interaction between MMP1 and a collagen peptide model 
 
 
3.4.1 Interaction between FL-MMP1 and triple helical peptide (THP) 
 
 
Titration experiment were performed using a triple labelled FL-MMP1 Cadmium 
sample containing a E219A mutation by adding volumes of concentrated THP. After addition 
of THP, TROSY spectra obtained resulted in a general intensity decrease of MMP1 signals 
(figure 11). However, the main decrease was observed for the HPX domain in the region 
located between residues I290-A330. This region corresponds to a group of three beta-sheets 
and one alpha-helix located on the surface constituting one of the four-blade beta-propeller of 
the HPX motif. Residues from the CAT domain also experienced some intensity decrease : in 
particular, in the segments N171-N180 and F207-E209, for the residues H228 and G233 and 
in the segment P238-T241. These residues are located at the protein surface on the side of the 
active site. 
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Figure 11. Peaks intensity decrease of FL-MMP1 by adding unlabelled THP for HN signals on TROSY 
spectra acquired at 310K on 900 MHz spectrometer. 
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Figure 12. Peaks intensity decrease of HPX-MMP1 by adding unlabelled THP for HN signals on 
TROSY spectra acquired at 310K on 900 MHz spectrometer. 
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3.4.2 Interaction between HPX-MMP1 and THP 
 
In order to confirm the interaction between HPX domain and the THP, a similar 
titration experiment was performed using isolated HPX of MMP1 with THP (figure 12). 
Intensity decrease observed in the isolated HPX domain corresponds to the same regions as 
observed in HPX domain inside the FL protein from the previous titration (figures 11 and 12). 
By looking into details, this HPX domain region is poorly conserved among the MMP family. 
For example, by fitting together HPX domains from MMP12 and MMP1 structures, it appears 
the main MMP1 fragment M305-R313 involved this interaction has a completely different 
backbone trajectory respect with the corresponding one in MMP12. This region may be 
important for MMP1 collagenase specificity. Moreover, this HPX domain area is partially 
covered by the pro-domain in the pro-MMP1 X-ray structure. Then, MMP1 pro-domain 
function could be not only to lock the CAT domain active site but also to prevent the HPX 
domain binding to collagen. 
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Figure 13. Chemical shift changes observed on THP by adding unlabelled HPX-MMP1 for proton 
signals on TOCSY spectra acquired at 310K on 700 MHz spectrometer. An asterisk* indicates repeated amino 
acids in the central region which haven’t been assigned sequentially. 
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Figure 14. Peaks intensity decrease on THP by adding unlabelled HPX-MMP1 for proton signals on 
TROSY spectra acquired at 310K on 700 MHz spectrometer. An asterisk* indicates repeated gly, pro and hyp in 
the lateral part of the peptide. 
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Complementary 2D HH TOCSY experiments performed on THP in absence and in 
presence of HPX allowed visualising important chemical shift differences on THP proton spin 
(figure 13). Although THP is unlabelled and contains several gly, pro and hyp residues which 
cannot be assigned sequentially, other residues can be identified. Else, chemical shifts 
changes were observed for ile, ala and arg (one residue per chain) and for gln and val (two 
residues per chain). All these residues are concentrated in the central part of the (GPHyp)4-
GPQ-GIA-GQR-GVV-GLP-(GPHyp)4 peptide. In addition, a broad cluster of signals 
corresponding to prolines and hydroxyprolines spin systems didn’t experience any chemical 
shift changes after addition of the HPX domain. 
Several volumes of THP cross-peak signals well resolved on the TOCSY spectra were 
integrated on the THP alone reference spectra and in the spectra of the complex HPX-THP 
(figure 14). While for some unassigned spin systems identified as prolines, hydroxyprolines 
and glycines, the intensity ratio remained close to 1, for the other amino-acid located in the 
central region of the peptide, intensity ratio decreased between 0.8 and 0.3. The strongest 
diminutions were measured for I17 and A18.  
 
 
3.4.3 Docking calculation for hemopexin-like domain of MMP1 and THP from chemical 
shift perturbation using Haddock program 
 
The docking strategy has consisted in first considering separately HPX domain and 
CAT domain of MMP1 to interact with THP.  
For the HPX domain, active residues were selected from both chemical shift 
perturbation and solvent accessibility. The threshold for peaks intensity decrease of HPX 
domain was defined at 35% ratio I/I0 (figure 12). This value corresponds to the average value 
minus the standard deviation value. HPX domain residue accessibility was calculated from the 
MMP1 X-ray structure (accession code 2CTL). For the residue selection, threshold for solvent 
accessibility given by Naccess was set at 50%. 
Then, the following residues were selected from HPX domain : 
R291, G292, N306, Y309, E311, E313, N315, F316, S318, V319 and F320. 
 
For the THP, residues were selected in the central region on the basis of experimental 
data from 2D-TOCSY experiments (figure 13 and 14). 
Q15, I17, A18, Q20, R21, V23, V24, 
Q54, I56, A57, Q59, R60, V62, V63, 
Q93, I95, A96, Q98, R99, V101,V102  
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Figure 15. Haddock docking calculation HPX with THP with all chains selected 
 68
The results from this run of calculation provided three clusters located respectively at 
1Å, 5Å and 21 Å from the best Haddock score :  
 
Haddock Score = Evdw + 0.2 Eelec + 0.1 Eviol + Edesolv 
 
In the cluster located at 21 Å from the best model (figure 15), the HPX domain 
orientation is not compatible with the CAT domain orientation suitable for enzymatic 
cleavage on collagen. Then, this solution was discarded. From the structures on the two 
remaining clusters the contact area observed between HPX domain and THP is concentrated 
around two of the three chains forming the triple helix. From this result, the third peptidic 
chain away from the HPX domain in the two main clusters was discarded for the next 
calculation.  
 
In the following step, calculation was run using only two chains of the triple helical peptide. 
Q54, I56, A57, Q59, R60, V62, V63, 
Q93, I95, A96, Q98, R99, V101, V102 
 
The same active residues as before were selected on HPX domain. 
R291, G292, N306, Y309, E311, E313, N315, F316, S318, V319 and F320. 
 
This time, only fourteen residues are selected from the peptide which is more likely to 
interact with eleven residues from the HPX domain. 
 
 
Docking calculations HPX-THP two chains active
-100
-80
-60
-40
-20
0
0 2 4 6 8 10 12 14 16 18 20 22 24
RMSD to the best model Å
H
ad
do
ck
 s
co
re
 
(k
C
al
.m
ol
-1
)
 
 
Figure 16. Haddock docking calculation HPX with THP with two chains selected 
 
 
Here, calculation resulted in only two clusters (figure 16). HPX domain binds the THP 
at the same position in the two clusters but with two opposite orientations. Compared with the 
first calculation, the two clusters are more homogeneous. Here, the cluster closer to the best 
calculated structure is not compatible with the CAT domain orientation suitable for cleavage, 
and then this solution was also discarded. In the other hand, the cluster at 21 Å of distance to 
the best structure has a HPX domain orientation compatible with the CAT domain position 
suitable for cleavage. Moreover, the latter cluster contains more structures (27 versus 13) and 
the two clusters have a comparable Haddock score. Then, the main cluster for the HPX-THP 
complex was selected to monitor the FL-MMP1 docking to THP. 
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3.4.4 Docking calculation on catalytic domain of MMP1 and THP (Fields) using Haddock 
program 
 
Prior to describe the interaction between FL-MMP1 and THP, a model for collagen 
peptide insertion inside the CAT domain active site is required. 
On the native collagen, the cleavage site corresponds to a GLY-ILE on α1 chain. 
However, no direct information about the interaction between the catalytic domain of MMP1 
and THP has been reported to date. From NMR titration of FL-MMP1 with THP (figure 11), 
some CAT-MMP1 residues were selected from their intensity decrease and solvent 
accessibility. Additionally, relying on the CAT-MMP1 homology structure with the CAT-
MMP12, the latter selection was completed by adding residues experiencing chemical shift 
changes from titration between MMP12 and elastin. Indeed most residues selected from CAT-
MMP12 are located in the same area as the residues from CAT-MMP1 even if the positions 
are lightly different.  
A first Haddock calculation for CAT-THP complex was run using the active residue 
from both CAT-MMP1 and CAT-MMP12 using CAT-MMP1 structure (from 2CLT) for the 
docking. Moreover, distance constraints were added to maintain the coordination between the 
catalytic zinc metal ion and the three histidines 218, 222, 228. Else, according the catalytic 
mechanism, other distance constraints were added to position properly the catalytic zinc ion 
close to the G-I cleavage site on collagen peptide. These distances were previously observed 
in a MMP12-peptidic ligand X-ray structure. 
 
From the previous calculation run with the HPX domain, only one chain from the 
triple helix remains accessible for the CAT domain. Then, residues selected on THP 
correspond to a fragment around the G-I cleavage site on the accessible chain for CAT 
domain. Docking calculation results are shown in figure 17.  
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Figure 17. Haddock docking calculation CAT with THP with one chain selected 
 
 
 
Active residues on CAT domain  
_ From FL-MMP1 titration with THP:   171, 178, 180, 207, 208, 209, 228, 233, 239 and 241 
_ From CAT-MMP12 interaction with ligands :  180, 181, 182, 183, 184, 185, 186, 187, 218, 219, 222, 228, 
238, 239 and 240  
Active residues on THP 
_ From THP around cleavage site :   G13, P14, Q15, G16, I17, A18, G19, Q20, R21 
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Calculations resulted in a unique cluster where the CAT domain reached an 
appropriate position for cleavage. Again, this CAT-THP interaction model obtained can be 
reported to the final calculation within the FL-protein with the THP. 
 
 
 
3.4.5 Fitting of MMP1 single domains to the THP from calculated complexes 
 
 
 
Once calculated the model structures for CAT-THP and HPX-THP separately, both 
complexes were fit on THP to define the single domain positions in a new model for a 
compatible structure with FL-MMP1. Here “simultaneous” interaction of HPX and CAT 
domain of FL-MMP1 with THP are required. Importantly, linker peptide extremities from 
each domain of MMP1 are located at a compatible distance whereas for the discarded HPX-
THP clusters, virtual distance between extremities of the linker was not compatible with the 
real linker length. 
 
THP CAT 
HPX 
 
 
 
Figure 18. Fitting of the two appropriate models HPX-THP and CAT-THP on the THP using molmol. Figure 
was displayed using pymol. 
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3.4.6 FL-MMP1 Structure from  THP-fixed single domains (HPX and CAT) using Modeller 
program 
 
 
 
Starting from the previous fitting (figure 18), the two reciprocally oriented domains 
were used as a scaffold in a calculation by using modeller. FL-MMP1 linker peptide was 
generated to provide the family of structures represented below (figure 19). By looking at the 
ensemble, numerous conformations for the linker peptide between the two domains were 
obtained. However considering the significant distance between the linker extremities, the 
preferential trajectory is relatively straight. From calculations, the structures were sorted on 
the basis of an energy term. 
 
 
 
 
CAT 
Linker 
peptide HPX 
 
 
 
Figure 19. Modeller calculation of FL-MMP1 from FIT CAT-THP – HPX-THP. Family of 49 structures where 
the linker peptide was generated keeping the two domains in their initial positions from the previous fitting. 
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3.4.7 Docking calculation by Haddock program using chemical shift perturbation on 
Modeller structure of FL-MMP1 and THP (Fields)  
 
 
A suitable FL-MMP1 structure was extracted from Modeller ensemble, and Haddock 
calculations were run combining all the constraints from the single domains docking.  
From 50 structures, a unique cluster was obtained with an average RMSD of 0.5 Å, Van der 
Waals energy = -123.5 +/- 3.6 kCal.mol-1, electrostatic energy = -419.8 +/- 31.9 kCal.mol-1, 
desolvation energy = -5.1 +/- 6.6 kCal.mol-1, restraints violation energy = 125.2 +/- 24.85 
kCal.mol-1 and a buried surface area of 3143.8 +/- 38.3 Å2.  
The final model obtained is shown here (figure 20). HPX-MMP1 interacts with two 
chains from THP and the CAT-MMP1 interacting with the released chain of the partially 
unwound THP. Final model obtained was superimposed with the X-Ray structure fitting on 
the HPX domains. In the final model, CAT domain reaches the cleavage site by a rotation of 
the linker peptide around the THP. 
 
 
THP 
HPX 
Model 
X-Ray 
 
 
Figure 20. Interaction model of the FL-MMP1 THP collagen-like complex 
 
CAT active residues : N171, G178, N180, L181, A182, H183, A184 , F185, Q186, F207, T208, E209, H218, 
H222, H228, G233, P238, S239, Y240, T241 
Fields peptide : P14, Q15, G16, I17, A18, G19, Q20, R21 Q54, I56, A57, Q59, R60, Q98, R99, V101 e V102 
HPX active residues : R291, G292, N306, Y309, E311, E313, N315, F316, S318, V319, F320 
Forced distances : metal ion position, hbonds CAT-THP and HPX-THP and distances from catalytic site to 
cleavage site.  
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4. Conclusion 
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Mobility of Matrix metalloproteinases MMP12 and MMP1 
 
 
During this research the question of inter-domain flexibility in solution for MMPs 
bearing short linkers has been addressed by NMR.1,2 In both MMP1 and MMP12 the 1H-15N 
HSQC or TROSY spectra of the FL construct is largely the superposition of the related 
catalytic and hemopexin domain spectra, consistent with the absence of an extensive contact 
between the two domains.  The absence of a stable contact between the HPX and CAT 
domain in MMP1 has been also observed by monitoring the effect of a soluble paramagnetic 
probe on the NH resonances of the FL protein. Further compelling evidence of interdomain 
flexibility has been obtained from NMR relaxation data, which are inconsistent with a rigid 
structure for these two full-length proteins. Actually the experimental R1 values for the 
residues of CAT and HPX domain in the FL protein were found sizably higher with respect to 
the theoretical data calculated on the respective rigid X-ray structures.3 At the same time the 
experimental R2 values were found systematically lower than the theoretical data for the two 
domains in the rigid full-length proteins. The fact that the R1 values are higher and R2 lower 
than expected indicates intrinsic flexibility of the full length proteins and independent motion 
of the two domains. 
 
The interdomain flexibility is further supported by the small NOE values found for 
some residues forming the linker region in both MMP1 and MMP12. The NMR analysis has 
been fruitfully integrated by synchrotron small-angle X-ray scattering (SAXS). Actually, the 
processed X-ray scattering pattern from the full length MMP1 and MMP12 can not be 
reproduced satisfactorily using either individual models, such as the respective experimental 
crystal structures, or averaging structures among open and closed conformations. For both 
proteins, the analysis indicates that the observed crystallographic conformations can be 
present also in solution, but they are flanked by a significant amount of extended 
conformations in equilibrium with the closed one(s). 
 
 
Interaction between matrix metalloproteinases and extracellular matrix components : 
 
 
The current interaction study between MMPs and ECM components have provided 
new and relevant information regarding the structural and dynamical features of these 
multidomain proteins that play a role in substrate recognition and processing. The NMR data 
collected on FL-MMP12 and on the isolated domains have shown that elastin peptides bind 
the catalytic domain alone at the active site in agreement with the generally accepted idea that 
the latter is responsible for the elastolysis in vivo. However, the observed interaction in vitro 
with the HPX domain in the FL protein and its cooperative nature suggest that in vivo also the 
full length MMP12 may participate to elastolysis. Moreover, the NMR data and the docking 
models of the complexes between CAT-MMP12 and selected elastin fragments have showed 
that an extensive interaction is required for hydrolysis. In particular, our analysis indicates 
that the active site of MMP12 interacts with 8-11 residues belonging to the elastin cleavage 
site.  
MMP12 and MMP1 are structurally similar. This is particularly true for CAT domains 
whereas the HPX domains are slightly more distinct. The structure-function relationship is a 
general concept in biology. Considering the structure similarity among the MMP family 
members, a common catalytic mechanism is expected. Therefore, the details of the catalytic 
mechanism revealed on CAT-MMP12 interacting with elastin can be taken as a general model 
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for the catalysis in all MMPs. At the same time, the preference of MMPs for the different 
ECM components seems mainly due to the properties of each HPX domain. 
 
For MMP1, the HPX domain is crucial for collagenolysis.4 NMR experiments 
performed on the FL-MMP1 protein in presence of a triple helical collagen-like model show 
that the HPX domain interacts with the peptide. This result was confirmed by titrating the 
HPX domain alone with the same peptide. Interestingly, amino-acids which experience the 
largest chemical shift perturbation are placed in a region poorly conserved among the MMP 
family.5 This region may be important for the specificity of MMP1 towards triple helical 
collagen.  
The NMR experiments have provided structural information that has been used as 
constraints to calculate a docking model of the HPX-THP adduct. The titration of the FL-
MMP1 with THP showed that both CAT and HPX domains interact with the collagen model.  
In particular, the amino-acids forming the active site of the CAT domain and those 
involved in the interaction in the HPX-THP experienced a sizable decrease in signal intensity. 
The chemical shifts changes observed for some THP resonances allowed us to identify the 
binding site on the collagen model. The binding mode of HPX and CAT domains on THP 
suggests that a reciprocal reorientation of the two domains in FL-MMP1 take place during 
triple helix unwinding and the following collagenolysis. To complete the model, only was 
missing the linker peptide which as itself constitutes a structural distance constraint for 
positioning the two domains of FL-MMP1. A similar approach was already described on 
MMP2 by removing completely the linker and using a distance constraint between extremities 
of the two domains.6 Of course, the two MMP1 isolated domains re-associated in solution can 
also perform cleavage on collagen.4 However, the linker peptide by keeping the two domains 
close, increases dramatically the enzyme efficiency by entropic contribution. 
All the information collected was used to calculate a model for the complex between 
FL-MMP1 and THP. 
The calculated structure during this research represents the first model of an MMP1-
collagen-like peptide adduct and provide new information in order to clarify the mechanism 
of collagenolysis. 
 
 
Perspectives 
 
 
In order to better characterise the interaction between MMP1 and the collagen peptide 
model, new experiments using a partially double labelled THP sample could be performed. 
Actually, the availability of such a sample permits a more detailed analysis of the structural 
features of the MMP1-THP complex allowing then to clarify the dynamical processes related 
to collagen unwinding. 
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1. Introduction 
 
 
S100 family 
 
Proteins which belong to the S100 family may have an intra or an extracellular 
location. They are called “S100” from their 100% solubility property in a saturated solution of 
ammonium sulphate.1 They usually consist in dimeric proteins containing two pairs of EF 
hand motifs. Each EF hand motif has a certain affinity to bind calcium ions. After protein 
activation mediated by a calcium ion binding, the S100 proteins interact with cellular 
receptors in order to activate different cellular functions.2 In particular, two observations have 
been reported regarding how the S100 proteins interact with their respective targets. The first 
one is that the binding of a calcium ion induces conformational changes from the dimeric 
protein which modify in particular the relative orientation of the final alpha helix. The second 
observation is that S100 proteins almost always interact in a dimeric form. The consequence 
is that a larger contact area is obtained to interact with the partner. Sometimes, because of 
symmetrical properties, a S100 dimer can interact simultaneously with two partners 
positioned at the two opposite contact faces of the molecule. Moreover, some S100 protein 
can form tetramers or even octamers, increasing then their ability to bind additional 
molecules. This multi-binding property may have an important functional role in the 
activation of receptors or in signalling pathways. 
 
Due to important differences in the physiological calcium availability inside and 
outside the cell, S100 proteins can play different roles depending on their sub-cellular 
localisation. Inside the cell, the S100 proteins can regulate protein phosphorylation by 
interacting with kinases often involved in signalisation pathways. S100 proteins can also 
inhibit some enzymes like phospholipase A2. Moreover, S100 proteins play a role in calcium 
homeostasis. Outside the cell, S100 proteins interact with cell surface receptors in particular 
with those involved in inflammation. Several S100 proteins, like S100B or S100P interacting 
with RAGE are responsible for activating different signalling pathways. 
S100 proteins expression is relatively low in mature tissues except in the tumour cell where 
the protein is overexpressed. In the recent years, an increased interest in the study of these 
proteins was developed in order to understand the activation mechanisms and to characterise 
the interaction between S100 and the different receptors. For example, in the case of prostate 
carcinoma, 3 S100P (originally extracted from human placenta) was highly expressed in 
particular in presence of an androgen. 
 
S100P is highly expressed in neoplastic cells. The origin of this presence in tumour 
cells can be partially explained by an interaction between S100P and RAGE (Receptor for 
Advanced Glycation End products) located at the cytoplasmic membrane. 4 This interaction 
provokes via different signalling pathways such as ERK and MAP kinases an increase of cell 
survival and cell proliferation by stimulating S100P expression in an autocrine manner.  
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Receptor for Advanced Glycation End products 
 
 
RAGE which belongs to the immunoglobulin superfamily is located at the cell surface. 
This protein contains an extracellular region composed by a variable domain V and two 
constant domains C1 and C2 corresponding respectively to the variable and constant domains 
of the soluble immunoglobulins. In addition, RAGE contains also a transmembrane region 
and a cytoplasmic domain (figure 1). 
 
 
 
 
Figure 1. Schematic depiction of RAGE-ligand 
interaction showing domains of the receptor. The V-
type domain is critical for binding of RAGE 
ligands. Deletion of the cytosolic tail results in a 
modified form of RAGE that binds ligands, remains 
firmly embedded in the cell membrane, but does not 
transmit RAGE-mediated cellular activation. Even 
in the presence of endogenous full-length RAGE, 
expression of dominant negative RAGE blocks 
signalling from the receptor. sRAGE, soluble 
RAGE; DN-RAGE, dominant negative RAGE 
(extracellular domain + transmembrane-spanning 
domain). 5 
 
 
 
 
RAGE was initially identified from its ability to bind Advanced Glycation End 
products (AGEs) which accumulates due to diabetes or renal failure.6 Indeed, AGE ligation to 
RAGE activates p21ras by recruiting downstream targets such as MEK and MAP kinases, 
followed by an activation of NF-kB transcription factor.  
 
RAGE is highly expressed during the central nervous system development. In adult 
animal, RAGE expression level is also relatively high in lungs which suggests several 
functions. 
 
To study the different functions of RAGE, a strategy has consisted in inhibiting RAGE 
activity by adding the extracellular soluble protein fraction also called sRAGE (figure 1) in 
order to compete with the natural ligand. In this way, the RAGE natural effects can be studied 
both in vitro and in vivo by using then different concentrations of sRAGE.5 
 
Among the molecules binding RAGE receptor, amphoterin is a variable peptide of 10-
15 amino-acid length. After amphoterin binding to the cell surface, intracellular ERK-RAGE 
interactions were evidenced by an enhanced ERK kinase activity constituting a starting point 
for the MAP kinases signalling pathway. 7 Else, inhibiting the interaction between RAGE and 
amphoterin significantly reduces this MAP kinases pathway and as a consequence tumour 
proliferation, invasion and expression of matrix metalloproteinases.8 
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1.1 Pathologies related to S100P and RAGE activity 
 
 
 
The S100 family members and RAGE receptor are involved in several pathologies 
such as diabetes, inflammation or cancer development. For example, increasing concentration 
of sRAGE has shown a significant decrease of the phenotype effects on diabetic mice 
indicating that RAGE is involved in diabetes.9 In addition, it was reported that RAGE effects 
in diabetes are mediated by the NF-KB pathway.10 In other studies, injection of sRAGE on 
mice accelerated the wound healing process. Else, RAGE is also involved in inflammatory 
process through activation by S100A12 followed by recruitment of lymphocytes and 
macrophages.6 
 
RAGE also interacts with αβ amyloids.5 Amyloid accumulates in particular in neurons 
which provokes critical troubles such as Alzheimer disease. In addition, RAGE expression is 
amplified by the interaction between RAGE and these αβ amyloids. 
 
Regarding the S100 family, a gene expression profile observed on patients showed 
that S100P is the one genes having the highest expression fold increase in adenocarcinoma 
cells respect with normal conditions.11 Indeed, cancer development is often connected to some 
changes in DNA modifying then the gene expression through an alteration of the promoter. 
For example, in breast cancer, lung cancer and pancreatic tumour, S100P expression is up-
regulated.12 
 
 
 
 
 
Figure 2. Example of RAGE signalling 
triggered by S100B or S100A6 in human  
 
SH-SY5Y neuroblastomas. Micromolar 
concentration of S100B and S100A6 triggered 
distinct cellular pathways involving Akt and 
JNK respectively, leading to either cell 
survival, proliferation (S100B), or apoptosis 
13(S100A6).  
 
kinase pathway 
and further activation of the NF-kB transcription factor was also evidenced.  
 
 
 
 
 
A complete interaction mechanism between S100P and RAGE was described in colon 
cancer. In particular S100P expression is much higher in colon cancer than in normal cell 
whereas the expression of RAGE is quite constant. Activation of ERK, MAP 
14
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1.2 Structural studies 
 
 
S100 proteins 
 
 
S100 proteins share some similar structural pattern with calmodulin, in particular the 
presence of EF hands motifs which are able to bind calcium ions. Initially, calmodulin 
structure was solved in its apo form.15 A comparison between the NMR structure of 
calmodulin apo form and the X-Ray structure of the Ca2+ complexed protein16 showed some 
important conformational changes occur during the calcium ion binding. Later on, these 
conformational changes were confirmed by the NMR structure of the Ca2+ complexed form of 
calmodulin17. Evidence of the rearrangement was obtained with the contribution of residual 
dipolar couplings useful to study different conformations in solution. 
 
From the S100 family, NMR solution structure of the S100A6 apo form of the rabbit18 
was solved. Intermolecular noe constraints were used to obtain the structure assuming a 
dimeric form of the protein indicated by the observed line width of the signals. In a similar 
way, the S100B apo-protein solution structure (figure 3) from the rat was obtained.19 
 
 
 
 
 
 
Figure 3. Solution structure of calcium-free S100B 
________from RCSB PDB database code 1SYM.19 
 
 
 
 
 
In the case of S100P, the use of a double hybrid approach with mutated proteins has 
allowed to evidence some amino-acids involved in hydrophobic contacts in the structure of 
the dimer.20 In particular, the important role of some hydrophobic residues (F15 > F89 > I11 > 
I12) in the dimer formation was shown. These residues are highly conserved in the S100 
family, especially the F15 which is present in all the S100 known to date. 
 
A crystal structure was also obtained for the Ca2+ bound state of S100P (figure 4).21 
Again, the interaction between the two monomers is driven by hydrophobic contacts. 
Moreover, in the case of S100P, no heterodimer was observed between a S100P monomer and 
a different S100 family member. For other S100 members, some heterodimer like a 
S100A1/S100B complex has been observed. 2 Subsequently, the apo S100P solution structure 
was obtained. 22 The N-terminal part of the latter structure is similar to the S100P Ca2+ bound 
state structure whereas the C-terminal part shows significant changes which may suggest a 
role in target recognition. 
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1j55 1ozo 
 
Figure 4. Conformational changes induced by binding of a calcium ion (green sphere) to S100P from the apo 
form (pdb entry 1ozo) 22 to the holo form (pdb entry 1j55).21 
 
 
Indeed, by looking at the differences in S100 structures between the apo forms and the 
holo forms into the different dimers, it appears that binding of the calcium ions induces 
approximately a 40° angle rotation in the C-terminal α-helix (figure 4). This conformational 
change position the EF hand in order to interact with the target.23 
 
 
Receptor for Advanced Glycation End products 
 
 
Structural studies were performed on RAGE receptor. Variable domain (V-domain, 
figure 5) was first solved by NMR (pdb entry 2e5e deposited in 2007 by Matsumoto S. et al. 
unpublished). Then, the second constant domain structure (C2, figure 7) was also solved by 
NMR (pdb entry 2ens deposited in 2008 by Wakabayashi, M. et al. unpublished). To date, the 
last RAGE structure available in the PDB database which consist in a V-C1 construct of 
RAGE was obtained by X-ray crystallography (pdb entry 3cjj deposited in 2009 by Koch M. 
et al. unpublished, figure 6). 
 
 
 
 
Figure 5. Solution structure of RAGE Variable 
domain (pdb entry 2e5e ; Matsumoto S. et al.)  
 
 
 
 
 
 
 
 
C2V C1
Figure 6. Crystal structure of RAGE contruct V 
and C1 domains (pdb entry 3cjj ; Koch M. et al.) 
Figure 7. Solution structure of RAGE C2 
domain (pdb entry 2ens ; Wakabayashi, M. et 
al.)
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 1.3 Aim of the project 
 
 
The relevant pathological role of RAGE activation by the S100 family members has 
stimulated the research aimed to clarify the structural feature of the complexes between 
extracellular domains of RAGE receptor and this important class of ligands. During this 
research, the interaction of S100P with RAGE V-domain has been investigated by NMR. The 
backbone resonances of holo S100P and RAGE V-domain have been assigned. The 
interaction between the two proteins has been monitored by 2D HSQC and TROSY 
experiments. The amino-acids involved in protein-protein interaction have been identified. 
Then, a model for the S100P-RAGE V-domain complex has been calculated from the 
available structures by applying the NMR data obtained. An investigation on the dynamical 
properties of the complex was also carried out. 
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2. Materials and Methods 
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2.1 NMR 
 
 
Protein assignment experiments 
 
 
The experiments for the S100P protein assignment, mobility measurements and 
titration experiments were performed on protein samples at concentrations ranging between 
0.4 and 1 mM. Sample conditions of S100P were usually at 75 mM of NaCl for ionic strength, 
10 mM of CaCl2 with a HEPES buffer at pH 7.  
For RAGE V-domain, samples were concentrated in a solution containing 250 mM of 
NaCl, 10 mM of sodium citrate buffer up to 0.5 mM with a pH adjusted at 6.  
All NMR experiments were performed and acquired on Bruker AVANCE900, 
AVANCE800, AVANCE700 and DRX 500 spectrometers. All instruments are equipped with 
a triple resonance CRYO-probes. 
 The assignment of the S100P-Ca2+ sample was obtained by the analysis of a HSQC, 
24,25,26,27 HNCA28, CBCA(CO)NH29, HNCACB30,31 experiments performed at the 500 MHz 
spectrometer with a 13C-15N enriched sample concentrated to 1 mM in the buffer conditions 
described above for S100P and at a temperature of 310K.  
The backbone resonance assignment of and V-domain of RAGE receptor was obtained 
by the analysis of HSQC, HNCA, CBCA(CO)NH and HNCACB spectra performed at 700 
MHz for HNCA and at 500 MHz spectrometer for the other 3D experiments. All these spectra 
were recorded at 298K. 
 
 
NMR titration experiments 
 
 
2H-13C-15N-labelled S100P with unlabelled V domain of RAGE 
 
 
A triple labelled 2H-13C-15N enriched sample of S100P-Ca2+ was prepared at a 
concentration of 0.5 mM with 75 mM of NaCl, 10 mM of CaCl2 and a HEPES buffer at pH 7. 
In order to study the interaction in solution by NMR between S100P and V-domain of 
RAGE, reference HSQC, 1H-15N trosy32 TROSY-HNCA33 experiments were performed at 
the 900 MHz at a temperature of 298K. 
Then unlabelled V-domain of RAGE protein was added to the initial sample reaching 
a final concentration of 0.39 mM for S100P and a 0.23 mM for V-domain of RAGE. Same 
experiments HSQC, TROSY and HNCA were repeated on the complex at the temperature of 
298K. 
 86
2H-13C-15N-labelled S100P with unlabelled V-C1 RAGE construct 
 
 
A similar S100P-Ca2+ protein sample at a concentration of 0.5 mM was prepared to 
study the interaction between S100P and the VC1 RAGE construct. Reference HSQC, 
TROSY and HNCA experiments were performed at the 900 MHz at a temperature of 310K. 
Same experiments were repeated at the same temperature after addition of an 
unlabelled VC1 construct. Final concentrations for the complex were respectively 0.435 mM 
for S100P and 0.26 mM for the VC1 construct. 
 
 
13C-15N-labelled V domain of RAGE with unlabelled S100P 
 
 
 To observe chemical shift changes on RAGE protein, a reciprocal titration experiment 
was done by using a 13C-15N double labelled sample of the RAGE V-domain protein and an 
unlabelled S100P-Ca2+ sample. Reference HSQC and TROSY spectra of a 13C-15N labelled 
RAGE V-domain were acquired at the 900 MHz spectrometer at a temperature of 298K. 
Initial concentration of V-domain sample was 0.33 mM. Solution also contains 250 mM of 
NaCl and 20 mM of MES buffer at a pH of 6. Unlabelled S100P-Ca2+ was progressively 
added to the initial sample from a 2.6 mM concentrated mother solution. Additions of several 
S100P amounts were done in order to reach respectively 0.5, 1 and 1.5 equivalent of S100P 
dimer respect with the RAGE V-domain concentration. 
 HSQC and TROSY spectra were performed after each addition of S100P at a 
temperature of 298K. 
 
 
Relaxation experiments T1 and T2 on S100P and S100P-Vdomain complex 
 
 
Mobility measurements on S100P 
 
 
The experiments for the determination of 15N longitudinal and transverse relaxation 
rates34 and 1H-15N NOE35 were recorded at 298 K and 500 MHz on 15N-enriched sample of 
S100P at a concentration of 0.5 mM. The 15N longitudinal relaxation rates (R1) were 
measured using a sequence modified to remove cross correlation effects during the relaxation 
delay36. Inversion recovery times used for the experiments were the following : 20, 100, 200, 
300, 400, 500, 700, 900, 1100, 1300 and 1500 ms, with a recycle delay of 3.5 s. The 15N 
transverse relaxation rates (R2) were measured using a Carr-Purcell-Meiboom-Gill (CPMG) 
sequence37 with the following delays of 8.5 , 17, 25.4, 33.9, 42.4, 50.9, 59.4, 67.8, 76.3 and 
84.8 ms for the S100P protein with a refocusing delay of 450 µs. 
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Mobility measurements on S100P-Vdomain complex 
 
The same pulse sequence was used for the determination of the 15N longitudinal 
relaxation rates (R1) on the complex S100P-V-RAGE. Complex was obtained from a mixture 
of 15N labelled S100P with an unlabelled V-domain of RAGE with the respective 
concentrations of 500 µM and 300 µM. Solution buffer is the same as used for the 
corresponding titration. Inversion recovery times used for the experiments where the 
following : 20, 100, 200, 300, 400, 500, 700, 900, 1100, 1300, 1500, 1700, 1900, 2200 and 
2500 ms, with a recycle delay of 3.5 s. 
 
 
Effect of protein concentration in solution 
  
 
 Considering, the S100P protein in solution is present as a dimer and the S100B have 
been shown to form tetramer or octamer. Effects of concentration on 15N S100P were 
analysed by preparing S100P samples in a similar buffer as described initially. Spectra were 
acquired at the 700 MHz at respectively 0.1, 0.2, 0.4, 0.7, 4 and 5 mM. Quality of spectra 
didn’t increase above 0.4 mM indicating some line broadening effects probably due to 
aggregation. 
 Regarding S100P- RAGE V-domain complex, TROSY spectra was acquired with a 
diluted complex (S100P 0.4 mM : RAGE 0.35 mM) and a concentrated sample (S100P 1.2 
mM : RAGE 1.05 mM). Again, the spectra quality decreases, in particular, some signals 
disappeared indicating some aggregation may occur. 
 
 
2.2 Assignment of the S100P and RAGE V-domain 
 
 
Backbone assignment was performed by using CARA38 programme in a similar way 
as described in part I (see p.34). 
S100P backbone assignment of the holo form used in the present study was compared 
with the deposited assignment of the S100P apo form (BMRB entry 5103). Moreover, X-ray 
structure21 of the dimeric S100P-Ca2+ form was used to run chemical shift prediction software 
Sparta39 and Proshift. 40 A table of resonances for backbone assignment is presented in the 
result section (see p.94). 
Regarding RAGE V-domain, the solution structure has been recently resolved (pdb 
entry 2e5e) and then, NMR assignment is also available (BMRB entry 7364). 
 
 
2.3 Mobility studies from relaxation data 
 
 
The same procedure as in part I (see p.35) was followed to study relaxation data. 
Estimates of R1 and R2 values for dimeric S100P and S100P-RAGE V-domain complex were 
determined by using the program HydroNMR41 which simulates conditions of magnetic field 
and temperature from the three-dimensional structures of the proteins taken as input for the 
programme with respectively the X-ray structure21 of the S100P-Ca2+ and the RAGE             
V-domain extracted from V-C1 construct X-ray structure (pdb entry 3cjj). 
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2.4 Docking Calculation 
 
  
 
 Haddock42 programme online was used to calculate the interaction model the dimeric 
S100P protein and V-domain of RAGE. A similar procedure was followed as in part I (see 
p.37). Active residues were selected from the basis on the chemical shift perturbations 
observed on the two partners. Considering S100P is a homodimer, selection was done first by 
using active residues on the two monomers and a second selection using only one monomer. 
 
Moreover, several possible combinations of active residues were compared in order to 
insure the correct binding. From S100P, three zones were selected, the main zone contains the 
C-terminal α-helices with stronger effects, the lateral part close to the linker between the two 
EF-hand with average effects and the opposite α-helix face with smaller effects. From the 
RAGE V-domain structure, two zones were selected corresponding to the two faces of the 
proteins formed by β-sheets. 
 
Crystal structures of S100P-Ca2+ bound form (pdb entry 1j55) and VC1 construct of 
RAGE (pdb entry 3cjj) were used for docking calculation. Naccess43 programme was run on 
the two protein structures. 
 
Then, calculation was run assuming an automatic flexibility selection around the 
active residues. The different clusters obtained were analysed with molmol programme. 44 All 
the structures from each calculation run were fit by using profit programme (Martin, A.C.R. 
and Porter, C.T., http://www.bioinf.org.uk/software/profit/) on the lowest energy structure of 
the corresponding calculation run. The energy score function was manually defined in the 
following way : 
 
Escore = 0.2 Eelec + Evdw + Edesolv 
 
 
Then, discarding the violation term of the energy score allows the comparison between 
different calculations with a different number of active residues selected. 
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3. Results 
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3.1 NMR backbone assignment of S100P-Ca2+ form 
 
 
 
Backbone assignment was obtained for the S100P-Ca2+ bound form of the protein 
(Table 1). The protein solution structure is described as a homodimer. Indeed, the two 
monomers cannot be distinguished on the spectra. Despite the relatively low molecular weight 
of each monomer (Mw = 10 kDa), the use of a triple labelled sample allowed to increase peak 
resolution considering that the molecular weight for the entire protein is higher than 20 kDa. 
Indeed, despite a relatively regular spectral window of 7 ppm for the amide protons and 32 
ppm for 15N, a large majority of the peaks found on HSQC are located in the central region of 
the spectra (around 1H = 8 ppm ; 15N = 120 ppm). As a result, the spectra are relatively 
crowded. 
Nevertheless, spreading of the signals is still slightly higher than in the apo form (from 
assignment in bmrb entry 5103). 
 
 Then backbone assignment reached more than 90% (table 1). Missing residues are 
located in particular in the flexible region (G23-T25). On a total of eight non-proline 
unassigned residues, two serines, two threonines and one glycine are missing. These residue 
types are usually well identified in NMR from the Cβ resonance (or the absence of Cβ in the 
case of a glycine). Most of the resonances in the present assignment are comparable with 
those of the apo-S100P assignment (BMRB 5103) and with chemical shift prediction from 
SPARTA and PROSHIFT programmes. However, it was not possible to identify these 
missing signals. Then, all visible peaks on the spectra were assigned. 
 
 Average standard deviation of resonances between the present assignment, the apo 
form assignment and these two predictions were respectively 0.3 ppm for HN, 1.5 ppm for N, 
0.7 ppm for CA and 0.5 ppm for CB. 
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Table 1 : NMR backbone resonances of holo S100P-Ca2+ form at 298°K. 
 
 
Residue  H N CA CB Residue  H N CA CB 
  
SER 47 8.00 116.55 56.00  GLY -4*     
GLY 48 8.30 110.73 42.45  SER -3*   65.58  
LYS 49 7.90 120.22 53.62 29.63 PHE -2* 8.33 121.92 54.48  
ASP 50 8.00 119.27 50.90 38.10 THR -1* 8.08 116.37 58.62  
LYS 51 8.27 122.84 54.73 29.14 MET 1 8.22 123.66 52.51 32.03 
ASP 52 8.26 119.87 51.21 37.58 THR 2 8.95 115.11 58.21 67.04 
ALA 53 7.77 123.78 52.24 16.04 GLU 3 9.53 126.15 57.63 26.22 
VAL 54 8.44 118.35 62.48 27.79 LEU 4 8.78 118.74 54.77 39.40 
ASP 55 7.70 121.56 54.56 37.61 GLU 5 7.89 117.66 56.52 27.42 
LYS 56 7.58 119.05 56.00 29.12 THR 6 8.57 118.22 63.71 65.20 
LEU 57 7.49 120.39 54.42 38.76 ALA 7 8.19 125.73 52.31 15.92 
LEU 58 8.27 118.32 55.70 38.12 MET 8 8.08 115.78 56.69 29.55 
LYS 59 7.36 116.62 56.02 28.83 GLY 9 8.09 105.08 43.93  
ASP 60 7.77 118.58 53.37 37.44 MET 10 8.09 121.76 56.16 31.70 
LEU 61 7.81 118.33 52.83 40.54 ILE 11 7.64 119.25 63.51 34.41 
ASP 62 7.99 117.72 50.31 36.38 ILE 12     
ALA 63 7.98 131.60 51.32 16.15 ASP 13   54.49 37.62 
ASN 64 7.91 111.91 48.71 34.20 VAL 14 8.38 120.16 63.81 28.14 
GLY 65 7.45 109.55 44.67  PHE 15 8.00 118.35 59.77 36.72 
ASP 66 8.16 120.58 50.16 37.08 SER 16 8.50 113.22 57.60 60.29 
ALA 67 10.19 122.69 50.23 12.96 ARG 17 7.89 121.91 55.56 26.38 
GLN 68 7.72 113.59 50.12 29.72 TYR 18 7.01 114.49 55.95 36.90 
VAL 69 9.78 126.14 57.82 30.07 SER 19 7.50 111.48 57.47 59.78 
ASP 70 9.00 129.00 49.25 38.38 GLY 20 7.89 113.00 42.70  
PHE 71 9.19 119.84 60.08 35.70 SER 21 7.48 117.91 57.78 60.87 
SER 72 8.08 115.20 58.69 59.42 GLU 22 9.19 120.19 51.40 30.09 
GLU 73 8.10 122.72 54.79 27.02 GLY 23     
PHE 74 8.52 120.57 57.49 37.06 SER 24     
ILE 75 8.62 119.39 57.92 33.81 THR 25   60.74 65.08 
VAL 76 6.75 120.80 62.85 28.23 GLN 26 8.55 117.63 52.15 27.11 
PHE 77 6.78 122.95 56.19 35.59 THR 27 7.04 104.21 55.48 70.58 
VAL 78 7.78 118.60 62.82 27.86 LEU 28 9.47 124.64 49.82 40.49 
ALA 79 8.40 123.96 52.18 14.97 THR 29 9.69 114.84 57.44 68.54 
ALA 80 7.53 122.11 52.07 14.84 LYS 30 8.95 119.56 57.67 28.92 
ILE 81 8.16 116.46 58.69 33.94 GLY 31 8.38 105.64 43.56  
THR 82     GLU 32 7.51 122.57 55.45 27.79 
SER 83   58.60 59.96 LEU 33 8.66 120.02 54.17 38.62 
ALA 84 7.72 123.34 51.43 15.08 LYS 34 8.00 118.61 57.22 29.64 
CYS 85 7.93 117.27 58.26 23.79 VAL 35 6.98 117.69 62.94 28.35 
HIS 86 7.91 120.85 56.61  LEU 36 7.64 120.98 56.26 38.61 
LYS 87   54.99 27.36 MET 37 8.36 117.00 54.01 27.28 
TYR 88 7.77 119.16 56.49 35.01 GLU 38 7.92 116.89 55.82 26.70 
PHE 89 7.71 118.86 55.67 35.73 LYS 39 8.01 114.74 54.00 30.33 
GLU 90 7.81 121.19 54.45 26.85 GLU 40 8.75 114.77 53.50 27.78 
LYS 91 7.81 120.82 53.56 29.38 LEU 41 7.71 120.06 49.28 40.08 
ALA 92 7.92 123.47 49.69 15.89 PRO 42   61.34 28.03 
GLY 93 7.98 107.39 42.13  GLY 43 8.68 109.95 42.34  
LEU 94 7.80 121.84 52.06 39.23 PHE 44 8.03 122.33 57.70 36.76 
LYS 95 7.66 126.70 54.31 30.51 LEU 45 8.37 119.03 51.55 38.94 
      GLN 46 8.12 121.34 52.50 25.32 
percentage H N CA CB  
assigned  91% 91% 96% 94%   
 *Correspond to the rest of the tag after cleavage 
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3.2 Interaction between S100P protein and V-domain of RAGE 
receptor  
 
 
 
Titration experiments were performed using a 2H-13C-15N-labelled S100P sample 
(0.5 mM) in presence of an unlabelled RAGE V-domain sample. Several chemical shifts 
changes were observed on the spectra indicating that the two proteins interact (figure 8). 
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Figure 8. Chemical shift changes on 2H-15N-13C labelled S100P sample by titration with an unlabelled 
RAGE V-domain sample. Chemical shift differences represented correspond to the sum of absolute value of 1H 
chemical shift difference and 0.2 * absolute value of N chemical shift difference between the reference spectra 
and in the presence of RAGE V-domain. Experimental conditions : [S100P]monomer = 0.39 mM ; [V-RAGE] = 
0.23 mM ; Magnetic Field = 21T (900 MHz) ; T = 298K ; 2D Trosy experiment. 
 
 
 
From the titration of 2H-13C-15N labelled S100P by the unlabelled RAGE V-domain, 
several changes can be observed. Some signals became broader, other simply shifted or 
disappeared. The stronger effects correspond to the amino-acids located in the α-helix at the 
C-terminal on EF-Hand 2 (residues 75-95). Many changes are observed also in the central part 
of the sequence in particular close to the linker peptide between the two EF-hands (residues 
43-55). 
Additionally, the titration between 2H-13C-15N S100P and the unlabelled V-C1 
construct of RAGE showed the same region experienced chemical shift changes respect with 
the previous titration performed on RAGE V-domain. Consequently, this result indicates that 
the RAGE constant domain C1 is probably not involved in the interaction with S100P. This 
observation is consistent with the situation observed in the interaction between an antigen and 
an immunoglobulin in which constant domains are not involved.  
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From the previous result, the RAGE V-domain was selected to study the interaction 
between RAGE and S100P. To confirm this interaction and to collect chemical shift changes 
on the RAGE V-domain, a titration was performed by using a 15N-labelled RAGE V-domain 
in presence of an unlabelled S100P sample (figure 9). 
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Figure 9. Chemical shift changes on 15N labelled RAGE V-domain sample by titration with an 
unlabelled S100P sample. Chemical shift differences represented correspond to the sum of absolute value of 1H 
chemical shift difference and 0.2 * absolute value of N chemical shift difference between the reference spectra 
and in the presence of S100P. Experimental conditions : [V-RAGE] = 0.33 mM ; [S100P]monomer = 0.5 mM ; 
Magnetic Field = 21T (900 MHz) ; T = 310K ; 2D Trosy experiment. 
 
 
Chemical shift changes observed were more modest comparing with the shifts observed 
previously between the triple labelled S100P and unlabelled RAGE V-domain. In the other 
hand, signal to noise ratio was better in this case and ambiguity was also lower considering 
RAGE V-domain is a monomer in solution. The most intense effects were observed for the 
amino-acids located in the central part of the protein corresponding to a β-sheet surface 
(residues 81, 86 and 88). Few effects are visible on the opposite face of the receptor probably 
due to a perturbation in the β-bonding provoked by the interaction with the partner. 
 
These titration experiments allowed a better understanding of the regions involved in the 
interaction from the two partners. 
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3.3 Docking calculation on a S100P-RAGE V-domain complex 
 
 
From the results obtained from titration experiments, amino-acids involved in the 
interaction were selected in order to drive the docking with Haddock programme. Chemical 
shift mapping of residues from changes observed on S100P and RAGE V-domain is reported 
in Figure 10. 
 
 
 
V-RAGE selection Docking Combinations 
Energy score (kCal.mol-1) (3)  (blue) (4)  (red) (3) + (4) 
(1) (red) -133.4 -134.1 -87.9
(2) (yellow – blue) -240.4 -154.5 -221.1
(1) + (2) -226.0 -157.1 -162.2
S100P 
selection 
Monomer (2) -140.4 -170.3 -133.9
 
V-RAGE 
S100P 
2 
3 
4 
Figure 10.  Mapping of chemical shift changes 
observed on S100P-RAGE V-domain 
interaction from titration studies. (1) Red 
selection on S100P correspond to small effects. 
(2) Yellow and blue selection on S100P 
corresponding to average and strong effects on 
S100P. (3) Blue selection on RAGE V-domain 
correspond to average effects. (4) Red selection 
correspond to the smaller effects observed on 
RAGE V-domain. 
C1-RAGE 
1 
 
Table 2.  Energy score obtained on docking calculations using different selections from both partners. 
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 Results obtained from docking calculations are reported in table 2. For all these 
different selections, an “energy score” was defined from the relation :  
 
Escore = 0.2 Eelec + Evdw + Edesolv 
  
According to this energy score, the best result was obtained from the selection 
constituted by the residues coloured in yellow and blue on the figure (EF-Hand 2 from S100P 
structure) from the S100P dimer and by the residues coloured in blue from the RAGE          
V-domain. The score reported in the table 2 refers each time to the best cluster from docking 
calculation. Interestingly, from the RAGE V-domain all the docking models based on the red 
selection (column (4) red from the table 2) have a significantly higher energy score respect 
with the best model obtained (bold in the table 2). The same observation can be done with the 
red selection from the S100P dimer (raw (1) red from the table 2). Eventually, docking control 
calculations performed by using a single monomer showed also a significantly worse energy 
score respect to the best calculation according to energy score (bold). The result from these 
calculations is somehow expected considering the selection from the most significant 
chemical shift changes observed corresponds to the best model obtained. Nevertheless, all 
combinations needed to be valuated to ensure finding the best matching possible. The table 
below contains the detail of the different selections. 
 
 
S100P*–Yellow (EF-Hand 2 motif, helix 4) 
D70, F71, S72, V76, F77, A79, A80, I81, A84, H86, Y88, F89, E90, K91, A92, G93, L94 
 
S100P*–Blue (EF-Hand 2 motif, helix 3) 
D52, A53, V54, D55, L57, D60, L61, A63, A67 
 
S100P*–Red (N-terminal region, helix 1) 
M1, E3, E5, T6, A7, S16, R17, Y18, S19 
 
V-RAGE-Blue 
E32, L34, V35, K37, C38, D73, S74, A76, R77, N81, G82, S83, F85, L86, A88, V89 
 
V-RAGE-Red 
E50, W51, K52, N54, G56, R57, Q92, I96, C99 
 
Table 3. Residues selected for docking calculations; symbol * indicates a selection for both monomers except 
contrary indication. 
 
 
Another element to characterise the docking is the contact area between the two 
partners (table 4). Usually, in interactions, the contact area is correlated with the quality of the 
energy function. Hence, the following table reports the contact area for these different models. 
 
V-RAGE selection  
Docking Combinations 
Contact area (Å2) 
(3)  (blue) (4)  (red) (3) + (4) 
(1) (red) 1841 1566 1742
(2) (yellow – blue) 3311 2983 3155
(1) + (2) 3212 3034 3320
S100P 
selection 
Monomer (2) 2292 2351 2311
 
Table 4. Contact area obtained on docking calculations using different selections from both partners.
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 Comparison between the contact areas of these different models showed significant 
differences respect with the best models from the energy score. In particular, a strong 
dependency can be noticed from the residue selection of S100P. It appears clearly, the 
interaction area between the two partners is significantly lower with the red selection of 
S100P (EF-Hand 1 motif) respect with the yellow-blue selection (EF-Hand 2 motif). As 
expected, the surface area is significantly lower on the selection from the monomer. 
  
Combining the information from the energy score and the surface area led us to 
consider the interaction model obtained with S100P yellow-blue selection (EF-Hand 2 motif) 
and V-RAGE blue selection as a model of reference for comparison. 
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Figure 11. Docking calculation results from the different run. Each model was compared to the best 
from the corresponding calculations. The different clusters can be represented on this plot. 
 
 
On the plot reported in Figure 11, it appears the calculation giving the lowest energy score 
(circles on Figure 11) is divided into four clusters. The best two clusters of the S100P – Blue Yellow 
(EF-Hand 2 motif) selection with V-RAGE Blue are comprised in an energy range between -180 
kCal.mol-1 and  -250 kCal.mol-1. In the other hand, one cluster has an average RMSD to the best 
value of 1.2 Å while the other one has an average value of 20.7 Å. Curiously, this “away” cluster 
from the best structure has similar energy statistics values respect to the closer one. 
 
By displaying these two clusters on molmol, it appears they are actually identical but the 
positions of the two homodimers of S100P from calculations are inverted. In fact, RMSD fitting 
doesn’t recognise the similarity of the two monomers. The presence of these “twin cluster” is 
observed in all the different calculation with comparable populations. 
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All the other calculations generated models with an energy score comprised in a range 
between -80 kCal.mol-1 and -180 kCal.mol-1 which are all higher than the best two clusters described 
above. 
An interaction model between S100P and RAGE V-domain from the best is a represented 
here. 
 
 
 
S100P dimer  
  
 V-domain C1-domain 
 
Figure 12. Interaction model from docking calculation between a S100P dimer forming a complex with RAGE 
V-domain. 
 
 
 
 
From this model obtained (figure 12), the interaction involved mainly the two α-
helices from EF-Hand 2 on S100P and a relatively disordered region of RAGE V-domain. 
Interestingly, these helices of S100P correspond to the ones experiencing some 
conformational changes during the calcium ion binding. 
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3.4 Effects of complex formation on dynamics 
 
 
In order to demonstrate the effects of interaction on S100P protein mobility, relaxation 
measurements were done on a S100P protein sample concentrated at 0.5 mM (figures 13a and 
13b). 
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Figure 13a. Relaxation rate R2 measurements of isolated S100P protein on 500 MHz spectrometer at 298K. 
 
 
R1 S100P
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
1,60
1,80
1 8 15 22 29 36 43 50 57 64 71 78 85 92
Residue
R
1 
(s
-1
)
Exp S100P
Calc S100P
 
 
Figure 13b. Relaxation rate R1 measurements of isolated S100P protein 500 MHz spectrometer at 298K. 
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Figure 13c. Relaxation rate R1 measurements of S100P-RAGE V-domain complex on 500 MHz spectrometer at 
298K. 
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From X-ray structure 1J55, the atomic coordinates for amino-acids contained in the 
loop between Q46 – K51 are missing. Interestingly, the authors reported possible mobility for 
the linker between the two EF-hands. 
Indeed, from the R2 and R1 plots (figures 13a and 13b), this loop presents an 
enhanced mobility respect with the rest of the protein. Calculated values were obtained using 
a model derived from the dimeric X-ray structure where the missing loop was rebuilt by 
modeller. Relaxation values were simulated by HydroNMR assuming the protein as a rigid 
body. Here, experimental R2 is lower than calculated for the Q46 – K51 loop and 
experimental R1 is higher for the same region. This indicates that this loop displays a local 
flexibility. 
Relaxation studies showed also the six C-terminal residues (E90-K95) present a 
significant mobility. Again R2/R1 ratio is lower respect with the rest of the protein. For these 
residues located close to the C-terminal extremity such mobility could be expected but in the 
other hand they are located in a α-helix secondary structure according to the X-Ray structure. 
For all the other residues, experimental and calculated data are matching confirming the 
protein is present as a dimer in solution. These data obtained on isolated S100P can be used as 
a reference to analyse data obtained the complex. It also validates the estimation of relaxation 
rates by HydroNMR.  
 
Relaxation measurements were performed on S100P-RAGE Vdomain complex (figure 
13c). Results obtained on T1 measurements showed, as expected, a general decrease of R1 
values for S100P residues indicating the formation of a bigger molecule. Interestingly, the 
mobility observed in the middle loop and at the C-terminal helix is retained. Most probably, 
these regions are not directly involved in close contact with V-domain but might participate in 
some conformational change. Calculated data were obtained using HydroNMR programme 
from a Haddock model of the S100P dimer-V-RAGE complex. Again, for the rest of the 
protein, experimental and calculated R1 data are matching confirming the complex in solution 
corresponds to a S100P homodimer with RAGE V-domain at the concentration used (0.5 mM 
for S100P monomer and 0.35 mM for V-domain). Although the structure of the interaction 
between S100P and RAGE V-domain has not been solved, mobility studies indicated that 
relaxation data are consistent with our model. 
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4. Conclusion 
 101
Interaction studies of a S100P-RAGE V-domain complex. 
 
 
Experimental data show that S100P is a ligand of RAGE. The S100P protein structures 
in its apo form in solution by NMR (1OZO) 22 and in its holo form by X-ray crystallography 
(1J55), 21 are dimers. Binding of the calcium ion induces some conformational change which 
modifies the interface between the two monomers. As reported, 4 only the calcium bound 
form of S100P is able to interact with V-domain. Interestingly, the most significant chemical 
shift changes observed on S100P in presence of RAGE V-domain correspond to the S100P C-
terminal residues where the structure is modified during the binding of calcium ion. 
Docking calculations were performed in order to find the best adduct using the 
chemical shift changes obtained from the titration experiments. The best docking model has 
been obtained considering energy values corresponding to the protein regions from the two 
partners in which the chemical shift perturbations were the most significant. Moreover, the 
same docking model had also the most extended contact area between the two partners. 
A series of relaxation time measurements was done on the holo-S100P alone and in 
complex with RAGE V-domain. Experiments on isolated holo-S100P indicated some 
flexibility in the linker between the two EF-hands of the protein and at the C-terminal region. 
These R1 and R2 measurements confirmed that S100P at 0.5 mM in solution is present as a 
homodimer. Experimental relaxation values were in agreement with the simulated values 
from HydroNMR programme. Indeed, most of the S100 family members are present in 
solution2 in a dimeric form. However, S100B which also interacts with RAGE can be found 
as tetramer or octamer in solution.45 Possibility of a tetramer formation was also simulated by 
the programme but results obtained were not consistent with the experimental relaxation 
values at this concentration. 
Comparison between relaxation data measured on S100P alone and in the presence of 
V-domain confirmed the formation of the complex constituted by a homodimer S100P with a 
monomeric RAGE V-domain. Moreover, the experimental relaxation data were consistent 
with calculated data from the model using HydroNMR. This agreement constitutes an 
important step to understand the interaction properties between S100P and RAGE. 
 
 
Perspectives 
 
 
 
Further studies should be carried out in order to describe the structure of the S100P-
RAGE V-domain complex in more detail. For example, experiments to obtain some distance 
constraints from intermolecular NOE can be performed. Another strategy would consist in 
mutating one of the calcium binding sites on S100P to substitute one of the calcium ions by a 
paramagnetic metal ion. In this way, a titration performed between a 15N-labelled RAGE V-
domain and a paramagnetic unlabelled S100P would allow identifying paramagnetic effect on 
RAGE V-domain. Such effects can provide new distance constraints between S100P and V-
domain useful in docking calculations. 
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